

# National ADAP Monitoring Project Annual Report

July 2013



# Acknowledgements

The National Alliance of State & Territorial AIDS Directors (NASTAD) thanks state ADAP and AIDS program managers and staff for their time and effort in completing the National ADAP Survey, which serves as the foundation for this report, and for providing ongoing updates to inform the National ADAP Monitoring Project. NASTAD also thanks Lanny Cross, NASTAD consultant, for his valuable contributions to NASTAD's ADAP Monitoring and Technical Assistance Program. Finally, without the guidance and support from Julie Scofield, NASTAD Executive Director, this report would not be possible.

The National ADAP Monitoring Project is one component of NASTAD's National ADAP Monitoring and Technical Assistance Program which provides ongoing technical assistance to all state and territorial ADAPs. The program also serves as a resource center, providing timely information on the status of ADAPs, particularly those experiencing resource constraints or other challenges, to national coalitions and organizations, policy makers, industry members, and state and federal government agencies. NASTAD received support for the National ADAP Monitoring and Technical Assistance Program in 2012 from the following companies: AbbVie (formerly Abbott Laboratories), Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics and ViiV Healthcare. NASTAD also receives funding to provide technical assistance to ADAPs through a Training and Technical Assistance Cooperative Agreement with the Health Resources and Services Administration (HRSA).

## **National Alliance of State and Territorial AIDS Directors**

444 North Capitol Street, NW, Suite 339 • Washington, DC 20001-1512

(202) 434-8090 (phone) • (202) 434-8092 (fax)

[www.NASTAD.org](http://www.NASTAD.org)

**Randy Mayer (Iowa), Chair (2012-2013)**

**Dawn Fukuda (Massachusetts), Chair (2013-2014)**

**Julie M. Scofield, Executive Director**

## Table Of Contents



<b>Module One Executive Summary .....</b>	<b>ix</b>
<b>Module Two Executive Summary .....</b>	<b>xiii</b>
<b>Key Dates in the History of ADAPs .....</b>	<b>xix</b>

## Module One (released in January 2013)

<b>Detailed Findings.....</b>	<b>1</b>
Methodology.....	3
About ADAP .....	4
ADAP Budget.....	4
ADAP Crisis .....	5
ADAP Client Enrollment and Utilization.....	5
ADAP Prescription Expenditures and Prescriptions Filled .....	6
ADAP Purchasing Models .....	7
ADAP Insurance Coordination.....	7
ADAP Eligibility Criteria .....	8
ADAP Formulary Coverage .....	8
ADAP and Hepatitis Vaccines .....	9

<b>Charts .....</b>	<b>11</b>
Chart 1: The National ADAP Budget, FY1996—FY2012.....	13
Chart 2: The National ADAP Budget, by Source, FY1996—FY2012.....	13
Chart 3: The National ADAP Budget, by Source, FY2012.....	14
Chart 4: ADAP Expenditures, FY2011.....	14
Chart 5: Part B ADAP Earmark, FY1996—FY2012 .....	15
Chart 6: Part B ADAP Supplemental Funding, FY2001—FY2012.....	15
Chart 7: Part B Base Contribution Directed to ADAP, FY1996—FY2012 .....	16
Chart 8: Part A Contribution Directed to ADAP, FY1996—FY2012 .....	16
Chart 9: State Contribution, FY1996—FY2012.....	17
Chart 10: Estimated Drug Rebates, FY1996—FY2012 .....	17
Chart 11: ADAP Client Enrollment, June 2003—2012 .....	18
Chart 12: ADAP Clients Enrolled and Top Ten States, by Clients Enrolled, FY2011.....	18
Chart 13: ADAP Client Utilization, June 1996—2012.....	19
Chart 14: ADAP Clients Served and Top Ten States, by Clients Served, June 2012 .....	19
Chart 15: ADAP Clients Served, by Race/Ethnicity, June 2012 .....	20
Chart 16: ADAP Clients Served, by Gender, June 2012 .....	20
Chart 17: ADAP Clients Served, by Age, June 2012.....	21
Chart 18: ADAP Clients Served, by Income Level, June 2012 .....	21
Chart 19: ADAP Clients Served, by HIV/AIDS Status, June 2012.....	22
Chart 20: ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2012.....	22

Chart 21: ADAP Drug Expenditures and Top 10 States, by Drug Expenditures, June 2012. ....	23
Chart 22: Percent Change in ADAP Drug Expenditures, June 1996-2012. ....	23
Chart 23: ADAP Drug Expenditures and Prescriptions Filled (Including Drug Purchases and Co-payments), June 2012. ....	24
Chart 24: ADAP Drug Expenditures and Prescriptions Filled (Including Drug Purchases and Co-payments), by Drug Category, June 2012. ....	24
Chart 25: Clients Served and Estimated Expenditures in Insurance Purchasing and Continuation, 2012. ....	25
Chart 26: ADAP Income Eligibility, as of June 30, 2012. ....	25

## **Tables ..... 27**

Table 1: The ADAP Budget, FY2011 and FY2012. ....	29
Table 2: The National ADAP Budget, by Source, FY2012. ....	30
Table 3: Major FY2012 Budget Categories Compared with FY2011. ....	32
Table 4: Growth of Federal ADAP Funding, FY2008 through FY2012. ....	34
Table 5: Growth of State Contribution to ADAP, FY2008 through FY2012. ....	36
Table 6: Growth of Estimated Drug Rebates, FY2008 through FY2012. ....	38
Table 7: Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY2012. ....	40
Table 8: Total Clients Enrolled/Served and Program Expenditures, FY2011. ....	42
Table 9: Total Clients Enrolled and Served, June 2011 and June 2012. ....	44
Table 10: ADAP Clients Served, by Race/Ethnicity June 2012. ....	45
Table 11: ADAP Clients Served, by Gender, June 2012. ....	46
Table 12: ADAP Clients Served, by Age, June 2012. ....	47
Table 13: ADAP Clients Served, by Income Level, June 2012. ....	48
Table 14: ADAP Clients Served, by HIV/AIDS Status, June 2012. ....	49
Table 15: ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2012. ....	50
Table 16: ADAP Drug Expenditures (Including Purchases and Co-payments), June 2012. ....	51
Table 17: ADAP Drug Expenditures (Including Purchases and Co-payments), by Drug Category, June 2012. ....	52
Table 18: ADAP Prescriptions Filled (Including Purchases and Co-payments), June 2012. ....	53
Table 19: ADAP Prescriptions Filled (Including Purchases and Co-payments), by Drug Category, June 2012. ....	54
Table 20: ADAP Drug Purchasing, June 2012. ....	55
Table 21: Federal ADAP Funds Used for and Number of Clients Served Through Insurance Purchasing and Continuation, 2012. ....	56
Table 22: ADAP Client Financial Eligibility Requirements, as of June 30, 2012. ....	57
Table 23: ADAP Client Eligibility Requirements, as of June 30, 2012. ....	58
Table 24: ADAP Client Enrollment Processes, as of June 30, 2012. ....	59
Table 25: ADAP Management Policies in Place, as of June 30, 2012. ....	60
Table 26: ADAP Prescription Distribution, June 2012. ....	62
Table 27: ADAP Coverage of HIV Antiretrovirals, June 2012. ....	64
Table 28: ADAP Coverage of "A1" Opportunistic Infection Medications, June 2012. ....	66
Table 29: ADAP Coverage of HIV Diagnostics, June 2012. ....	68
Table 30: ADAP Coverage of Hepatitis B Treatment, June 2012. ....	69
Table 31: ADAP Utilization of Hepatitis B Treatment, June 2012 and FY2011. ....	70

Table 32: ADAP Coverage of Hepatitis C Treatment, June 2012 .....	71
Table 33: ADAP Utilization of Hepatitis C Treatment, June 2012 and FY2011 .....	72
Table 34: ADAP Coverage of Hepatitis C Diagnostics, June 2012 .....	73
Table 35: ADAP Coverage of Hepatitis A and B Vaccines, June 2012 .....	74
Table 36: HIV/AIDS Antiretroviral and Opportunistic Infection Medications.....	75
 <b>Module Two (released April 2013) .....</b>	<b>77</b>
 <b>Detailed Findings.....</b>	<b>79</b>
Methodology.....	81
About ADAP .....	82
ADAP Client Enrollment and Utilization.....	82
ADAP Coordination with Medicaid .....	82
ADAP Coordination with Medicare Part D.....	82
ADAP Coordination with Pre-existing Condition Insurance Plans .....	83
ADAP Coordination with State-run High-risk Insurance Pools (not PCIP).....	83
 <b>Charts .....</b>	<b>85</b>
Chart 1: ADAP Clients Enrolled, June 2011 through December 2012 .....	87
Chart 2: ADAP Clients Served, June 2011 through December 2012.....	87
Chart 3: ADAP Data Sharing Agreements, December 2012.....	88
Chart 4: ADAP Policies Related to Medicare Part D, as of December 31, 2012 .....	88
Chart 5: ADAP Clients Enrolled in Medicare Part D, December 2012 .....	89
Chart 6: ADAP Coordination with Pre-existing Condition Insurance Plans, December 2012.....	89
 <b>Tables .....</b>	<b>91</b>
Table 1: Total Clients Enrolled and Served, June 2012 and December 2012 .....	93
Table 2: ADAP Clients Enrolled in Medicaid, December 2012.....	94
Table 3: ADAP Policies Related to Medicare Part D, as of December 31, 2012.....	95
Table 4: ADAP Clients Enrolled in Medicare Part D, December 2012 .....	96
Table 5: ADAP Coordination with Pre-existing Condition Insurance Plans (PCIP), December 2012 .....	97
Table 6: ADAP Coordination with State-run High-risk Insurance Pools (not PCIP), December 2012.....	98
 <b>Glossary .....</b>	<b>99</b>





# **Module One Executive Summary**



# The Current ADAP Environment

The HIV/AIDS epidemic has reached an important juncture and for the first time in the disease's history there is viable hope for an end to AIDS. Universal access to treatment is essential to this goal. The AIDS Drug Assistance Program (ADAP) plays a crucial role in ensuring and maintaining access to care for people living with HIV/AIDS.

ADAP's role of providing drugs to people living with HIV/AIDS (PLWHA) is important to optimizing care outcomes and preventing new infections, as illustrated in the [prevention to care continuum](#). Among the services needed to improve health outcomes is the need for linkage to, and retention in, care and access to medication, in order to achieve suppressed viral load. A [suppressed viral load](#) greatly reduces the risk of transmitting HIV and could lead to fewer new infections. In the future, with an optimized prevention to care continuum and reduced infection rates, ADAP could see fewer clients needing services.

ADAP is crucial to achieving the goals of the [National HIV/AIDS Strategy](#) (NHAS). The NHAS was released in July 2010 with anticipation of improving HIV/AIDS prevention, care, and treatment efforts in the United States. The NHAS seeks to increase the proportion of newly diagnosed HIV-positive patients linked to care within three months of diagnosis from 65 to 80 percent by 2015. In order to meet this goal, approaches such as the Ryan White Program and ADAP, which connect people to services and keep them in care, must be coordinated with the [Affordable Care Act](#) (ACA). The ACA provides a platform for improvements in health care coverage, while the NHAS provides a roadmap to help ensure that PLWHA and HIV health care providers are included in various coverage expansions while the law is being implemented.

Full implementation of the ACA – including

significant expansion of public and private insurance coverage, investments in health care infrastructure and commitment to prevention and wellness – will help expand access to care for tens of thousands of people living with HIV. State and federal planning will continue in preparation for full implementation. Each state will have the flexibility to decide if it will develop a state run or rely on a federally run exchange and each state will also need to opt into Medicaid expansion. States who do not expand their Medicaid will not be eligible for federal matching funds for the expansion. ADAP will need to continue to serve PLWHA throughout ACA implementation, as well as after the ACA is implemented to ensure that clients do not experience gaps in coverage.

The comprehensive reforms envisioned by the ACA have significant implications for a range of public health and safety net systems, including the Ryan White Program. It is important for the Ryan White Program to adapt to a post-ACA world in order to continue to meet the needs of PLWHA as well as the goals of the NHAS. However, it is also imperative that federal agencies, providers and consumers leverage health system reform and ensure that the HIV community retains the Ryan White Program expertise, services, and models of care that have been successful at getting people into care and keeping them healthy. Even with full implementation of the ACA, the Ryan White Program is needed to fill gaps in covered services and populations and to continue to provide vital enabling and support services. The Ryan White Program must be able to provide an adequate period for transition of clients to other care systems to ensure care continuity. After this period, the Ryan White Program can be adapted to the new systems of care in the ACA.

Fully funding ADAP is crucial to the program's success in providing medications to low-income individuals with HIV who have limited or no coverage from private insurance, Medicare and/or

Medicaid. ADAPs' FY2012 began on April 1, 2012. ADAP received an increase of \$15 million from the [Consolidated Appropriations Act of 2012](#), for a program total of \$900 million. In August 2012, the [Department of Health and Human Services](#) (HHS) released \$75 million in FY2012 emergency funding for ADAPs, including \$35 million in new funding that President Obama announced on World AIDS Day (2011) and \$40 million in continued emergency funding from FY2011 that was included in the [Department of Defense and Full-year Continuing Appropriations Act of 2011](#). This emergency funding has resulted in the reduction and elimination of most ADAP waiting lists and other cost-containment measures currently in place. Several states were able to clear their existing waiting lists but immediately began enrolling new clients onto a waiting list. This demonstrates that ADAP enrollment is not static. Other ADAPs continue to experience increased strain on their programs due to new enrollment of individuals based on increased efforts to identify new individuals living with HIV and re-engagement of individuals lost to care. As such, ADAPs continue to require additional funding to keep new waiting lists from being implemented and continue coverage for existing individuals.

ADAPs will face other changes and challenges in FY2013. As part of the current legislation of the Ryan White Program, FY2013 will bring two significant changes to bear that could have an impact on program funding. Only name-based HIV cases will be used for formula award calculations moving forward. Reported code-based cases will not be used in the formula award calculation for the Ryan White Program, which could result in funding shifts. As well, the hold harmless provision, which ensures that states do not receive a formula award that is less than a specified percentage, is reduced to 92.5 percent of their FY2012 award, which could also result in funding shifts from state to state.

In addition, the federal government is currently being funded until March 2013 through a [continuing resolution](#) (CR). The result is approximately flat funding for ADAP, the entire Ryan White Program, and other discretionary programs for a portion of FY2013. FY2013 awards could be delayed and/or only partially funded as a result until a final, year-long budget is available.

To add to this complex funding picture, the [American Taxpayer Relief Act of 2012](#), signed into law on January 2, 2013, postpones the [budget sequestration](#) that would cut non-defense discretionary programs, including ADAP. Sequestration is delayed for two months while further negotiations on deficit reduction occur. Non-defense discretionary programs could face further overall cuts in the form of reduced budget funding caps and the possibility remains for approximately eight percent or more cuts to ADAP in FY2013 and further cuts in following fiscal years. Thus, future ADAP funding remains unclear.

All of these fiscal challenges for federal programs pose threats to access to life-saving medications for PLWHA that are necessary through ADAP. Work must continue through a three-pronged approach that includes securing additional resources for ADAPs from the federal government; maintaining, restoring, and increasing resources for ADAPs from state governments; and, continuing pricing agreements between ADAPs and pharmaceutical manufacturers to provide financial stability and augmenting existing agreements, when applicable.

## **Module Two Executive Summary**



# Using ADAP Data To Prepare For Health Reform

As states prepare for open enrollment through the exchanges/marketplaces beginning in October 2013 and for the Medicaid and private insurance coverage expansions that take effect in January 2014, it is crucial that HIV/AIDS programs – and AIDS Drug Assistance Programs (ADAPs) in particular – share information and data with state health reform decision makers to inform the transition and to ensure that systems and policies are being implemented in ways that complement ADAP systems, providers, and public health functions. The National ADAP Monitoring Project *Annual Report* data offers a useful way to begin conversations with state policymakers about the role of ADAP and the Ryan White Program as we transition to 2014. Several action steps are identified below to assist programs in identifying state decision makers and assembling necessary program information and data. For questions, please contact [Amy Killelea](#) or [Britten Pund](#).

## 1) Identify health reform decision makers in your state.

State HIV/AIDS programs must communicate with the broad range of state agencies and other policy makers charged with implementing health reform. These entities include:

- Interagency council, task force, or dedicated office on health reform.
    - **Example: [Minnesota Health Care Reform Task Force](#)**
      - Includes agency representatives from HIV/AIDS Program
      - Divided into topic-specific work groups
      - Stakeholder engagement opportunities
  - State exchange board
    - State-based exchanges/marketplaces (which are operating in [18 states](#)) have formed boards or other entities charged with running with the exchanges/marketplaces. To find out if your state has established an exchange board, check [here](#).
  - Medicaid program
  - State department of insurance
    - Even in states with a federally facilitated exchange/marketplace, the state department of insurance will continue to have oversight over insurance regulation. These agencies will also be working with the federal Department of Health and Human Services (HHS) as exchanges/marketplaces are designed and implemented to coordinate state and federal activities.
- ## 2) Share basic information about the purpose and structure of ADAP and the role it plays.
- Many state policymakers – particularly those charged with running newly formed state-run exchanges/marketplaces – are not familiar with the purpose of the Ryan White Program or ADAP and the basics of how those programs work. State HIV/AIDS programs and ADAPs should be prepared to educate policy makers about the role and structure of their programs. Basic program information should include:
- *Mission and purpose of the program*

ADAP administrators should be prepared to educate other agencies and policymakers about the role of ADAP, including payer of last resort requirements.
  - *ADAP structure*

ADAP administrators should also share information on the basic structure of ADAP in their state, particularly the structure of insurance purchasing and continuation programs.
  - *ADAP formulary*

[State private insurance benchmark plans](#) have been selected and will provide the standards for the scope of prescription drug coverage available through private insurance plans in 2014. Plans sold through exchanges/marketplaces will be required to cover *the greater of* one drug per category and class or the same number of drugs per

USP Classification for HIV and Viral Hepatitis Medications	
Class	Category
Anti-viral	Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
	Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
	Protease Inhibitors
	Anti-Cytomegalovirus (CMV) agents
	Anti-HIV agents, other
	Anti-hepatitis agents

2014 ACA Coverage Option	Income Eligibility Threshold
Medicaid Expansion	Income up to 138% FPL
Advance Premium Tax Credit for purchase of private insurance through exchanges/marketplaces	Income between 100 and 400% FPL (ineligible for Medicaid or affordable employer-based coverage)
Cost-sharing subsidies to offset out-of-pocket costs of private insurance through exchanges/marketplaces	Income between 100 and 250% FPL (ineligible for Medicaid or affordable employer-based coverage)

category and class as covered by the benchmark plan (the rule uses the [U.S. Pharmacopeia drug classification system](#)). Plans that have to meet this standard, however, may cover different drugs than are covered by the benchmark plan, as long as they cover at least the same number of drugs in each category and class.

ADAP formularies offer a useful comparison point to the formularies included in the benchmark plans for private insurance (as well as the prescription drug coverage for the Medicaid expansion population, which could be different). Because plans will be able to cover different drugs than the benchmark formulary, the ADAP formulary will also need to be compared to the formularies of every plan sold through the exchange/marketplace to assess cost-sharing affordability and to ensure that the plan formulary is comparable to the ADAP formulary. Discrepancies between ADAP formularies and private insurance plans sold through the exchanges/marketplaces is particularly concerning given that ADAPs are able to pay premium and co-payments for clients enrolled in private insurance, but only if the plans “at a minimum provide prescription coverage equivalent to the [ADAP] formulary.”<sup>1</sup>

### 3) Identify and prepare program data to inform health reform transition planning.

State HIV/AIDS programs should be prepared to share ADAP data to help inform planning for the public and private insurance expansion that go into effect in 2014. ADAP client demographic data should be compared to income thresholds for the Medicaid expansion as well as federal subsidies to purchase private insurance.

***Note:** in states that do not expand Medicaid, people with income under 100% FPL are not eligible for subsidies to purchase private insurance. However, ADAP may be able to pay the unsubsidized private insurance premium and cost-sharing obligations for this population if cost-effective.*

Data sharing should include the following:

#### **Client demographic data to forecast 2014 insurance coverage transitions**

Based on ADAP and Ryan White Program client data, we know that the number of people living with HIV who will be transitioning to Medicaid and private insurance will be significant. The following table is a useful way to break down ADAP demographic data to plan for the transition to new coverage options.

*\* Categorically ineligible for federal programs includes populations who are barred from accessing Medicaid or other federal programs because of immigration status*

<sup>1</sup> Health Resources and Services Administration, Policy Notice 07-05, The Use of the Ryan White HIV/AIDS Part B ADAP Funds to Purchase Health Insurance, September 19, 2007.



ADAP Clients by Income and Insurance Status		
Reporting Time Frame: DATE		
TOTAL ADAP CLIENTS	Raw #	Percent
<b>Total ADAP clients with income up to 100% FPL</b>		
ADAP Full Pay (uninsured)		
Medicare Part D		
Pre-existing Condition Insurance Plan (PCIP)		
State-run High-risk Insurance Pool		
Private Insurance		
Medicaid		
Categorically Ineligible for Federal Programs*		
<b>Total ADAP clients with income up to 138% FPL</b>		
ADAP Full Pay (uninsured)		
Medicare Part D		
Pre-existing Condition Insurance Plan (PCIP)		
State-run High-risk Insurance Pool		
Private Insurance		
Medicaid		
Categorically Ineligible for Federal Programs*		
<b>Total ADAP clients between 139% and 250% FPL</b>		
ADAP Full Pay (uninsured)		
Medicare Part D		
Pre-existing Condition Insurance Plan (PCIP)		
State-run High-risk Insurance Pool		
Private Insurance		
Medicaid		
Categorically Ineligible for Federal Programs*		
<b>Total ADAP clients between 251% and 400% FPL</b>		
ADAP Full Pay (uninsured)		
Medicare Part D		
Pre-existing Condition Insurance Plan (PCIP)		
State-run High-risk Insurance Pool		
Private Insurance		
Medicaid		
Categorically Ineligible for Federal Programs*		

*(e.g., undocumented immigrants or legal immigrants within the five-year Medicaid ban) and, in some cases, individuals who are incarcerated in local, county jails.*

### ***ADAP Pharmacy Information to Inform Network Adequacy Standards***

Depending on how the ADAP is structured, an ADAP may have a single pharmacy or a pharmacy network through which clients access medications. ADAPs with insurance purchasing and continuation programs must be able to coordinate with pharmacies in private insurance networks, particularly around payment of client cost-sharing obligations. Therefore, it is essential for ADAP pharmacies to be included in the provider networks of private insurance plans sold through the exchanges/marketplaces. Exchanges/marketplaces are developing provider network adequacy standards that will govern what providers need to be included. Standards include a requirement that plans contract with a sufficient number of “Essential Community Providers” (which include Ryan White Program providers). In addition, many plans may choose to use a mail order pharmacy, and ADAPs must be able to coordinate with these pharmacies. ADAPs should be prepared to share information about where clients are getting care to ensure they are included in provider networks.

## **HEALTH REFORM RESOURCES**

- [NASTAD Health Reform Resources](#)  
NASTAD has developed a series of issue briefs, presentations, and other resources to provide information to health departments on what health care reform implementation will mean for HIV/AIDS and viral hepatitis programs.
- [HIV Health Reform](#)  
This website is a useful source for news and information on the impact of national health reform on the lives and health of people living with HIV. HIV Health Reform hosts frequent webinars on various health reform topics and the impact on HIV services, providers, and clients

- [State Refo\(ru\)m](#)  
State Refor(u)m is an online clearinghouse for state ACA implementation resources, documents, and information. The website houses various state reports, legislative language, and updates from state health officials, advocates, and other health reform stakeholders
- [Center for Consumer Information and Oversight \(CCIIO\)](#)  
CCIIO is the federal agency charged with overseeing and implementing many of the private insurance reforms, including implementation of the federally facilitated exchanges. The website includes federal regulations and guidance related to the private insurance reforms.

# Key Dates in the History of ADAPS

- 1987:** First antiretroviral (AZT, an NRTI) approved by the FDA; Federal government provides grants to states to help them purchase AZT, marking beginning of federally funded, state-administered “AZT Assistance Programs.”
- 1990:** ADAPs incorporated into Title II of the newly created Ryan White CARE Act.
- 1995:** First protease inhibitor approved by FDA, and the highly active antiretroviral therapy (HAART) era begins.
- 1996:** First reauthorization of CARE Act—federal ADAP earmark created; first non-nucleoside reverse transcriptase inhibitor (NNRTI) approved by FDA.
- 2000:** Second reauthorization of CARE Act. Changes for ADAPs include: allowance of insurance purchasing and maintenance; flexibility to provide other limited services (e.g., adherence support and outreach); and creation of ADAP supplemental grants program.
- 2003:** NASTAD’s ADAP Crisis Task Force formed to negotiate with pharmaceutical companies on pricing of antiretroviral medications; first fusion inhibitor approved by FDA.
- 2004:** President’s ADAP Initiative (PAI) announced, allocating \$20 million in one-time funding outside of the ADAP system to reduce ADAP waiting lists in 10 states.
- 2006:** Third reauthorization of the CARE Act, now called, “Title XXVI of the PHS Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2006” or the “Ryan White Program.” Changes for ADAP include: new formula for determining state awards, which incorporates living HIV and AIDS cases; new minimum formulary requirement; and an increase in the ADAP Supplemental set-aside and changes in eligibility and matching requirements.
- 2007:** New minimum formulary requirement effective July 1; first CCR5 antagonist and integrase inhibitor approved by FDA.
- 2009:** Fourth reauthorization of the Ryan White Program. The reauthorization was for four years and included several technical changes.
- 2010:** Patient Protection and Affordable Care Act (PPACA) signed into law. ADAP emergency funding announced by the Obama Administration, allocating \$25 million in funding to address ADAP waiting lists and cost-containment measures.
- 2011:** ADAP emergency funding continued at \$40 million. In December 2011, President Obama announced an additional \$35 million for ADAPs to address ADAP waiting lists and cost containment measures. Awards from this funding will be available to states based on a competitive application.
- 2012:** ADAP emergency funding awarded at \$75 million, including the continuation of FY2011 funding the allocation of an additional \$35 million announced by President Obama in December 2011.



# Module One

*January 2013*

*Prepared by*

National Alliance of State & Territorial AIDS Directors (NASTAD)

Ann Lefert

Emily McCloskey

Britten Pund



# **Module One: Detailed Findings**





## Highlights

New data provided in this year's *Report* include the HIV/AIDS status of ADAP clients and a complete listing of ADAP formulary coverage.

Other highlights from the data included in this *Report*:

- In FY2011, ADAP expenditures on prescription drugs and insurance premiums, co-payments, and deductibles accounts for 95% of all program expenditures; only 2% of ADAP funding was expended on program administration.
- For the first time in the history of ADAP, the budget has exceeded \$2 billion.
- ADAP utilization reached its highest level, with the program serving almost 150,000 in June 2012.
- ADAPs reported an estimated \$227 million in insurance expenditures for FY2012.

## Methodology

Since 1996, NASTAD's National ADAP Monitoring Project has surveyed all jurisdictions receiving federal ADAP earmark funding through the Ryan White Program. In FY2012, 59 jurisdictions received earmark funding and were surveyed; 52 responded. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond; these jurisdictions represent less than one percent of estimated living HIV and AIDS cases. This 18<sup>th</sup> release of the *Annual Report* updates prior findings with data from ADAP's fiscal year 2012 as well as a detailed snapshot of data from the month of June 2012. This module of the *Annual Report* reflects the latest available data and discusses recent policy and programmatic changes affecting ADAPs.

The annual survey requests data and other program information for a one-month period (June), the current fiscal year, and other periods as specified. After the survey is distributed, NASTAD conducts extensive follow-up to ensure completion by as many ADAPs as possible. Data used in this report are from June 2012 and FY2012, unless otherwise noted.

All data reflect the status of ADAPs as reported by survey respondents. It is important to note that some program information may have changed between data collection and this report's release. Due to differences in data collection and availability across ADAPs, some are not able to respond to all survey questions. Where trend data are presented, only states that provided data in relevant periods are included. In some cases, ADAPs have provided revised program data from prior years and these revised data are incorporated where possible. Therefore, data from prior year reports may not be comparable for assessing trends. It is also important to note that data from a one-month snapshot may be subject to one-time only events or changes that could in turn appear to impact trends; these are noted where information is available. Data exceptions specific to a particular jurisdiction are provided in the notes section on relevant charts and tables.

**A**IDS Drug Assistance Programs (ADAPs) provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS in all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, American Samoa, the Federated States of Micronesia, Guam, the Northern Mariana Islands, Republic of Palau and the Republic of the Marshall Islands. In addition, some ADAPs provide insurance continuation and Medicare Part D and Medicaid wrap-around services to eligible individuals. ADAPs are a component of the federal Ryan White Part B Program that provides necessary medical and support services to low income, uninsured and underinsured individuals living with HIV/AIDS in all states, territories and associated jurisdictions.

## ADAP BUDGET

The national ADAP budget grew to \$2.03 billion in FY2012, an increase of approximately \$140 million (8%) over FY2011.<sup>1</sup> This also represents the first time that the ADAP budget has ever exceeded \$2 billion (see Charts 1-10 and Tables 1-3, 7).

- In FY2012, the ADAP earmark was \$825 million. The earmark was one-quarter of the national ADAP budget in FY1996, the year it was created, rose to more than two-thirds (68%) of the budget in FY2000 and has most recently declined as a share of the overall budget to less than half (41%) in FY2012.
- ADAP Supplemental Drug Treatment Grants (36 states in FY2012) accounted for 2% (\$42.9 million) of the overall ADAP budget. ADAP Supplemental Drug Treatment Grants are, by law, a five percent set-aside of the ADAP earmark and represent a portion of the overall federal contribution.
- Transfers to ADAP by states from their Part B “base” awards accounted for 1% (\$28.7 million) of the overall budget in FY2012.
- Transfers to ADAP by states from their Part B Supplemental funding accounted for 1% (\$10.2 million) of the overall budget in FY2012.
- In August 2012, ADAPs received \$75 million to address ADAP waiting lists and other unmet ADAP needs. ADAP emergency funding awards were made to 25 states, with funding amounts ranging from \$74,324 in North Dakota to \$10.1 million in California. Funding allocated through FY2011 emergency relief funding was added to the Part B ADAP earmark appropriation in FY2012. This funding is, however, distributed separately from the ADAP earmark.
- Transfers to ADAP from Part A jurisdictions represented \$16.1 million or 1% of the ADAP budget in FY2012.
- State contributions accounted for \$274 million, or 13% of the overall ADAP budget in FY2012.
- Drug rebates accounted for \$735.8 million, or 36%, of the overall ADAP budget in FY2012. This funding represents money that is paid to the state as a result of active filing of rebate claims with manufacturers based on drug purchases.<sup>2</sup>
- ADAP budget composition varies by state. The federal earmark is provided to all eligible jurisdictions (59 in FY2012) based on a formula of living HIV (non-AIDS) and AIDS cases. The remaining federal funds are either awarded on a competitive basis or allocated as a result of demonstrated need. The breakdown of other sources of funding across the country is as follows (among 52 ADAPs reporting data) (see Table 2):
  - o Part B ADAP Supplemental Treatment Grants: 36 ADAPs were eligible and applied for, and received, funding;
  - o Part B Base Funds: 23 ADAPs received these transfer of funds;
  - o Part B Supplemental Funds: 18 ADAPs received transfer of these funds;
  - o ADAP Emergency Funding: 25 ADAPs received funding;
  - o Part A Funds: 9 ADAPs received transfer of these funds;
  - o State Contributions: 40 ADAPs received funding;
  - o Drug Rebates: 44 ADAPs received funding;
  - o Other State/Federal Funds: 8 received funding.

- While most ADAPs had increases in their budgets between FY2011 and FY2012, some had overall decreases or reductions in specific funding streams (see Tables 1 and 3)<sup>3</sup>:
  - o Overall Budget: 36 ADAPs had increases or level funding, 16 had decreases;
  - o Part B ADAP Earmark Funds: 54 ADAPs had increases or level funding, 5 had a decrease;
  - o Part B ADAP Supplemental Drug Treatment Grants: 35 ADAPs had increases or level funding, 1 had a decrease;
  - o Part B Base Funds: 16 ADAPs had increases or level funding, 13 had decreases;
  - o Part B Supplemental Funds: 16 ADAPs had increases or level funding, 13 had decreases;
  - o ADAP Emergency Funding: 24 had increases or level funding, 9 had decreases;
  - o Part A Funds: 5 ADAPs had increases or level funding, 7 had decreases;
  - o State Contributions: 33 ADAPs had increases or level funding, 11 had decreases;
  - o Drug Rebates: 31 ADAPs had increases or level funding, 12 had decreases.
- While not counted as an ADAP budget category in this report (due to its high variability and significant delays in receipt of funds), “cost recovery” for medications purchased through ADAP (other than drug rebates), represented \$34 million in FY2012 (see Table 7).
- In FY2011, ADAPs expended \$1.5 billion on prescription drugs, representing 79% of all ADAP expenditures. Insurance premiums, deductibles, and co-payments represented 16% of ADAP expenditures. Two percent of ADAP funds were expended for program administration costs (see Chart 4 and Table 8).

## ADAP CRISIS

ADAP waiting lists began to appear in FY2002. In May 2004, ADAP waiting lists reached their highest documented point, at 1,629 individuals. Following this peak, ADAP waiting lists began to dwindle and fell to zero individuals in FY2007. FY2008 saw a marked increase in ADAP waiting lists. ADAP waiting lists surpassed their previous maximum and reached their highest point in the program’s history on September

1, 2011 with 9,298 individuals eligible for ADAP in 11 states, yet unable to access services due to a waiting list. FY2012 saw a steady decrease in the number of individuals on ADAP waiting lists due to a variety of factors. However, NASTAD continues to pursue a coordinated strategy to ensure ADAPs remain fiscally viable. This three-pronged approach includes securing additional resources for ADAPs from the federal government; maintaining, restoring, and increasing resources for ADAPs from state governments; and, continuing pricing agreements between ADAPs and pharmaceutical manufacturers to provide financial stability and augment existing agreements, when applicable (see Tables 4, 5 and 6).

- From FY2008 to FY2012, federal ADAP funding (including Part B ADAP Earmark, Part B ADAP Supplemental and ADAP Emergency Funding) increased 24%.
- From FY2008 to FY2012, state contributions to ADAP decreased 12%.
- From FY2008 to FY2012, estimated drug rebates increased 127%.

## ADAP CLIENT ENROLLMENT AND UTILIZATION

- During FY2011, 230,932 clients were enrolled in ADAPs nationwide, including 34,636 new clients enrolled throughout the year. Client enrollment ranged from 122 in Alaska to 44,390 in California in FY2011. Typically, fewer clients are served in ADAPs than are enrolled at any given time—ADAPs served 206,461 clients in FY2011 (see Table 8).
- ADAPs provided medications to 143,926 clients across the country in June 2012. Client utilization in June 2012 increased by 5% between June 2011 and June 2012 (see Table 9).
- Mirroring the national epidemic, most ADAP clients are concentrated in states with the highest number of people living with HIV. Ten states accounted for 64% (148,396 clients) of total enrollment in FY2011; five states accounted for 49% (California, New York, Texas, Florida, and New Jersey) of total FY2011 enrollment (see Chart 12). The distribution is similar for clients served in June 2012 (see Chart 14).

- ADAPs primarily serve low-income, uninsured clients, most of whom are minorities. Client demographics have remained fairly constant over time, although there are significant variations by state and region. In June 2012, client demographics were as follows (see Charts 15-20 and Tables 10-15).
  - o African Americans and Hispanics represented 55% (32% and 23%, respectively) of clients served. Non-Hispanic whites comprised 34% of clients served. Combined, Asians, Native Hawaiian/Pacific Islanders, and Alaskan Native/American Indians represented approximately 3% of the total ADAP population. Multi-racial ADAP clients represented 5% of the total ADAP population.
  - o Three-quarters (78%) of ADAP clients were men.
  - o Almost half of clients (41%) were between the ages of 25 and 44. Those between the ages of 45 and 64 represented 50% of clients served by ADAP.
  - o Three-quarters (78%) of clients had income levels at or below 200% of the Federal Poverty Level (FPL). In 2012, the FPL was \$11,170 annually (slightly higher in Alaska and Hawaii) for a family of one.
  - o Almost two-thirds (59%) of clients have income levels at or below 138% FPL. In 2014, the ACA expands Medicaid eligibility to most people with income up to 133% of the federal poverty level (FPL). However, in addition to new income counting rules for most Medicaid populations (called “Modified Adjusted Gross Income”), there is an additional 5% disregard of income, effectively bumping the Medicaid income eligibility threshold to 138% FPL.
  - o Over one third of ADAP clients (38%) were HIV-positive (non AIDS). One third of ADAP clients (31%) were HIV-positive with an unknown AIDS status. One-fifth (21%) of ADAP clients had AIDS, as defined by the Centers for Disease Control and Prevention (CDC).
  - o CD4 count information of clients was reported by 30 ADAPs and reflects clients enrolled in ADAPs over the last 12 months or the most recent 12 months for which data are available. Almost half of ADAP clients (40%) had CD4 counts of 350 or below (at

time of enrollment or at recertification), one potential indication of more advanced HIV disease for ADAP clients.

## **ADAP PRESCRIPTION EXPENDITURES AND PRESCRIPTIONS FILLED**

The distribution of drug expenditures and prescriptions varies across the country, reflecting differing formularies, drug prices and prescribing patterns. Antiretrovirals, the standard of care for HIV, account for the majority of ADAP drug expenditures and prescriptions filled.

- ADAP drug expenditures were \$138,753,407 in June 2012, ranging from a low of \$18,295 in New Mexico, which heavily relies on insurance purchasing for client coverage, to a high of \$38.1 million in California (see Table 16). Ten states accounted for 74% (\$102,969,798) of all drug spending; five states (California, New York, Texas, New Jersey, and Pennsylvania) accounted for almost two-thirds (59%) of all drug spending (see Chart 21).
- Between June 2011 and June 2012, drug expenditures increased 3% (see Chart 22).
- The average monthly cost per client served by ADAP was \$1,054 in June 2012. Estimated annual per client expenditures were \$12,648.<sup>4</sup> In states that purchase via a pharmacy network (rebate) model, average monthly cost per client does not include rebates on expenditures, which would reduce the cost paid for prescriptions and, therefore, the average cost per client. States must actively file for rebates with manufacturers on past drug purchases.
- In June 2012, the average expenditure per prescription was \$309, compared to \$303 in June 2011, representing a 2% increase. Average expenditures per prescription was significantly higher for antiretrovirals (\$473) than non-antiretrovirals (\$66 for “A1” OIs and \$53 for all other drugs).
- ADAPs filled a total of 449,154 prescriptions in June 2012 (see Chart 23 and Table 18), representing an increase of less than 1% compared to June 2011 (445,202 prescriptions filled).



- Most ADAP drug spending is on FDA-approved HIV antiretrovirals<sup>5</sup> (93% in June 2012). The “A1” drugs highly recommended for the prevention and treatment of HIV-related opportunistic infections (OIs)<sup>6,7</sup> accounted for 1% of expenditures and 7% of prescriptions filled. All other drugs (including medications for depression, hypertension and diabetes), accounted for 6% of drug expenditures, but 33% of prescriptions filled (see Chart 24 and Tables 17 and 19).
- ADAPs purchase or continue insurance and pay for co-pays and deductibles on behalf of ADAP clients as a “wrap-around” of existing other payer sources. A subset of overall drug expenditures, ADAP payment of client co-payments, was 4% of overall drug purchases (see Table 16). In June 2012, 21% of all prescriptions filled were via co-payment expenditures (see Table 18).
- Three ADAPs reported purchasing through a hybrid model.
- Twenty ADAPs reported purchasing through a dual model – both purchasing directly from wholesalers and seeking rebates.
- The District of Columbia participates in the 340B program, but is able to purchase most of its medications through the Department of Defense, allowing it to access the Federal Ceiling Price, a lower price only available to certain federal purchasers. Several other states that participate in the 340B program also have state laws regarding negotiation processes that result in lower prices.
- NASTAD’s ADAP Crisis Task Force negotiates on behalf of all ADAPs directly with manufacturers for pharmaceutical pricing below the 340B price. When such agreements are reached, they are provided to all states. There are currently agreements in place with all manufacturers of antiretroviral medications and with several other companies that manufacture other high-cost medications. The cumulative savings of the Task Force agreements from 2003 to 2011 is estimated at more than \$1.8 billion. NASTAD provides logistical support to the Task Force.

## ADAP PURCHASING MODELS

The federal 340B Drug Discount Program, authorized under the Veterans Health Care Act of 1992, enables ADAPs to purchase drugs at or below the statutorily defined 340B ceiling price. All ADAPs participate in the 340B program (see Table 20). ADAPs may purchase drugs directly from wholesalers at 340B (or sub-340B) prices (“direct purchase ADAPs”), through retail pharmacy networks at a higher than 340B price (“rebate ADAPs”), as a direct purchase state that utilizes an existing entity (e.g., University Hospital) to purchase and distribute ADAP drugs (“hybrid ADAPs”), or as a combination of a direct purchase and rebate ADAP (“dual purchaser”). For rebate states, ADAPs then submit rebate requests to drug manufacturers, maintaining compliance with the 340B price requirement. Direct purchase ADAPs can also choose to participate in the HRSA Prime Vendor Program created by the federal government to negotiate pharmaceutical pricing below the 340B price.

- Six ADAPs reported only purchasing directly from wholesalers; 25 also participated in the HRSA Prime Vendor Program.
- Twenty-three ADAPs reported only purchasing through a pharmacy network and then seeking rebates.

## ADAP INSURANCE COORDINATION

The Ryan White Program allows states to use ADAP dollars to purchase health insurance and pay insurance premiums, co-payments and/or deductibles for individuals eligible for ADAP, provided the insurance has comparable formulary benefits to that of the ADAP.<sup>8,9</sup> States are increasingly using ADAP funds for this purpose.

- Forty ADAPs reported using funds for insurance purchasing/continuation in 2012 representing \$227 million in estimated expenditures in FY2012. ADAPs reported spending over \$20.3 million on insurance purchasing/continuation in June 2012 (see Table 21).
- In June 2012, 46,653 ADAP clients were covered by such arrangements (see Chart 25 and Table 21). Clients served through insurance coordination increased by 14% from June 2011 (41,085 clients served).

- Spending on insurance purchasing/continuation represented an estimated \$434 per capita in June 2012, about 59% of the average monthly cost per client for medications purchased by ADAPs, based on overall drug expenditures, in that month (\$1,054).

## ADAP ELIGIBILITY CRITERIA

The Ryan White Program requires all ADAP clients to be HIV-positive as well as low-income and uninsured or underinsured, but each ADAP determines its own income eligibility criteria. This determination is made by targeting those who may not qualify for other low-income programs, such as Medicaid, and by determining how many clients their program can serve given annual ADAP budgets. As a result of these factors, eligibility criteria vary by state, although some ADAPs set their eligibility criteria consistent with other health programs within their state (see Chart 26 and Tables 22-23).

- All ADAPs require that individuals provide clinical documentation of HIV infection. Three ADAPs reported additional clinical eligibility criteria (e.g., specific CD4 counts or viral load levels).
- ADAP income eligibility in June 2012 ranged from 200% FPL in eight states to 500% FPL in five. Overall, 21 states set income eligibility at greater than 300% FPL. Twenty-three states were between 201% and 300% FPL.
- A quarter of ADAPs (14) recognize domestic partnerships in the calculation of income.
- Thirteen ADAPs reported having asset limits in place in June 2012.
- All ADAPs require enrollees to be residents of the state in which they are seeking medications. Many ADAPs require documentation of residency and a few have specific residency requirements (e.g., must be a resident for 30 days).

## ADAP FORMULARY COVERAGE

- Antiretrovirals, the standard of care for HIV, are available on all ADAP formularies. Of the 32 antiretrovirals that are currently

available, ADAP coverage ranges from 28 in Wyoming to all 32 in 18 states (see Table 27).

- Coverage of “A1” opportunistic infection (OI) medications varies across all states. There are currently 31 medications classified as “A1” OIs by the CDC (see Table 28).
- Hepatitis B medications available on some ADAP formularies include Adefovir Dipivoxil (Hepsera), Entecavir (Baraclude), Interferon Alfa-2b (Intron A), Lamivudine (Epivir-HBV, Zeffix, Heptodin), Peginterferon alfa-2a (Pegasys) and Telbivudine (Tyzeka, Sebivo) (see Tables 30-31).
  - o In June 2012, 29 ADAPs covered at least one of these medications for HBV on their formularies.
  - o ADAPs filled 325 hepatitis B treatment prescriptions for 314 clients in June 2012. In FY2011, ADAPs filled 3,473 hepatitis B prescriptions.
- Hepatitis C (HCV) is classified as an HIV-related opportunistic infection, due to the relatively high co-infection rate of HIV and HCV.<sup>10</sup> Because there is no national funding source specifically for HCV treatment, most of the burden for treating co-infected patients has fallen on ADAPs and other parts of the Ryan White Program. Hepatitis C medications available on some ADAP formularies include Interferon Alfa-2b (Intron A), Recombinant Interferon Alfa-2a (Roferon), Consensus Interferon (Infergen), Peginterferon Alfa-2a (Pegasys), Peginterferon Alfa-2b (PEG-Intron), Recombinant Interferon Alfa-2a (Roferon), Ribavirin, Incivek (Telaprevir) and Victrelis (Boceprevir) (see Tables 32-34).
  - o In June 2012, 27 ADAPs covered at least one of these medications for HCV on their formularies.
  - o ADAPs filled 336 hepatitis C treatment prescriptions for 242 clients in June 2012.
  - o Ten ADAPs reported providing coverage for hepatitis C diagnostics in June 2012, including:
    - Nine ADAPs covered HCV screening.
    - Nine ADAPs covered qualitative HCV RNA.
    - Ten ADAPs covered quantitative viral load.
    - Seven ADAPs covered HCV genotype.

## ADAP AND HEPATITIS VACCINES

Hepatitis A and B vaccines are recommended for those at high risk for and living with HIV (see Table 35).<sup>11</sup>

- Twenty-five ADAPs covered the hepatitis A and B combination vaccine in June 2012.
- Twenty-five ADAPs covered the hepatitis A vaccine in June 2012.
- Twenty-five ADAPs covered the hepatitis B vaccine in June 2012.

## CHARTS AND TABLES

Charts for each major finding and tables, with data provided by states, are included in this module.

## ENDNOTES

- 1 For purposes of determining the overall ADAP budget, federal, state and drug rebate funds are counted.
- 2 The Ryan White Program requires that rebate funds, once received, remain in the Ryan White Part B program. This funding is considered a part of the national ADAP budget as it facilitates additional drug purchases and thus drives overall program expenditures.
- 3 This section contains all jurisdictions that received an increase in funding (either new funding or an increase in existing funding), level funding, or a decrease in existing funding (either eliminating a funding category or a reduction in the amount of funding received from a source) in FY2012.
- 4 This estimate is based on annualizing June 2012 average monthly cost per client. It is important to note that June 2012 expenditures may not be representative of monthly expenditures overall as prescribing patterns may not totally match that month's utilization.
- 5 U.S. Food and Drug Administration, "Drugs Used in the Treatment of HIV Infection." Available at: <http://www.fda.gov/oashi/aids/virals.html> (accessed January 3, 2013).
- 6 Centers for Disease Control and Prevention, "Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus." *MMWR* 2002; 51(RR08): 1-46. Available at: <http://www.aidsinfo.nih.gov/> (accessed January 3, 2013).
- 7 Centers for Disease Control and Prevention, "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents." *MMWR* 2004; 53(RR15): 1-112. Available at: <http://www.aidsinfo.nih.gov/> (accessed January 3, 2013).
- 8 Health Resources and Services Administration, HIV/AIDS Bureau, Policy Notice 07-05, "The Use of Ryan White HIV/AIDS Program Part B ADAP Funds to Purchase Health Insurance."
- 9 Health Resources and Services Administration, HIV/AIDS Bureau, DSS Program Policy Guidance No. 2, "Allowable Uses of Funds for Discretely Defined Categories of Services," Formerly Policy No. 97-02, First Issued: February 1, 1997, June 1, 2000.
- 10 Centers for Disease Control and Prevention, "Frequently Asked Questions and Answers About Coinfection with HIV and Hepatitis C Virus." Available at [http://www.cdc.gov/hiv/resources/qa/HIV-HCV\\_Coinfection.htm](http://www.cdc.gov/hiv/resources/qa/HIV-HCV_Coinfection.htm) (accessed April 15, 2011).
- 11 Centers for Disease Control and Prevention, "Sexually Transmitted Diseases Treatment Guidelines, 2006." *MMWR*, Vol. 55, September 2006.






## **Module One: Charts**




**Chart 1: The National ADAP Budget, FY1996-FY2012**




Note: The total FY2012 budget includes federal and state allocations as well as drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget. Percentages noted represent changes between the two years indicated, not aggregate changes since FY1996.

**Chart 2: The National ADAP Budget, by Source, FY1996-FY2012**




**Chart 3: The National ADAP Budget, by Source, FY2012**




Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. The total FY2012 budget does not include cost recovery funds, with the exception of drug rebate dollars.

**Chart 4: ADAP Expenditures, FY2011**




Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond.

**Chart 5: Part B ADAP Earmark, FY1996-FY2012**




Note: ADAP earmark does not include ADAP Supplemental Fund set-aside from FY2001-2012. Percentages noted represent changes between the two years indicated, not aggregate changes since FY1996.

**Chart 6: Part B ADAP Supplemental Funding, FY2001-FY2012**




Note: All Part B ADAP supplemental funds are reported. Percentages noted represent changes between the two years indicated, not aggregate changes since FY2001. The 2006 reauthorization of the Ryan White Program raised the percentage allocated to the ADAP supplemental from three percent to five percent of the ADAP Earmark, beginning in FY2007.

**Chart 7: Part B Base Contribution Directed to ADAP, FY1996-FY2012**




Note: Percentages noted represent changes between the two years indicated, not aggregate changes since FY1996.

**Chart 8: Part A Contribution Directed to ADAP, FY1996-FY2012**




Note: Percentages noted represent changes between the two years indicated, not aggregate changes since FY1996.

**Chart 9: State Contribution, FY1996-FY2012**




Note: Percentages noted represent changes between the two years indicated, not aggregate changes since FY1996.

**Chart 10: Estimated Drug Rebates, FY1996-FY2012**




Note: Percentages noted represent changes between the two years indicated, not aggregate changes since FY1996.

**Chart 11: ADAP Client Enrollment, June 2003-2012**



Note: Includes clients enrolled by ADAPs reporting data for June in a given year. Data on client enrollment in ADAP is not available prior to June 2003. Percentages noted represent changes between the two years indicated, not aggregate since 2003.

**Chart 12: ADAP Clients Enrolled and Top Ten States, by Clients Enrolled, FY2011**




State	Clients Enrolled, FY2011
California	44,390
New York	24,533
Texas	20,267
Florida	15,722
New Jersey	7,835
Maryland	7,441
Illinois	7,129
Pennsylvania	7,108
Massachusetts	7,104
North Carolina	6,867
<b>Total</b>	<b>148,396</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond.




**Chart 13: ADAP Client Utilization, June 1996-2012**



Note: Includes clients served by ADAPs reporting data for June in a given year. Percentages noted represent changes between the two years indicated, not aggregate since 1996.


**Chart 14: ADAP Clients Served and Top Ten States, by Clients Served, June 2012**



State	Clients Served, June 2012
California	26,253
New York	16,477
Florida	12,005
Texas	10,881
New Jersey	4,655
Puerto Rico	4,535
Illinois	4,484
North Carolina	4,419
Pennsylvania	4,249
Massachusetts	4,121
<b>Total</b>	<b>92,079</b>


Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond.

**Chart 15: ADAP Clients Served, by Race/Ethnicity, June 2012**




Note: 51 ADAPs reported data. American Samoa, Colorado, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Percentages may not total 100% due to rounding.

**Chart 16: ADAP Clients Served, by Gender, June 2012**




Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Percentages may not total 100% due to rounding.

**Chart 17: ADAP Clients Served, by Age, June 2012**




Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Percentages may not total 100% due to rounding.

**Chart 18: ADAP Clients Served, by Income Level, June 2012**




Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. The 2012 Federal Poverty Level (FPL) was \$11,170 (slightly higher in Alaska and Hawaii) for a household of one. Percentages may not total 100% due to rounding.

**Chart 19: ADAP Clients Served, by HIV/AIDS Status, June 2012**




Note: 49 ADAPs reported data. American Samoa, Colorado, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Republic of Palau, and Virgin Islands (U.S.) did not respond. Percentages may not total 100% due to rounding.

**Chart 20: ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2012**



Note: 30 ADAPs reported data (see Table 15).


**Chart 21: ADAP Drug Expenditures and Top 10 States, by Drug Expenditures, June 2012**



State	Clients Served, June 2012
California	\$38,142,929
New York	\$22,363,929
Texas	\$7,801,601
New Jersey	\$7,634,344
Pennsylvania	\$6,329,735
District of Columbia	\$5,180,507
Puerto Rico	\$4,268,509
Illinois	\$4,224,648
Michigan	\$3,636,995
North Carolina	\$3,386,601
<b>Total</b>	<b>\$102,969,798</b>


Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not respond.

**Chart 22: Percent Change in ADAP Drug Expenditures, June 1996-2012**




Note: Percentages noted represent changes between the two years indicated, not aggregate since 1996.

**Chart 23: ADAP Drug Expenditures and Prescriptions Filled  
(Including Drug Purchases and Co-Payments), June 2012**




**Total = \$138.8 million**




**Total = 449,154 prescriptions (Rx) filled**

Note: 49 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Kentucky, Marshall Islands, Mississippi, Northern Mariana Islands, Republic of Palau, and Virgin Islands (U.S.) did not respond.

**Chart 24: ADAP Drug Expenditures and Prescriptions Filled  
(Including Drug Purchases and Co-Payments), by Drug Category, June 2012**




**Total = \$138.8 million**



**Total = 449,154 prescriptions filled**


Note: 49 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Kentucky, Marshall Islands, Mississippi, Northern Mariana Islands, Republic of Palau, and Virgin Islands (U.S.) did not respond.

Chart 25: Clients Served and Estimated Expenditures in Insurance Purchasing and Continuation, 2012



Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Health insurance programs include purchasing health insurance and paying insurance premiums, co-payments, and/or deductibles. Client data for June 2002 and 2003 represent clients enrolled; June 2004-2012 data represent clients served. All ADAPs that have reported having insurance purchasing/maintenance programs since 2002 are included.

Chart 26: ADAP Income Eligibility, as of June 30, 2012



Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. The 2012 Federal Poverty Level (FPL) was \$11,170 (slightly higher in Alaska and Hawaii) for a household of one.





## **Module One: Tables**



**Table 1: The ADAP Budget, FY2011 and FY2012**

State/Territory	ADAP FY2011 Total Budget	ADAP FY2012 Total Budget	% Change
Alabama	\$17,725,286	\$19,209,519	8%
Alaska	\$639,879	\$820,344	28%
American Samoa	\$2,663	\$2,663	0%
Arizona	\$23,798,731	\$28,736,067	21%
Arkansas	\$5,049,258	\$4,869,589	-4%
California	\$452,181,453	\$444,712,103	-2%
Colorado	\$20,986,888	\$19,765,916	-6%
Connecticut	\$23,567,283	\$26,486,026	12%
Delaware	\$6,562,038	\$3,146,550	-52%
District of Columbia	\$16,432,779	\$15,234,732	-7%
Federated States of Micronesia	\$8,186	\$8,186	0%
Florida	\$114,427,754	\$135,441,397	18%
Georgia	\$49,349,266	\$56,828,928	15%
Guam	\$86,530	\$86,530	0%
Hawaii	\$3,758,420	\$3,579,397	-5%
Idaho	\$3,571,340	\$3,952,717	11%
Illinois	\$52,198,030	\$60,787,759	16%
Indiana	\$21,091,935	\$19,669,507	-7%
Iowa	\$3,584,364	\$4,506,593	26%
Kansas	\$9,858,934	\$10,950,805	11%
Kentucky	\$10,222,985	\$15,702,181	54%
Louisiana	\$20,012,105	\$25,962,124	30%
Maine	\$1,636,209	\$1,829,411	12%
Marshall Islands	\$0	\$2,820	--
Maryland	\$59,338,057	\$63,769,515	7%
Massachusetts	\$25,546,195	\$25,958,973	2%
Michigan	\$32,843,704	\$39,996,772	22%
Minnesota	\$12,165,439	\$14,312,009	18%
Mississippi	\$6,507,264	\$8,533,479	31%
Missouri	\$28,280,709	\$31,145,688	10%
Montana	\$1,099,364	\$1,584,096	44%
Nebraska	\$2,954,078	\$4,361,592	48%
Nevada	\$12,857,572	\$14,508,218	13%
New Hampshire	\$3,603,521	\$3,843,955	7%
New Jersey	\$82,498,782	\$92,741,939	12%
New Mexico	\$2,199,786	\$5,257,390	139%
New York	\$283,500,000	\$321,922,076	14%
North Carolina	\$57,516,959	\$59,081,650	3%
North Dakota	\$603,816	\$430,324	-29%
Northern Mariana Islands	\$8,845	\$7,276	-18%
Ohio	\$28,280,821	\$27,179,619	-4%
Oklahoma	\$10,321,074	\$12,817,932	24%
Oregon	\$11,240,296	\$9,464,609	-16%
Pennsylvania	\$70,193,736	\$75,381,428	7%
Puerto Rico	\$32,198,205	\$31,382,975	-3%
Republic of Palau	\$2,654	\$2,650	-0%
Rhode Island	\$7,552,533	\$8,121,128	8%
South Carolina	\$27,856,243	\$28,905,158	4%
South Dakota	\$429,263	\$1,420,845	231%
Tennessee	\$30,430,298	\$32,019,647	5%
Texas	\$102,383,814	\$117,957,639	15%
Utah	\$6,310,006	\$4,754,907	-25%
Vermont	\$1,162,356	\$992,356	-15%
Virgin Islands (U.S.)	\$821,138	\$2,043,439	149%
Virginia	\$30,502,722	\$30,349,460	-1%
Washington	\$35,327,625	\$34,497,293	-2%
West Virginia	\$3,879,033	\$5,001,442	29%
Wisconsin	\$17,370,799	\$19,167,472	10%
Wyoming	\$1,961,563	\$1,093,843	-44%
<b>Total</b>	<b>\$1,886,500,586</b>	<b>\$2,032,300,659</b>	
<b>Comparison Total¹</b>	<b>\$1,881,310,597</b>	<b>\$2,027,107,850</b>	<b>8%</b>

¹ **Comparison Totals** are based on only those states that reported data for both time periods.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. The total FY2012 budget includes federal, state, and drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget.

**Table 2: The National ADAP Budget, by Source, FY2012**

State/Territory	Part B ADAP Earmark	% of Total Budget	Part B ADAP Supplemental <sup>1</sup>	% of Total Budget	Part B Base Contribution Directed to ADAP	% of Total Budget	Part B Supplemental Directed to ADAP	% of Total Budget	ADAP Emergency Funding
Alabama	\$10,026,662	52%	\$794,332	4%	\$443,857	2%	\$0	0%	\$3,638,484
Alaska	\$589,363	72%	\$46,457	6%	\$0	0%	\$10,910	1%	\$173,614
American Samoa	\$2,663	100%	\$0	0%	--	--	--	--	\$0
Arizona	\$10,866,559	38%	\$860,870	3%	\$0	0%	\$0	0%	\$556,255
Arkansas	\$4,512,130	93%	\$357,459	7%	\$0	0%	\$0	0%	\$0
California	\$106,356,976	24%	\$8,425,807	2%	\$0	0%	\$2,129,954	0%	\$10,141,268
Colorado	\$9,879,172	50%	\$782,647	4%	\$0	0%	\$0	0%	\$1,059,508
Connecticut	\$10,972,770	41%	\$0	0%	\$0	0%	\$0	0%	\$0
Delaware	\$3,146,550	100%	\$0	0%	--	--	--	--	\$0
District of Columbia	\$15,234,732	100%	\$0	0%	\$0	0%	\$0	0%	\$0
Federated States of Micronesia	\$8,186	100%	\$0	0%	--	--	--	--	\$0
Florida	\$87,464,142	65%	\$6,929,081	5%	\$5,328,198	4%	\$1,862,436	1%	\$13,093,050
Georgia	\$31,517,790	55%	\$2,496,901	4%	\$0	0%	\$653,057	1%	\$9,092,692
Guam	\$86,530	100%	\$0	0%	--	--	--	--	\$0
Hawaii	\$2,049,128	57%	\$159,734	4%	\$0	0%	\$0	0%	\$0
Idaho	\$723,319	18%	\$57,303	1%	\$0	0%	\$0	0%	\$570,295
Illinois	\$29,557,287	49%	\$2,260,833	4%	\$0	0%	\$620,171	1%	\$7,877,968
Indiana	\$7,772,804	40%	\$615,777	3%	\$2,026,543	10%	\$0	0%	\$0
Iowa	\$1,616,206	36%	\$128,039	3%	\$25,418	1%	\$0	0%	\$703,948
Kansas	\$2,450,805	22%	\$0	0%	\$0	0%	\$0	0%	\$0
Kentucky	\$4,772,666	30%	\$378,100	2%	\$0	0%	\$0	0%	\$2,551,415
Louisiana	\$16,129,386	62%	\$1,277,802	5%	\$2,649,728	10%	\$203,993	1%	\$3,534,465
Maine	\$1,019,181	56%	\$0	0%	\$160,230	9%	\$0	0%	\$0
Marshall Islands	\$2,820	100%	\$0	0%	--	--	--	--	\$0
Maryland	\$29,800,019	47%	\$0	0%	\$0	0%	\$0	0%	\$0
Massachusetts	\$15,045,733	58%	\$0	0%	\$0	0%	\$0	0%	\$0
Michigan	\$12,996,772	32%	\$0	0%	\$0	0%	\$0	0%	\$0
Minnesota	\$5,976,431	42%	\$0	0%	\$74,619	1%	\$80,795	1%	\$0
Mississippi	\$7,533,479	88%	\$0	0%	\$0	0%	\$0	0%	\$0
Missouri	\$10,245,688	33%	\$0	0%	\$0	0%	\$0	0%	\$0
Montana	\$342,671	22%	\$27,147	2%	\$207,740	13%	\$0	0%	\$436,954
Nebraska	\$1,569,398	36%	\$124,331	3%	\$131,955	3%	\$124,331	3%	\$811,577
Nevada	\$6,188,392	43%	\$0	0%	\$2,165,324	15%	\$0	0%	\$0
New Hampshire	\$1,014,766	26%	\$0	0%	\$0	0%	\$0	0%	\$0
New Jersey	\$31,615,321	34%	\$2,497,671	3%	\$665,817	1%	\$0	0%	\$5,358,130
New Mexico	\$2,257,390	43%	\$0	0%	\$0	0%	\$0	0%	\$0
New York	\$119,859,704	37%	\$0	0%	\$1,190,357	0%	\$2,357,778	1%	\$0
North Carolina	\$22,302,764	38%	\$1,766,869	3%	\$0	0%	\$407,253	1%	\$3,000,000
North Dakota	\$167,803	39%	\$13,296	3%	\$93,901	22%	\$0	0%	\$74,324
Northern Mariana Islands	\$7,276	100%	\$0	0%	--	--	--	--	\$0
Ohio	\$15,547,375	57%	\$1,157,679	4%	\$0	0%	\$0	0%	\$0
Oklahoma	\$4,370,823	34%	\$346,266	3%	\$1,300,843	10%	\$0	0%	\$0
Oregon	\$4,603,980	49%	\$364,736	4%	\$0	0%	\$0	0%	\$0
Pennsylvania	\$30,114,428	40%	\$0	0%	\$0	0%	\$0	0%	\$0
Puerto Rico	\$19,811,944	63%	\$1,307,957	4%	\$3,350,554	11%	\$344,477	1%	\$2,525,278
Republic of Palau	\$2,650	100%	\$0	0%	--	--	--	--	\$0
Rhode Island	\$2,372,930	29%	\$197,236	0%	\$343,628	0%	\$0	0%	\$0
South Carolina	\$12,987,817	45%	\$1,027,601	4%	\$0	0%	\$230,884	1%	\$0
South Dakota	\$380,648	27%	\$30,155	2%	\$500,000	35%	\$0	0%	\$320,042
Tennessee	\$14,260,592	45%	\$1,129,752	4%	\$5,364,347	17%	\$276,756	1%	\$2,367,526
Texas	\$60,121,110	51%	\$4,495,450	4%	\$0	0%	\$0	0%	\$0
Utah	\$2,109,900	44%	\$167,151	4%	\$590,020	12%	\$38,481	1%	\$931,936
Vermont	\$392,356	40%	\$0	0%	\$0	0%	\$0	0%	\$0
Virgin Islands (U.S.)	\$613,013	30%	\$40,161	2%	\$0	0%	\$0	0%	\$1,190,265
Virginia	\$18,077,665	60%	\$1,401,312	5%	\$938,561	3%	\$384,466	1%	\$3,500,000
Washington	\$9,765,242	28%	\$773,621	2%	\$0	0%	\$95,215	0%	\$1,146,046
West Virginia	\$1,379,516	28%	\$109,288	2%	\$500,000	10%	\$0	0%	\$0
Wisconsin	\$4,682,583	24%	\$349,477	2%	\$450,755	2%	\$349,477	2%	\$344,960
Wyoming	\$210,195	19%	\$16,652	2%	\$200,000	18%	\$0	0%	\$0
Total	\$825,486,201	41%	\$42,914,950	2%	\$28,702,395	1%	\$10,170,434	1%	\$75,000,000

<sup>1</sup> Part B ADAP supplemental awards were provided to 36 states that met federal eligibility criteria, applied for funding, and were able to meet the mandated matching requirement or receive a waiver.

% of Total Budget	Part A Contribution Directed to ADAP	% of Total Budget	State Contribution	% of Total Budget	Estimated Drug Rebates	% of Total Budget	Other State or Federal	% of Total Budget	Total FY 2012 Budget
19%	\$0	0%	\$4,239,953	22%	\$66,231	0%	\$0	0%	\$19,209,519
21%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$820,344
0%	--	--	--	--	--	--	\$0	--	\$2,663
2%	\$0	0%	\$7,452,383	26%	\$9,000,000	31%	\$0	0%	\$28,736,067
0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$4,869,589
2%	\$0	0%	\$33,135,058	7%	\$284,523,040	64%	\$0	0%	\$444,712,103
5%	\$0	0%	\$4,477,589	23%	\$3,567,000	18%	\$0	0%	\$19,765,916
0%	\$0	0%	\$0	0%	\$15,513,256	59%	\$0	0%	\$26,486,026
0%	--	--	--	--	--	--	\$0	--	\$3,146,550
0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$15,234,732
0%	--	--	--	--	--	--	\$0	--	\$8,186
10%	\$0	0%	\$17,227,475	13%	\$3,537,015	3%	\$0	0%	\$135,441,397
16%	\$0	0%	\$11,668,488	21%	\$0	0%	\$1,400,000	2%	\$56,828,928
0%	--	--	--	--	--	--	\$0	0%	\$86,530
0%	\$0	0%	\$440,535	12%	\$930,000	26%	\$0	0%	\$3,579,397
14%	\$0	0%	\$801,800	20%	\$1,800,000	46%	\$0	0%	\$3,952,717
13%	\$0	0%	\$18,571,500	31%	\$1,900,000	3%	\$0	0%	\$60,787,759
0%	\$249,118	1%	\$0	0%	\$9,005,265	46%	\$0	0%	\$19,669,507
16%	\$0	0%	\$547,982	12%	\$1,485,000	33%	\$0	0%	\$4,506,593
0%	\$0	0%	\$3,000,000	27%	\$5,500,000	50%	\$0	0%	\$10,950,805
16%	\$0	0%	\$0	0%	\$8,000,000	51%	\$0	0%	\$15,702,181
14%	\$166,750	1%	\$0	0%	\$2,000,000	8%	\$0	0%	\$25,962,124
0%	\$0	0%	\$50,000	3%	\$600,000	33%	\$0	0%	\$1,829,411
0%	--	--	--	--	--	--	\$0	--	\$2,820
0%	\$0	0%	\$0	0%	\$33,969,496	53%	\$0	0%	\$63,769,515
0%	\$1,519,865	6%	\$1,893,375	7%	\$7,500,000	29%	\$0	0%	\$25,958,973
0%	\$0	0%	\$0	0%	\$27,000,000	68%	\$0	--	\$39,996,772
0%	\$120,000	1%	\$2,041,678	14%	\$6,018,486	42%	\$0	0%	\$14,312,009
0%	\$0	0%	\$1,000,000	12%	\$0	0%	\$0	0%	\$8,533,479
0%	\$0	0%	\$4,400,000	14%	\$16,500,000	53%	\$0	0%	\$31,145,688
28%	\$0	0%	\$271,041	17%	\$6,000	0%	\$292,543	18%	\$1,584,096
19%	\$0	0%	\$900,000	21%	\$700,000	16%	\$0	0%	\$4,361,592
0%	\$0	0%	\$1,844,797	13%	\$4,309,705	30%	\$0	0%	\$14,508,218
0%	\$549,189	14%	\$180,000	5%	\$2,100,000	55%	\$0	0%	\$3,843,955
6%	\$105,000	0%	\$6,500,000	7%	\$46,000,000	50%	\$0	0%	\$92,741,939
0%	\$0	0%	\$1,000,000	19%	\$0	0%	\$2,000,000	38%	\$5,257,390
0%	\$11,928,695	4%	\$42,300,000	13%	\$128,285,542	40%	\$16,000,000	5%	\$321,922,076
5%	\$0	0%	\$28,604,764	48%	\$3,000,000	5%	\$0	0%	\$59,081,650
17%	\$0	0%	\$0	0%	\$81,000	19%	\$0	0%	\$430,324
0%	--	--	--	--	--	--	\$0	--	\$7,276
0%	\$0	0%	\$5,474,565	20%	\$5,000,000	18%	\$0	0%	\$27,179,619
0%	\$0	0%	\$1,800,000	14%	\$5,000,000	39%	\$0	0%	\$12,817,932
0%	\$0	0%	\$1,225,000	13%	\$3,270,893	35%	\$0	0%	\$9,464,609
0%	\$0	0%	\$10,267,000	14%	\$35,000,000	46%	\$0	0%	\$75,381,428
8%	\$0	0%	\$4,042,765	13%	\$0	0%	\$0	0%	\$31,382,975
0%	--	--	--	--	--	--	\$0	--	\$2,650
0%	\$0	0%	\$1,944,384	24%	\$1,200,000	15%	\$2,062,950	0%	\$8,121,128
0%	\$0	0%	\$5,658,856	20%	\$8,000,000	28%	\$1,000,000	3%	\$28,905,158
23%	\$0	0%	\$0	0%	\$190,000	13%	\$0	0%	\$1,420,845
7%	\$0	0%	\$1,000,000	3%	\$6,500,000	20%	\$1,120,674	3%	\$32,019,647
0%	\$945,035	1%	\$32,396,044	27%	\$20,000,000	17%	\$0	0%	\$117,957,639
20%	\$0	0%	\$101,714	2%	\$815,706	17%	\$0	0%	\$4,754,907
0%	\$0	0%	\$0	0%	\$600,000	60%	\$0	0%	\$992,356
58%	\$0	0%	\$200,000	10%	\$0	0%	\$0	0%	\$2,043,439
12%	\$0	0%	\$5,047,456	17%	\$1,000,000	3%	\$0	0%	\$30,349,460
3%	\$475,226	1%	\$10,766,541	31%	\$11,316,438	33%	\$158,964	0%	\$34,497,293
0%	\$0	0%	\$27,322	1%	\$2,985,316	60%	\$0	0%	\$5,001,442
2%	\$0	0%	\$1,306,220	7%	\$11,684,000	61%	\$0	0%	\$19,167,472
0%	\$0	0%	\$367,500	34%	\$299,496	27%	\$0	0%	\$1,093,843
4%	\$16,058,878	1%	\$274,173,785	13%	\$735,758,885	36%	\$24,035,131	1%	\$2,032,300,659

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. The total FY2012 budget includes federal, state, and drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget. A dash (--) indicates the ADAP did not report data.

**Table 3: Major FY2012 Budget Categories Compared with FY2011**

State/Territory	2011 Part B ADAP Earmark	2012 Part B ADAP Earmark	% Change	2011 Part B ADAP Supplemental	2012 Part B ADAP Supplemental	% Change	2011 Part B Base Contribution Directed to ADAP	2012 Part B Base Contribution Directed to ADAP	% Change	2011 Part B Supplemental Directed to ADAP	2012 Part B Supplemental Directed to ADAP	
Alabama	\$9,677,468	\$10,026,662	4%	\$745,200	\$794,332	7%	\$1,500,000	\$443,857	-70%	\$82,000	\$0	
Alaska	\$589,363	\$589,363	0%	\$44,817	\$46,457	4%	\$0	\$0	--	\$5,699	\$10,910	
American Samoa	\$2,663	\$2,663	0%	\$0	\$0	--	--	--	--	--	--	
Arizona	\$10,674,315	\$10,866,559	2%	\$821,961	\$860,870	5%	\$803,550	\$0	-100%	\$0	\$0	
Arkansas	\$4,415,494	\$4,512,130	2%	\$340,009	\$357,459	5%	\$250,000	\$0	-100%	\$0	\$0	
California	\$103,750,158	\$106,356,976	3%	\$8,028,154	\$8,425,807	5%	\$0	\$0	--	\$1,376,784	\$2,129,954	
Colorado	\$9,731,767	\$9,879,172	2%	\$747,312	\$782,647	5%	\$0	\$0	--	\$104,962	\$0	
Connecticut	\$10,972,770	\$10,972,770	0%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
Delaware	\$3,146,550	\$3,146,550	--	\$0	\$0	--	\$0	--	--	\$0	--	
District of Columbia	\$15,257,867	\$15,234,732	-0%	\$1,174,912	\$0	-100%	\$0	\$0	--	\$0	\$0	
Federated States of Micronesia	\$8,186	\$8,186	0%	\$0	\$0	--	--	--	--	--	--	
Florida	\$86,207,390	\$87,464,142	1%	\$6,638,284	\$6,929,081	4%	\$3,024,805	\$5,328,198	76%	\$1,077,279	\$1,862,436	
Georgia	\$30,721,825	\$31,517,790	3%	\$2,365,693	\$2,496,901	6%	\$1,500,000	\$0	-100%	\$382,700	\$653,057	
Guam	\$86,530	\$86,530	0%	\$0	\$0	--	--	--	--	--	--	
Hawaii	\$2,049,128	\$2,049,128	0%	\$151,751	\$159,734	5%	\$274,000	\$0	-100%	\$0	\$0	
Idaho	\$689,921	\$723,319	5%	\$53,126	\$57,303	8%	\$50,918	\$0	-100%	\$8,202	\$0	
Illinois	\$29,557,287	\$29,557,287	0%	\$2,201,478	\$2,260,833	3%	\$0	\$0	--	\$344,830	\$620,171	
Indiana	\$7,685,542	\$7,772,804	1%	\$591,815	\$615,777	4%	\$2,096,044	\$2,026,543	-3%	\$0	\$0	
Iowa	\$1,555,860	\$1,616,206	4%	\$119,807	\$128,039	7%	\$0	\$25,418	--	\$0	\$0	
Kansas	\$2,498,752	\$2,450,805	-2%	\$0	\$0	--	\$0	\$0	--	\$60,182	\$0	
Kentucky	\$4,225,323	\$4,772,666	13%	\$325,365	\$378,100	16%	\$0	\$0	--	\$0	\$0	
Louisiana	\$15,606,365	\$16,129,386	3%	\$1,201,747	\$1,277,802	6%	\$0	\$2,649,728	--	\$203,993	\$203,993	
Maine	\$958,813	\$1,019,181	6%	\$0	\$0	--	\$127,396	\$160,230	26%	\$0	\$0	
Marshall Islands	\$0	\$2,820	--	\$0	\$0	--	--	--	--	--	--	
Maryland	\$30,408,708	\$29,800,019	-2%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
Massachusetts	\$15,013,298	\$15,045,733	0%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
Michigan	\$12,574,251	\$12,996,772	3%	\$0	\$0	--	\$269,453	\$0	-100%	\$0	\$0	
Minnesota	\$5,738,727	\$5,976,431	4%	\$0	\$0	--	\$0	\$74,619	--	\$71,908	\$80,795	
Mississippi	\$6,507,264	\$7,533,479	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
Missouri	\$10,246,210	\$10,245,688	-0%	\$0	\$0	--	\$0	\$0	--	\$126,843	\$0	
Montana	\$330,808	\$342,671	4%	\$25,473	\$27,147	7%	\$213,494	\$207,740	-3%	\$7,095	\$0	
Nebraska	\$1,423,183	\$1,569,398	10%	\$109,590	\$124,331	13%	\$21,305	\$131,955	519%	\$0	\$124,331	
Nevada	\$6,212,826	\$6,188,392	-0%	\$0	\$0	--	\$2,189,758	\$2,165,324	-1%	\$57,198	\$0	
New Hampshire	\$1,007,461	\$1,014,766	1%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
New Jersey	\$31,615,321	\$31,615,321	0%	\$2,415,686	\$2,497,671	3%	\$352,764	\$665,817	89%	\$367,128	\$0	
New Mexico	\$2,199,786	\$2,257,390	3%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
New York	\$119,859,704	\$119,859,704	0%	\$0	\$0	--	\$1,190,357	\$1,190,357	0%	\$1,401,646	\$2,357,778	
North Carolina	\$21,500,767	\$22,302,764	4%	\$1,655,638	\$1,766,869	7%	\$0	\$0	--	\$177,406	\$407,253	
North Dakota	\$165,404	\$167,803	1%	\$12,737	\$13,296	4%	\$50,029	\$93,901	88%	\$1,322	\$0	
Northern Mariana Islands	\$8,845	\$7,276	-18%	\$0	\$0	--	--	--	--	--	--	
Ohio	\$15,066,049	\$15,547,375	3%	\$1,157,679	\$1,157,679	0%	\$0	\$0	--	\$0	\$0	
Oklahoma	\$4,281,048	\$4,370,823	2%	\$329,656	\$346,266	5%	\$228,070	\$1,300,843	470%	\$0	\$0	
Oregon	\$4,566,746	\$4,603,980	1%	\$351,656	\$364,736	4%	\$0	\$0	--	\$0	\$0	
Pennsylvania	\$30,028,414	\$30,114,428	0%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
Puerto Rico	\$19,811,944	\$19,811,944	0%	\$1,237,710	\$1,307,957	6%	\$4,119,975	\$3,350,554	-19%	\$199,352	\$344,477	
Republic of Palau	\$2,654	\$2,650	-0%	\$0	\$0	--	--	--	--	--	--	
Rhode Island	\$2,259,933	\$2,372,930	5%	\$0	\$197,236	--	\$0	\$343,628	--	\$26,795	\$0	
South Carolina	\$13,043,044	\$12,987,817	-0%	\$1,004,362	\$1,027,601	2%	\$0	\$0	--	\$149,981	\$230,884	
South Dakota	\$356,459	\$380,648	7%	\$27,449	\$30,155	10%	\$45,355	\$500,000	1002%	\$0	\$0	
Tennessee	\$13,778,959	\$14,260,592	3%	\$1,061,030	\$1,129,752	6%	\$400,000	\$5,364,347	1241%	\$168,479	\$276,756	
Texas	\$58,379,694	\$60,121,110	3%	\$4,495,450	\$4,495,450	0%	\$0	\$0	--	\$584,119	\$0	
Utah	\$2,066,225	\$2,109,900	2%	\$0	\$167,151	--	\$836,527	\$590,020	-29%	\$26,006	\$38,481	
Vermont	\$392,356	\$392,356	0%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	
Virgin Islands (U.S.)	\$613,013	\$613,013	0%	\$38,687	\$40,161	4%	--	\$0	--	--	\$0	
Virginia	\$18,197,991	\$18,077,665	-1%	\$1,401,312	\$1,401,312	0%	\$921,479	\$938,561	2%	\$230,895	\$384,466	
Washington	\$9,494,373	\$9,765,242	3%	\$731,101	\$773,621	6%	\$614,143	\$0	-100%	\$121,213	\$95,215	
West Virginia	\$1,370,633	\$1,379,516	1%	\$103,120	\$109,288	6%	\$460,000	\$500,000	9%	\$0	\$0	
Wisconsin	\$4,538,441	\$4,682,583	3%	\$349,477	\$349,477	0%	\$450,795	\$450,755	-0%	\$0	\$349,477	
Wyoming	\$212,283	\$210,195	-1%	\$16,347	\$16,652	2%	\$325,000	\$200,000	-38%	\$3,958	\$0	
<b>Total</b>	<b>\$813,342,159</b>	<b>\$825,486,201</b>	<b>1%</b>	<b>\$42,075,591</b>	<b>\$42,914,950</b>	<b>2%</b>	<b>\$22,315,217</b>	<b>\$28,702,395</b>	<b>29%</b>	<b>\$7,367,975</b>	<b>\$10,170,434</b>	

<sup>1</sup> Part B ADAP Supplemental awards were provided to states that met federal eligibility criteria, applied for funding, and were able to meet the mandated matching requirement or receive a waiver.

	% Change	2011 ADAP Emergency Funding	2012 ADAP Emergency Funding	% Change	2011 Part A Contribution Directed to ADAP	2012 Part A Contribution Directed to ADAP	% Change	2011 State Contribution	2012 State Contribution	% Change	2011 Estimated Drug Rebates	2012 Estimated Drug Rebates	% Change
	-100%	\$1,054,365	\$3,638,484	245%	\$0	\$0	--	\$4,426,253	\$4,239,953	-4%	\$240,000	\$66,231	-72%
	91%	\$0	\$173,614	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
	--	\$0	\$0	--	--	--	--	--	--	--	--	--	--
	--	\$455,866	\$556,255	22%	\$0	\$0	--	\$7,356,261	\$7,452,383	1%	\$3,233,505	\$9,000,000	178%
	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
	55%	\$2,574,357	\$10,141,268	294%	\$0	\$0	--	\$78,714,574	\$33,135,058	-58%	\$264,153,045	\$284,523,040	8%
	-100%	\$285,430	\$1,059,508	271%	\$200,000	\$0	-100%	\$4,652,179	\$4,477,589	-4%	\$5,265,238	\$3,567,000	-32%
	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$12,594,513	\$15,513,256	23%
	--	\$0	\$0	--	\$0	--	--	\$0	--	--	\$3,415,488	--	--
	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
	--	\$0	\$0	--	--	--	--	--	--	--	--	--	--
	73%	\$6,979,996	\$13,093,050	88%	\$0	\$0	--	\$10,500,000	\$17,227,475	64%	\$0	\$3,537,015	--
	71%	\$3,000,000	\$9,092,692	203%	\$0	\$0	--	\$11,379,048	\$11,668,488	3%	\$0	\$0	--
	--	\$0	\$0	--	--	--	--	--	--	--	--	--	--
	--	\$243,541	\$0	-100%	\$0	\$0	--	\$440,000	\$440,535	0%	\$600,000	\$930,000	55%
	-100%	\$467,373	\$570,295	22%	\$0	\$0	--	\$801,800	\$801,800	0%	\$1,500,000	\$1,800,000	20%
	80%	\$722,935	\$7,877,968	990%	\$0	\$0	--	\$18,571,500	\$18,571,500	0%	\$800,000	\$1,900,000	138%
	--	\$0	\$0	--	\$320,534	\$249,118	-22%	\$0	\$0	--	\$10,398,000	\$9,005,265	-13%
	--	\$709,751	\$703,948	-1%	\$0	\$0	--	\$498,946	\$547,982	10%	\$700,000	\$1,485,000	112%
	-100%	\$0	\$0	--	\$0	\$0	--	\$800,000	\$3,000,000	275%	\$6,500,000	\$5,500,000	-15%
	--	\$2,090,956	\$2,551,415	22%	\$0	\$0	--	\$81,341	\$0	-100%	\$3,500,000	\$8,000,000	129%
	0%	\$3,000,000	\$3,534,465	18%	\$0	\$166,750	--	\$0	\$0	--	\$0	\$2,000,000	--
	--	\$0	\$0	--	\$0	\$0	--	\$50,000	\$50,000	0%	\$500,000	\$600,000	20%
	--	\$0	\$0	--	--	--	--	--	--	--	--	--	--
	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$28,929,349	\$33,969,496	17%
	--	\$0	\$0	--	\$1,139,522	\$1,519,865	33%	\$1,893,375	\$1,893,375	0%	\$7,500,000	\$7,500,000	0%
	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$20,000,000	\$27,000,000	35%
	12%	\$0	\$0	--	\$0	\$120,000	--	\$0	\$2,041,678	--	\$6,354,804	\$6,018,486	-5%
	--	\$0	\$0	--	\$0	\$0	--	\$0	\$1,000,000	--	\$0	\$0	--
	-100%	\$307,656	\$0	-100%	\$0	\$0	--	\$4,200,000	\$4,400,000	5%	\$13,400,000	\$16,500,000	23%
	-100%	\$348,241	\$436,954	25%	\$0	\$0	--	\$164,036	\$271,041	65%	\$10,217	\$6,000	-41%
	--	\$0	\$811,577	--	\$0	\$0	--	\$900,000	\$900,000	0%	\$500,000	\$700,000	40%
	-100%	\$0	\$0	--	\$0	\$0	--	\$1,840,198	\$1,844,797	0%	\$2,557,592	\$4,309,705	69%
	--	\$0	\$0	--	\$516,060	\$549,189	6%	\$180,000	\$180,000	0%	\$1,900,000	\$2,100,000	11%
	-100%	\$736,383	\$5,358,130	628%	\$187,500	\$105,000	-44%	\$6,509,000	\$6,500,000	-0%	\$40,000,000	\$46,000,000	15%
	--	\$0	\$0	--	\$0	\$0	--	\$0	\$1,000,000	--	\$0	\$0	--
	68%	\$0	\$0	--	\$13,186,324	\$11,928,695	-10%	\$42,300,000	\$42,300,000	0%	\$104,152,679	\$128,285,542	23%
	130%	\$3,000,000	\$3,000,000	0%	\$0	\$0	--	\$28,617,246	\$28,604,764	-0%	\$0	\$3,000,000	--
	-100%	\$74,324	\$74,324	0%	\$0	\$0	--	\$0	\$0	--	\$300,000	\$81,000	-73%
	--	\$0	\$0	--	--	--	--	--	--	--	--	--	--
	--	\$1,237,528	\$0	-100%	\$395,000	\$0	-100%	\$5,424,565	\$5,474,565	1%	\$5,000,000	\$5,000,000	0%
	--	\$0	\$0	--	\$0	\$0	--	\$1,482,300	\$1,800,000	21%	\$4,000,000	\$5,000,000	25%
	--	\$321,920	\$0	-100%	\$0	\$0	--	\$1,725,000	\$1,225,000	-29%	\$4,026,664	\$3,270,893	-19%
	--	\$0	\$0	--	\$0	\$0	--	\$10,267,000	\$10,267,000	0%	\$29,000,000	\$35,000,000	21%
	73%	\$2,069,536	\$2,525,278	22%	\$0	\$0	--	\$0	\$4,042,765	--	\$0	\$0	--
	--	\$0	\$0	--	--	--	--	--	--	--	--	--	--
	-100%	\$427,606	\$0	-100%	\$0	\$0	--	\$2,134,715	\$1,944,384	-9%	\$1,036,923	\$1,200,000	16%
	54%	\$3,000,000	\$0	-100%	\$0	\$0	--	\$4,658,856	\$5,658,856	21%	\$6,000,000	\$8,000,000	33%
	--	\$0	\$320,042	--	\$0	\$0	--	\$0	\$0	--	\$0	\$190,000	--
	64%	\$1,021,830	\$2,367,526	132%	\$0	\$0	--	\$7,000,000	\$1,000,000	-86%	\$7,000,000	\$6,500,000	-7%
	-100%	\$786,424	\$0	-100%	\$0	\$945,035	--	\$32,138,127	\$32,396,044	1%	\$6,000,000	\$20,000,000	233%
	48%	\$931,936	\$931,936	0%	\$0	\$0	--	\$427,220	\$101,714	-76%	\$1,000,000	\$815,706	-18%
	--	\$0	\$0	--	\$0	\$0	--	\$70,000	\$0	-100%	\$700,000	\$600,000	-14%
	--	\$169,438	\$1,190,265	602%	--	\$0	--	--	\$200,000	--	--	\$0	--
	67%	\$3,000,000	\$3,500,000	17%	\$909,832	\$0	-100%	\$4,899,336	\$5,047,456	3%	\$750,000	\$1,000,000	33%
	-21%	\$660,158	\$1,146,046	74%	\$491,635	\$475,226	-3%	\$11,825,586	\$10,766,541	-9%	\$11,389,416	\$11,316,438	-1%
	--	\$0	\$0	--	\$0	\$0	--	\$25,780	\$27,322	6%	\$1,919,500	\$2,985,316	56%
	--	\$180,263	\$344,960	91%	\$0	\$0	--	\$1,306,220	\$1,306,220	0%	\$10,545,603	\$11,684,000	11%
	-100%	\$142,187	\$0	-100%	\$0	\$0	--	\$735,000	\$367,500	-50%	\$526,788	\$299,496	-43%
	<b>38%</b>	<b>\$40,000,000</b>	<b>\$75,000,000</b>	<b>88%</b>	<b>\$17,346,407</b>	<b>\$16,058,878</b>	<b>-7%</b>	<b>\$308,995,462</b>	<b>\$274,173,785</b>	<b>-11%</b>	<b>\$627,899,324</b>	<b>\$735,758,885</b>	<b>17%</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. This table does not include the "Other State or Federal" category (\$24,035,131), which is reported in the total budget in Tables 1 and 2. A dash (--) indicates the ADAP did not report data.

**Table 4: Growth of Federal ADAP Funding, FY2008 through FY2012**

State/Territory	2008 Federal Contribution	2009 Federal Contribution	% Change	2009 Federal Contribution	2010 Federal Contribution	% Change	2010 Federal Contribution
Alabama	\$11,238,171	\$10,961,499	-2%	\$10,961,499	\$10,966,525	0%	\$10,966,525
Alaska	\$633,064	\$686,621	8%	\$686,621	\$717,360	4%	\$717,360
American Samoa	\$1,978	\$2,803	42%	\$2,803	\$2,663	-5%	\$2,663
Arizona	\$9,610,361	\$11,624,545	21%	\$11,624,545	\$12,561,368	8%	\$12,561,368
Arkansas	\$4,245,310	\$4,174,689	-2%	\$4,174,689	\$5,015,754	20%	\$5,015,754
California	\$89,623,287	\$94,104,451	5%	\$94,104,451	\$101,232,811	8%	\$101,232,811
Colorado	\$9,527,197	\$9,612,191	1%	\$9,612,191	\$9,953,123	4%	\$9,953,123
Connecticut	\$11,471,742	\$11,550,284	1%	\$11,550,284	\$10,972,770	-5%	\$10,972,770
Delaware	\$3,291,545	\$2,664,690	-19%	\$2,664,690	\$2,289,869	-14%	\$2,289,869
District of Columbia	\$14,392,258	\$14,429,241	0%	\$14,429,241	\$14,964,194	4%	\$14,964,194
Federated States of Micronesia	\$4,934	\$7,475	51%	\$7,475	\$8,186	10%	\$8,186
Florida	\$83,509,558	\$83,621,697	0%	\$83,621,697	\$92,168,431	10%	\$92,168,431
Georgia	\$31,004,376	\$31,475,700	2%	\$31,475,700	\$34,478,154	10%	\$34,478,154
Guam	\$91,055	\$91,084	0%	\$91,084	\$86,530	-5%	\$86,530
Hawaii	\$2,057,066	\$2,427,295	18%	\$2,427,295	\$2,509,815	3%	\$2,509,815
Idaho	\$731,554	\$741,062	1%	\$741,062	\$1,081,022	46%	\$1,081,022
Illinois	\$27,628,149	\$29,009,556	5%	\$29,009,556	\$34,065,199	17%	\$34,065,199
Indiana	\$9,279,327	\$9,078,290	-2%	\$9,078,290	\$8,681,396	-4%	\$8,681,396
Iowa	\$1,694,654	\$1,720,997	2%	\$1,720,997	\$2,378,775	38%	\$2,378,775
Kansas	\$2,265,222	\$2,456,542	8%	\$2,456,542	\$2,439,308	-1%	\$2,439,308
Kentucky	\$4,307,876	\$4,562,107	6%	\$4,562,107	\$6,546,932	44%	\$6,546,932
Louisiana	\$18,748,508	\$18,750,876	0%	\$18,750,876	\$18,749,261	-0%	\$18,749,261
Maine	\$871,574	\$866,121	-1%	\$866,121	\$898,597	4%	\$898,597
Marshall Islands	\$2,893	\$2,968	3%	\$2,968	\$0	-100%	\$0
Maryland	\$26,541,994	\$27,869,094	5%	\$27,869,094	\$29,262,549	5%	\$29,262,549
Massachusetts	\$14,782,288	\$14,865,398	1%	\$14,865,398	\$15,013,298	1%	\$15,013,298
Michigan	\$11,681,534	\$12,219,172	5%	\$12,219,172	\$12,433,924	2%	\$12,433,924
Minnesota	\$5,143,281	\$5,444,759	6%	\$5,444,759	\$5,548,017	2%	\$5,548,017
Mississippi	\$7,277,816	\$7,610,703	5%	\$7,610,703	\$7,533,479	-1%	\$7,533,479
Missouri	\$9,789,559	\$10,102,752	3%	\$10,102,752	\$10,375,045	3%	\$10,375,045
Montana	\$364,893	\$361,090	-1%	\$361,090	\$505,782	40%	\$505,782
Nebraska	\$1,256,366	\$1,626,559	29%	\$1,626,559	\$1,611,121	-1%	\$1,611,121
Nevada	\$5,784,830	\$6,224,050	8%	\$6,224,050	\$6,101,000	-2%	\$6,101,000
New Hampshire	\$998,421	\$999,945	0%	\$999,945	\$1,002,281	0%	\$1,002,281
New Jersey	\$33,221,747	\$33,279,285	0%	\$33,279,285	\$32,258,048	-3%	\$32,258,048
New Mexico	\$2,238,552	\$2,243,691	0%	\$2,243,691	\$2,150,993	-4%	\$2,150,993
New York	\$125,611,598	\$126,168,109	0%	\$126,168,109	\$119,859,704	-5%	\$119,859,704
North Carolina	\$18,587,094	\$23,920,644	29%	\$23,920,644	\$26,472,130	11%	\$26,472,130
North Dakota	\$143,526	\$150,440	5%	\$150,440	\$223,758	49%	\$223,758
Northern Mariana Islands	\$3,958	\$5,606	42%	\$5,606	\$7,276	30%	\$7,276
Ohio	\$14,529,892	\$13,805,298	-5%	\$13,805,298	\$16,304,363	18%	\$16,304,363
Oklahoma	\$5,277,945	\$5,101,885	-3%	\$5,101,885	\$4,919,318	-4%	\$4,919,318
Oregon	\$5,214,754	\$5,204,101	-0%	\$5,204,101	\$5,372,354	3%	\$5,372,354
Pennsylvania	\$28,159,902	\$16,341,059	-42%	\$16,341,059	\$30,028,414	84%	\$30,028,414
Puerto Rico	\$22,287,304	\$24,008,337	8%	\$24,008,337	\$24,123,215	0%	\$24,123,215
Republic of Palau	\$0	\$0	--	\$0	\$0	--	\$0
Rhode Island	\$2,002,014	\$2,102,115	5%	\$2,102,115	\$2,286,237	9%	\$2,286,237
South Carolina	\$16,520,224	\$15,922,450	-4%	\$15,922,450	\$16,517,826	4%	\$16,517,826
South Dakota	\$305,924	\$329,844	8%	\$329,844	\$378,178	15%	\$378,178
Tennessee	\$12,597,325	\$12,945,202	3%	\$12,945,202	\$15,781,399	22%	\$15,781,399
Texas	\$67,228,159	\$67,359,999	0%	\$67,359,999	\$66,057,009	-2%	\$66,057,009
Utah	\$2,583,743	\$2,492,188	-4%	\$2,492,188	\$3,052,913	22%	\$3,052,913
Vermont	\$402,212	\$413,006	3%	\$413,006	\$392,356	-5%	\$392,356
Virgin Islands (U.S.)	\$640,973	\$517,680	-19%	\$517,680	\$730,213	41%	\$730,213
Virginia	\$20,865,729	\$20,737,520	-1%	\$20,737,520	\$21,131,215	2%	\$21,131,215
Washington	\$8,694,418	\$9,487,916	9%	\$9,487,916	\$9,516,983	0%	\$9,516,983
West Virginia	\$1,373,538	\$1,374,271	0%	\$1,374,271	\$1,579,674	15%	\$1,579,674
Wisconsin	\$5,334,671	\$5,222,988	-2%	\$5,222,988	\$5,203,906	-0%	\$5,203,906
Wyoming	\$180,188	\$193,421	7%	\$193,421	\$280,854	45%	\$280,854
<b>Total</b>	<b>\$813,858,031</b>	<b>\$821,273,361</b>	<b>1%</b>	<b>\$821,273,361</b>	<b>\$866,782,875</b>	<b>6%</b>	<b>\$866,782,875</b>

Note: Federal funding to ADAP includes only funding distributed directly to states from HRSA (ADAP Earmark, ADAP Supplemental and ADAP Emergency Relief Funding, when applicable).



2011 Federal Contribution	% Change	2011 Federal Contribution	2012 Federal Contribution	% Change	2008 Federal Contribution	2012 Federal Contribution	% Change
\$11,477,033	5%	\$11,477,033	\$14,903,335	30%	\$11,238,171	\$25,513,583	127%
\$634,180	-12%	\$634,180	\$820,344	29%	\$633,064	\$820,344	30%
\$2,663	0%	\$2,663	\$2,663	0%	\$1,978	\$2,663	35%
\$11,952,142	-5%	\$11,952,142	\$12,283,684	3%	\$9,610,361	\$12,283,684	28%
\$4,755,503	-5%	\$4,755,503	\$4,869,589	2%	\$4,245,310	\$4,869,589	15%
\$114,352,669	13%	\$114,352,669	\$127,054,005	11%	\$89,623,287	\$127,054,005	42%
\$10,764,509	8%	\$10,764,509	\$11,721,327	9%	\$9,527,197	\$11,721,327	23%
\$10,972,770	0%	\$10,972,770	\$10,972,770	0%	\$11,471,742	\$10,972,770	-4%
\$3,146,550	37%	\$3,146,550	\$3,146,550	0%	\$3,291,545	\$3,146,550	-4%
\$16,432,779	10%	\$16,432,779	\$15,234,732	-7%	\$14,392,258	\$15,234,732	6%
\$8,186	0%	\$8,186	\$8,186	0%	\$4,934	\$8,186	66%
\$99,825,670	8%	\$99,825,670	\$114,676,907	15%	\$83,509,558	\$114,676,907	37%
\$36,087,518	5%	\$36,087,518	\$43,760,440	21%	\$31,004,376	\$43,760,440	41%
\$86,530	0%	\$86,530	\$86,530	0%	\$91,055	\$86,530	-5%
\$2,444,420	-3%	\$2,444,420	\$2,208,862	-10%	\$2,057,066	\$2,208,862	7%
\$1,210,420	12%	\$1,210,420	\$1,350,917	12%	\$731,554	\$1,350,917	85%
\$32,481,700	-5%	\$32,481,700	\$40,316,259	24%	\$27,628,149	\$40,316,259	46%
\$8,277,357	-5%	\$8,277,357	\$10,664,242	29%	\$9,279,327	\$10,664,242	15%
\$2,385,418	0%	\$2,385,418	\$2,473,611	4%	\$1,694,654	\$2,473,611	46%
\$2,498,752	2%	\$2,498,752	\$2,450,805	-2%	\$2,265,222	\$2,450,805	8%
\$6,641,644	1%	\$6,641,644	\$7,702,181	16%	\$4,307,876	\$7,702,181	79%
\$19,808,112	6%	\$19,808,112	\$23,962,124	21%	\$18,748,508	\$23,962,124	28%
\$958,813	7%	\$958,813	\$1,179,411	23%	\$871,574	\$1,179,411	35%
\$0	--	\$0	\$2,820	--	\$2,893	\$2,820	-3%
\$30,408,708	4%	\$30,408,708	\$29,800,019	-2%	\$26,541,994	\$29,800,019	12%
\$15,013,298	0%	\$15,013,298	\$16,565,598	10%	\$14,782,288	\$16,565,598	12%
\$12,574,251	1%	\$12,574,251	\$12,996,772	3%	\$11,681,534	\$12,996,772	11%
\$5,738,727	3%	\$5,738,727	\$6,251,845	9%	\$5,143,281	\$6,251,845	22%
\$6,507,264	-14%	\$6,507,264	\$7,533,479	16%	\$7,277,816	\$7,533,479	4%
\$10,553,866	2%	\$10,553,866	\$10,245,688	-3%	\$9,789,559	\$10,245,688	5%
\$704,522	39%	\$704,522	\$1,014,512	44%	\$364,893	\$1,014,512	178%
\$1,532,773	-5%	\$1,532,773	\$2,761,592	80%	\$1,256,366	\$2,761,592	120%
\$6,212,826	2%	\$6,212,826	\$8,353,716	34%	\$5,784,830	\$8,353,716	44%
\$1,007,461	1%	\$1,007,461	\$1,563,955	55%	\$998,421	\$1,563,955	57%
\$34,767,390	8%	\$34,767,390	\$40,241,939	16%	\$33,221,747	\$40,241,939	21%
\$2,199,786	2%	\$2,199,786	\$2,257,390	3%	\$2,238,552	\$2,257,390	1%
\$119,859,704	0%	\$119,859,704	\$135,336,534	13%	\$125,611,598	\$135,336,534	8%
\$26,156,405	-1%	\$26,156,405	\$27,476,886	5%	\$18,587,094	\$27,476,886	48%
\$252,465	13%	\$252,465	\$349,324	38%	\$143,526	\$349,324	143%
\$8,845	22%	\$8,845	\$7,276	-18%	\$3,958	\$7,276	84%
\$17,461,256	7%	\$17,461,256	\$16,705,054	-4%	\$14,529,892	\$16,705,054	15%
\$4,610,704	-6%	\$4,610,704	\$6,017,932	31%	\$5,277,945	\$6,017,932	14%
\$5,240,322	-2%	\$5,240,322	\$4,968,716	-5%	\$5,214,754	\$4,968,716	-5%
\$30,028,414	0%	\$30,028,414	\$30,114,428	0%	\$28,159,902	\$30,114,428	7%
\$23,119,190	-4%	\$23,119,190	\$27,340,210	18%	\$22,287,304	\$27,340,210	23%
\$2,654	--	\$2,654	\$2,650	-0%	\$0	\$2,650	--
\$2,861,562	25%	\$2,861,562	\$2,913,794	2%	\$2,002,014	\$2,913,794	46%
\$17,047,406	3%	\$17,047,406	\$14,246,302	-16%	\$16,520,224	\$14,246,302	-14%
\$383,908	2%	\$383,908	\$1,230,845	221%	\$305,924	\$1,230,845	302%
\$15,861,819	1%	\$15,861,819	\$23,398,973	48%	\$12,597,325	\$23,398,973	86%
\$63,661,568	-4%	\$63,661,568	\$65,561,595	3%	\$67,228,159	\$65,561,595	-2%
\$2,998,161	-2%	\$2,998,161	\$3,837,488	28%	\$2,583,743	\$3,837,488	49%
\$392,356	0%	\$392,356	\$392,356	0%	\$402,212	\$392,356	-2%
\$821,138	12%	\$821,138	\$1,843,439	124%	\$640,973	\$1,843,439	188%
\$22,599,303	7%	\$22,599,303	\$24,302,004	8%	\$20,865,729	\$24,302,004	16%
\$10,885,632	14%	\$10,885,632	\$12,255,350	13%	\$8,694,418	\$12,255,350	41%
\$1,473,753	-7%	\$1,473,753	\$1,988,804	35%	\$1,373,538	\$1,988,804	45%
\$5,068,181	-3%	\$5,068,181	\$6,177,252	22%	\$5,334,671	\$6,177,252	16%
\$370,817	32%	\$370,817	\$426,847	15%	\$180,188	\$426,847	137%
<b>\$895,591,773</b>	<b>3%</b>	<b>\$895,591,773</b>	<b>\$998,332,858</b>	<b>11%</b>	<b>\$813,858,031</b>	<b>\$1,008,943,106</b>	<b>24%</b>

**Table 5: Growth of State Contribution to ADAP, FY2008 through FY2012**

State/Territory	2008 State Contribution	2009 State Contribution	% Change	2009 State Contribution	2010 State Contribution	% Change	2010 State Contribution
Alabama	\$5,075,403	\$2,225,000	-56%	\$2,225,000	\$4,465,057	101%	\$4,465,057
Alaska	\$31,221	\$0	-100%	\$0	\$0	--	\$0
American Samoa	--	--	--	--	--	--	--
Arizona	\$1,000,000	\$1,000,000	0%	\$1,000,000	\$1,000,000	0%	\$1,000,000
Arkansas	\$0	\$0	--	\$0	\$0	--	\$0
California	\$96,349,000	\$70,849,000	-26%	\$70,849,000	\$126,019,004	78%	\$54,406,000
Colorado	\$5,083,028	\$3,732,915	-27%	\$3,732,915	\$3,945,265	6%	\$3,945,265
Connecticut	\$606,678	\$606,678	0%	\$606,678	\$606,678	0%	\$606,678
Delaware	\$0	\$0	--	\$0	\$0	--	\$0
District of Columbia	\$0	\$0	--	\$0	\$0	--	\$0
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	\$10,500,000	\$9,500,000	-10%	\$9,500,000	\$9,500,000	0%	\$9,500,000
Georgia	\$9,500,000	\$10,000,000	5%	\$10,000,000	\$12,487,036	25%	\$12,487,036
Guam	\$0	\$0	--	\$0	--	--	\$0
Hawaii	\$440,535	\$440,535	0%	\$440,535	\$440,535	0%	\$440,535
Idaho	\$779,300	\$801,300	3%	\$801,300	\$721,300	-10%	\$721,300
Illinois	\$13,814,074	\$14,504,778	5%	\$14,504,778	\$20,587,045	42%	\$20,587,045
Indiana	\$0	\$0	--	\$0	\$0	--	\$0
Iowa	\$555,000	\$526,078	-5%	\$526,078	\$498,868	-5%	\$498,868
Kansas	\$0	\$500,000	--	\$500,000	\$500,000	0%	\$500,000
Kentucky	\$0	\$0	--	\$0	\$0	--	\$0
Louisiana	\$0	\$0	--	\$0	\$0	--	\$0
Maine	\$66,550	\$50,000	-25%	\$50,000	\$50,000	0%	\$50,000
Marshall Islands	--	--	--	--	--	--	--
Maryland	\$0	\$0	--	\$0	\$0	--	\$0
Massachusetts	\$1,958,523	\$1,893,375	-3%	\$1,893,375	\$1,893,375	0%	\$2,076,147
Michigan	\$0	\$0	--	\$0	\$0	--	\$0
Minnesota	\$0	\$4,525,577	--	\$4,525,577	\$0	-100%	\$0
Mississippi	\$0	--	--	--	--	--	--
Missouri	\$3,649,634	\$4,390,000	20%	\$4,390,000	\$4,200,000	-4%	\$4,200,000
Montana	\$147,018	\$58,154	-60%	\$58,154	\$164,036	182%	\$164,036
Nebraska	\$900,000	\$900,000	0%	\$900,000	\$954,794	6%	\$954,794
Nevada	\$1,633,261	\$0	-100%	\$0	\$1,900,000	--	\$1,900,000
New Hampshire	\$500,000	\$0	-100%	\$0	\$180,000	--	\$180,000
New Jersey	\$4,700,000	\$8,600,000	83%	\$8,600,000	\$17,220,000	100%	\$17,220,000
New Mexico	\$0	\$0	--	\$0	\$0	--	\$0
New York	\$55,000,000	\$3,302,461	-94%	\$3,302,461	\$42,300,000	1181%	\$42,300,000
North Carolina	\$14,551,663	\$10,695,504	-26%	\$10,695,504	\$25,543,127	139%	\$25,543,127
North Dakota	\$0	\$0	--	\$0	\$0	--	\$0
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	\$3,000,000	\$693,100	-77%	\$693,100	\$1,512,148	118%	\$1,512,148
Oklahoma	\$1,646,179	\$1,620,000	-2%	\$1,620,000	\$1,559,664	-4%	\$1,559,664
Oregon	\$1,157,157	\$1,643,278	42%	\$1,643,278	\$1,149,000	-30%	\$1,149,000
Pennsylvania	\$16,267,000	\$16,150,699	-1%	\$16,150,699	\$16,227,000	0%	\$16,227,000
Puerto Rico	\$1,315,671	\$4,105,788	212%	\$4,105,788	\$4,121,255	0.4%	\$0
Republic of Palau	--	--	--	--	--	--	\$0
Rhode Island	\$1,700,000	\$549,911	-68%	\$549,911	\$1,500,000	173%	\$1,500,000
South Carolina	\$5,900,000	\$4,634,467	-21%	\$4,634,467	\$1,870,249	-60%	\$1,870,249
South Dakota	\$0	\$0	--	\$0	\$0	--	\$0
Tennessee	\$7,300,000	\$7,200,000	-1%	\$7,200,000	\$7,000,000	-3%	\$7,000,000
Texas	\$35,475,307	\$26,887,609	-24%	\$26,887,609	\$25,000,000	-7%	\$25,000,000
Utah	\$0	\$94,412	--	\$94,412	\$77,021	-18%	\$44,500
Vermont	\$0	\$140,000	--	\$140,000	\$140,000	0%	\$140,000
Virgin Islands (U.S.)	\$0	\$0	--	\$0	\$150,000	--	\$150,000
Virginia	\$2,612,200	\$1,611,172	-38%	\$1,611,172	\$3,223,646	100%	\$3,182,217
Washington	\$8,809,064	\$8,944,861	2%	\$8,944,861	\$8,957,681	0%	\$8,957,681
West Virginia	\$0	\$0	--	\$0	\$52,260	--	\$52,260
Wisconsin	\$464,000	\$926,200	100%	\$926,200	\$2,200,800	138%	\$2,200,800
Wyoming	\$0	\$367,500	--	\$367,500	\$367,500	0%	\$367,500
<b>Total</b>	<b>\$312,487,466</b>	<b>\$224,670,352</b>	<b>-28%</b>	<b>\$224,670,352</b>	<b>\$350,284,344</b>	<b>56%</b>	<b>\$274,658,907</b>

2011 State Contribution	% Change	2011 State Contribution	2012 State Contribution	% Change	2008 State Contribution	2012 State Contribution	% Change
\$4,426,253	-1%	\$4,426,253	\$4,239,953	-4%	\$5,075,403	\$4,239,953	-16%
\$0	--	\$0	\$0	--	\$31,221	\$0	-100%
--	--	--	--	--	--	--	--
\$7,356,261	636%	\$7,356,261	\$7,452,383	1%	\$1,000,000	\$7,452,383	645%
\$0	--	\$0	\$0	--	\$0	\$0	--
\$78,714,574	45%	\$78,714,574	\$33,135,058	-58%	\$96,349,000	\$33,135,058	-66%
\$4,652,179	18%	\$4,652,179	\$4,477,589	-4%	\$5,083,028	\$4,477,589	-12%
\$0	-100%	\$0	\$0	--	\$606,678	\$0	-100%
\$0	--	\$0	--	--	\$0	--	--
\$0	--	\$0	\$0	--	\$0	\$0	--
--	--	--	--	--	--	--	--
\$10,500,000	11%	\$10,500,000	\$17,227,475	64%	\$10,500,000	\$17,227,475	64%
\$11,379,048	-9%	\$11,379,048	\$11,668,488	3%	\$9,500,000	\$11,668,488	23%
--	--	--	--	--	\$0	--	--
\$440,000	-0%	\$440,000	\$440,535	0%	\$440,535	\$440,535	0%
\$801,800	11%	\$801,800	\$801,800	0%	\$779,300	\$801,800	3%
\$18,571,500	-10%	\$18,571,500	\$18,571,500	0%	\$13,814,074	\$18,571,500	34%
\$0	--	\$0	\$0	--	\$0	\$0	--
\$498,946	0%	\$498,946	\$547,982	10%	\$555,000	\$547,982	-1%
\$800,000	60%	\$800,000	\$3,000,000	275%	\$0	\$3,000,000	--
\$81,341	--	\$81,341	\$0	-100%	\$0	\$0	--
\$0	--	\$0	\$0	--	\$0	\$0	--
\$50,000	0%	\$50,000	\$50,000	0%	\$66,550	\$50,000	-25%
--	--	--	--	--	--	--	--
\$0	--	\$0	\$0	--	\$0	\$0	--
\$1,893,375	-9%	\$1,893,375	\$1,893,375	0%	\$1,958,523	\$1,893,375	-3%
\$0	--	\$0	\$0	--	\$0	\$0	--
\$0	--	\$0	\$2,041,678	--	\$0	\$2,041,678	--
\$0	--	\$0	\$1,000,000	--	\$0	\$1,000,000	--
\$4,200,000	0%	\$4,200,000	\$4,400,000	5%	\$3,649,634	\$4,400,000	21%
\$164,036	0%	\$164,036	\$271,041	65%	\$147,018	\$271,041	84%
\$900,000	-6%	\$900,000	\$900,000	0%	\$900,000	\$900,000	0%
\$1,840,198	-3%	\$1,840,198	\$1,844,797	0%	\$1,633,261	\$1,844,797	13%
\$180,000	0%	\$180,000	\$180,000	0%	\$500,000	\$180,000	-64%
\$6,509,000	-62%	\$6,509,000	\$6,500,000	-0%	\$4,700,000	\$6,500,000	38%
\$0	--	\$0	\$1,000,000	--	\$0	\$1,000,000	--
\$42,300,000	0%	\$42,300,000	\$42,300,000	0%	\$55,000,000	\$42,300,000	-23%
\$28,617,246	12%	\$28,617,246	\$28,604,764	-0%	\$14,551,663	\$28,604,764	97%
\$0	--	\$0	\$0	--	\$0	\$0	--
--	--	--	--	--	--	--	--
\$5,424,565	259%	\$5,424,565	\$5,474,565	1%	\$3,000,000	\$5,474,565	82%
\$1,482,300	-5%	\$1,482,300	\$1,800,000	21%	\$1,646,179	\$1,800,000	9%
\$1,725,000	50%	\$1,725,000	\$1,225,000	-29%	\$1,157,157	\$1,225,000	6%
\$10,267,000	-37%	\$10,267,000	\$10,267,000	0%	\$16,267,000	\$10,267,000	-37%
\$0	--	\$0	\$4,042,765	--	\$1,315,671	\$4,042,765	207%
--	--	--	--	--	--	--	--
\$2,134,715	42%	\$2,134,715	\$1,944,384	-9%	\$1,700,000	\$1,944,384	14%
\$4,658,856	149%	\$4,658,856	\$5,658,856	21%	\$5,900,000	\$5,658,856	-4%
\$0	--	\$0	\$0	--	\$0	\$0	--
\$7,000,000	0%	\$7,000,000	\$1,000,000	-86%	\$7,300,000	\$1,000,000	-86%
\$32,138,127	29%	\$32,138,127	\$32,396,044	1%	\$35,475,307	\$32,396,044	-9%
\$427,220	860%	\$427,220	\$101,714	-76%	\$0	\$101,714	--
\$70,000	-50%	\$70,000	\$0	-100%	\$0	\$0	--
--	--	--	\$200,000	--	\$0	\$200,000	--
\$4,899,336	54%	\$4,899,336	\$5,047,456	3%	\$2,612,200	\$5,047,456	93%
\$11,825,586	32%	\$11,825,586	\$10,766,541	-9%	\$8,809,064	\$10,766,541	22%
\$25,780	-51%	\$25,780	\$27,322	6%	\$0	\$27,322	--
\$1,306,220	-41%	\$1,306,220	\$1,306,220	0%	\$464,000	\$1,306,220	182%
\$735,000	100%	\$735,000	\$367,500	-50%	\$0	\$367,500	--
<b>\$308,995,462</b>	<b>13%</b>	<b>\$308,995,462</b>	<b>\$274,173,785</b>	<b>-11%</b>	<b>\$312,487,466</b>	<b>\$274,173,785</b>	<b>-12%</b>

**Table 6: Growth of Estimated Drug Rebates, FY2008 through FY2012**

State/Territory	2008 Estimated Drug Rebates	2009 Estimated Drug Rebates	% Change	2009 Estimated Drug Rebates	2010 Estimated Drug Rebates	% Change	2010 Estimated Drug Rebates
Alabama	\$0	\$320,000	--	\$320,000	\$260,000	-19%	\$260,000
Alaska	\$10,000	\$10,000	0%	\$10,000	\$11,000	10%	\$11,000
American Samoa	--	--	--	--	--	--	--
Arizona	\$0	\$0	--	\$0	\$0	--	\$0
Arkansas	\$0	\$0	--	\$0	\$0	--	\$0
California	\$135,915,000	\$248,257,000	83%	\$248,257,000	\$207,018,607	-17%	\$207,018,607
Colorado	\$20,000	\$0	-100%	\$0	\$112,000	--	\$112,000
Connecticut	\$7,500,000	\$8,100,000	8%	\$8,100,000	\$9,488,447	17%	\$9,488,447
Delaware	\$281,775	\$691,483	145%	\$691,483	\$1,693,706	145%	\$1,693,706
District of Columbia	\$0	\$0	--	\$0	\$0	--	\$0
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	\$0	\$0	--	\$0	\$0	--	\$0
Georgia	\$0	\$0	--	\$0	\$0	--	\$0
Guam	\$0	\$0	--	\$0	--	--	--
Hawaii	\$21,000	\$100,000	376%	\$100,000	\$150,000	50%	\$150,000
Idaho	\$700,000	\$875,000	25%	\$875,000	\$1,500,000	71%	\$1,500,000
Illinois	\$0	\$0	--	\$0	\$0	--	\$0
Indiana	\$205,000	\$5,360,000	2515%	\$5,360,000	\$6,960,000	30%	\$6,960,000
Iowa	\$20,000	\$34,000	70%	\$34,000	\$400,000	1076%	\$400,000
Kansas	\$3,200,000	\$4,000,000	25%	\$4,000,000	\$4,000,000	0%	\$4,000,000
Kentucky	\$2,500,000	\$0	-100%	\$0	\$6,000,000	--	\$6,000,000
Louisiana	\$500,000	\$620,000	24%	\$620,000	\$3,634,736	486%	\$3,634,736
Maine	\$150,000	\$0	-100%	\$0	\$280,000	--	\$280,000
Marshall Islands	--	--	--	--	--	--	--
Maryland	\$20,000,000	\$14,500,000	-28%	\$14,500,000	\$27,165,793	87%	\$27,165,793
Massachusetts	\$1,500,000	\$1,500,000	0%	\$1,500,000	\$1,500,000	0%	\$1,500,000
Michigan	\$9,000,000	\$11,200,000	24%	\$11,200,000	\$19,900,000	78%	\$19,900,000
Minnesota	\$3,928,270	\$3,529,075	-10%	\$3,529,075	\$6,399,086	81%	\$6,399,086
Mississippi	\$208,000	--	--	--	--	--	--
Missouri	\$3,200,000	\$4,685,000	46%	\$4,685,000	\$10,250,000	119%	\$10,250,000
Montana	\$12,500	\$10,679	-15%	\$10,679	\$10,217	-4%	\$10,217
Nebraska	\$28,000	\$54,400	94%	\$54,400	\$134,273	147%	\$134,273
Nevada	\$110,000	\$500,000	355%	\$500,000	\$1,194,626	139%	\$1,194,626
New Hampshire	\$100,000	\$1,400,000	1300%	\$1,400,000	\$1,200,000	-14%	\$1,200,000
New Jersey	\$31,549,324	\$30,000,000	-5%	\$30,000,000	\$35,000,000	17%	\$35,000,000
New Mexico	\$0	\$5,000	--	\$5,000	\$0	-100%	\$0
New York	\$69,344,600	\$111,490,965	61%	\$111,490,965	\$100,192,653	-10%	\$100,192,653
North Carolina	\$0	\$0	--	\$0	\$785,687	--	\$785,687
North Dakota	\$150,000	\$180,000	20%	\$180,000	\$0	-100%	\$0
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	\$250,000	\$0	-100%	\$0	\$5,000,000	--	\$5,000,000
Oklahoma	\$960,000	\$900,000	-6%	\$900,000	\$1,500,000	67%	\$1,500,000
Oregon	\$5,076,000	\$4,866,722	-4%	\$4,866,722	\$11,903,707	145%	\$11,903,707
Pennsylvania	\$13,560,000	\$21,244,084	57%	\$21,244,084	\$27,875,107	31%	\$27,875,107
Puerto Rico	\$0	\$0	--	\$0	\$0	--	\$0
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	\$582,000	\$2,315,347	298%	\$2,315,347	\$1,088,091	-53%	\$1,088,091
South Carolina	\$3,400,000	\$3,000,000	-12%	\$3,000,000	\$4,700,000	57%	\$4,700,000
South Dakota	\$116,160	\$189,000	63%	\$189,000	\$80,000	-58%	\$80,000
Tennessee	\$1,500,000	\$3,000,000	100%	\$3,000,000	\$4,500,000	50%	\$4,500,000
Texas	\$0	\$0	--	\$0	\$0	--	\$0
Utah	\$1,056,926	\$1,471,486	39%	\$1,471,486	\$1,113,150	-24%	\$1,113,150
Vermont	\$600,000	\$500,000	-17%	\$500,000	\$500,000	0%	\$500,000
Virgin Islands (U.S.)	\$0	\$0	--	\$0	\$0	--	\$0
Virginia	\$500,000	\$454,419	-9%	\$454,419	\$338,702	-25%	\$338,702
Washington	\$4,310,546	\$8,047,200	87%	\$8,047,200	\$9,788,830	22%	\$9,788,830
West Virginia	\$945,000	\$1,100,000	16%	\$1,100,000	\$1,700,000	55%	\$1,700,000
Wisconsin	\$3,994,154	\$4,763,723	19%	\$4,763,723	\$6,960,380	46%	\$6,960,380
Wyoming	\$100,000	\$240,000	140%	\$240,000	\$300,000	25%	\$300,000
<b>Total</b>	<b>\$327,104,255</b>	<b>\$499,514,583</b>	<b>53%</b>	<b>\$499,514,583</b>	<b>\$522,588,798</b>	<b>5%</b>	<b>\$522,588,798</b>

2011 Estimated Drug Rebates	% Change	2011 Estimated Drug Rebates	2012 Estimated Drug Rebates	% Change	2008 Estimated Drug Rebates	2012 Estimated Drug Rebates	% Change
\$240,000	-8%	\$240,000	\$66,231	-72%	\$0	\$66,231	--
\$0	-100%	\$0	\$0	--	\$10,000	\$0	-100%
--	--	--	--	--	--	--	--
\$3,233,505	--	\$3,233,505	\$9,000,000	178%	\$0	\$9,000,000	--
\$0	--	\$0	\$0	--	\$0	\$0	--
\$264,153,045	28%	\$264,153,045	\$291,025,768	10%	\$135,915,000	\$291,025,768	114%
\$5,265,238	4601%	\$5,265,238	\$3,567,000	-32%	\$20,000	\$3,567,000	17735%
\$12,594,513	33%	\$12,594,513	\$15,513,256	23%	\$7,500,000	\$15,513,256	107%
\$3,415,488	102%	\$3,415,488	--	--	\$281,775	--	--
\$0	--	\$0	\$0	--	\$0	\$0	--
--	--	--	--	--	--	--	--
\$0	--	\$0	\$3,537,015	--	\$0	\$3,537,015	--
\$0	--	\$0	\$0	--	\$0	\$0	--
--	--	--	--	--	\$0	--	--
\$600,000	300%	\$600,000	\$930,000	55%	\$21,000	\$930,000	4329%
\$1,500,000	0%	\$1,500,000	\$1,800,000	20%	\$700,000	\$1,800,000	157%
\$800,000	--	\$800,000	\$1,900,000	138%	\$0	\$1,900,000	--
\$10,398,000	49%	\$10,398,000	\$9,005,265	-13%	\$205,000	\$9,005,265	4293%
\$700,000	75%	\$700,000	\$1,485,000	112%	\$20,000	\$1,485,000	7325%
\$6,500,000	63%	\$6,500,000	\$5,500,000	-15%	\$3,200,000	\$5,500,000	72%
\$3,500,000	-42%	\$3,500,000	\$8,000,000	129%	\$2,500,000	\$8,000,000	220%
\$0	-100%	\$0	\$2,000,000	--	\$500,000	\$2,000,000	300%
\$500,000	79%	\$500,000	\$600,000	20%	\$150,000	\$600,000	300%
--	--	--	--	--	--	--	--
\$28,929,349	6%	\$28,929,349	\$33,969,496	17%	\$20,000,000	\$33,969,496	70%
\$7,500,000	400%	\$7,500,000	\$7,500,000	0%	\$1,500,000	\$7,500,000	400%
\$20,000,000	1%	\$20,000,000	\$27,000,000	35%	\$9,000,000	\$27,000,000	200%
\$6,354,804	-1%	\$6,354,804	\$6,018,486	-5%	\$3,928,270	\$6,018,486	53%
\$0	--	\$0	\$0	--	\$208,000	\$0	-100%
\$13,400,000	31%	\$13,400,000	\$16,500,000	23%	\$3,200,000	\$16,500,000	416%
\$10,217	0%	\$10,217	\$6,000	-41%	\$12,500	\$6,000	-52%
\$500,000	272%	\$500,000	\$700,000	40%	\$28,000	\$700,000	2400%
\$2,557,592	114%	\$2,557,592	\$4,309,705	69%	\$110,000	\$4,309,705	3818%
\$1,900,000	58%	\$1,900,000	\$2,100,000	11%	\$100,000	\$2,100,000	2000%
\$40,000,000	14%	\$40,000,000	\$46,000,000	15%	\$31,549,324	\$46,000,000	46%
\$0	--	\$0	\$0	--	\$0	\$0	--
\$104,152,679	4%	\$104,152,679	\$128,285,542	23%	\$69,344,600	\$128,285,542	85%
\$0	-100%	\$0	\$3,000,000	--	\$0	\$3,000,000	--
\$300,000	--	\$300,000	\$81,000	-73%	\$150,000	\$81,000	-46%
--	--	--	--	--	--	--	--
\$5,000,000	0%	\$5,000,000	\$5,000,000	0%	\$250,000	\$5,000,000	1900%
\$4,000,000	167%	\$4,000,000	\$5,000,000	25%	\$960,000	\$5,000,000	421%
\$4,026,664	-66%	\$4,026,664	\$3,270,893	-19%	\$5,076,000	\$3,270,893	-36%
\$29,000,000	4%	\$29,000,000	\$35,000,000	21%	\$13,560,000	\$35,000,000	158%
\$0	--	\$0	\$0	--	\$0	\$0	--
--	--	--	--	--	--	--	--
\$1,036,923	-5%	\$1,036,923	\$1,200,000	16%	\$582,000	\$1,200,000	106%
\$6,000,000	28%	\$6,000,000	\$8,000,000	33%	\$3,400,000	\$8,000,000	135%
\$0	-100%	\$0	\$190,000	--	\$116,160	\$190,000	64%
\$7,000,000	56%	\$7,000,000	\$6,500,000	-7%	\$1,500,000	\$6,500,000	333%
\$6,000,000	--	\$6,000,000	\$20,000,000	233%	\$0	\$20,000,000	--
\$1,000,000	-10%	\$1,000,000	\$815,706	-18%	\$1,056,926	\$815,706	-23%
\$700,000	40%	\$700,000	\$600,000	-14%	\$600,000	\$600,000	0%
--	--	--	\$0	--	\$0	\$0	--
\$750,000	121%	\$750,000	\$1,000,000	33%	\$500,000	\$1,000,000	100%
\$11,389,416	16%	\$11,389,416	\$11,316,438	-1%	\$4,310,546	\$11,316,438	163%
\$1,919,500	13%	\$1,919,500	\$2,985,316	56%	\$945,000	\$2,985,316	216%
\$10,545,603	52%	\$10,545,603	\$11,684,000	11%	\$3,994,154	\$11,684,000	193%
\$526,788	76%	\$526,788	\$299,496	-43%	\$100,000	\$299,496	199%
<b>\$627,899,324</b>	<b>20%</b>	<b>\$627,899,324</b>	<b>\$742,261,613</b>	<b>18%</b>	<b>\$327,104,255</b>	<b>\$742,261,613</b>	<b>127%</b>

**Table 7: Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY2012**

State/Territory	Private Insurance	Medicaid	Other	Total
Alabama	\$0	\$236,644	\$0	\$236,644
Alaska	\$830,748	\$0	\$0	\$830,748
American Samoa	--	--	--	--
Arizona	\$0	\$0	\$0	\$0
Arkansas	\$0	\$0	\$0	\$0
California	\$0	\$0	\$0	\$0
Colorado	\$0	\$0	\$0	\$0
Connecticut	\$2,661,027	\$0	\$0	\$2,661,027
Delaware	--	--	--	--
District of Columbia	\$0	\$0	\$0	\$0
Federated States of Micronesia	--	--	--	--
Florida	\$0	\$0	\$0	\$0
Georgia	\$0	\$0	\$0	\$0
Guam	--	--	--	--
Hawaii	\$0	\$0	\$0	\$0
Idaho	\$0	\$0	\$0	\$0
Illinois	\$0	\$90,907	\$0	\$90,907
Indiana	\$0	\$0	\$0	\$0
Iowa	\$127,077	\$9,067	\$0	\$136,144
Kansas	\$0	\$0	\$0	\$0
Kentucky	\$0	\$0	\$0	\$0
Louisiana	\$0	\$0	\$0	\$0
Maine	\$7,909	\$0	\$0	\$7,909
Marshall Islands	--	--	--	--
Maryland	\$0	\$0	\$0	\$0
Massachusetts	\$0	\$0	\$0	\$0
Michigan	\$0	\$750,000	\$0	\$750,000
Minnesota	\$0	\$0	\$0	\$0
Mississippi	\$0	\$0	\$0	--
Missouri	\$40,000	\$2,000,000	\$0	\$2,040,000
Montana	\$1,003	\$0	\$0	\$1,003
Nebraska	\$0	\$0	\$201,231	\$201,231
Nevada	\$0	\$0	\$0	\$0
New Hampshire	\$0	\$0	\$0	\$0
New Jersey	\$7,000,000	\$390,000	\$0	\$7,390,000
New Mexico	\$0	\$0	\$0	\$0
New York	\$0	\$1,500,000	\$0	\$1,500,000
North Carolina	\$0	\$0	\$0	\$0
North Dakota	\$0	\$0	\$0	\$0
Northern Mariana Islands	--	--	--	--
Ohio	\$0	\$0	\$0	\$0
Oklahoma	\$120,000	\$30,000	\$0	\$150,000
Oregon	\$2,388,482	\$0	\$31,996	\$2,420,478
Pennsylvania	\$0	\$0	\$5,000,000	\$5,000,000
Puerto Rico	\$0	\$0	\$10,127,513	\$10,127,513
Republic of Palau	--	--	--	--
Rhode Island	\$0	\$0	\$0	\$0
South Carolina	\$0	\$0	\$0	\$0
South Dakota	\$0	\$0	\$0	\$0
Tennessee	\$0	\$0	\$0	\$0
Texas	\$0	\$0	\$0	\$0
Utah	\$0	\$57,189	\$0	\$57,189
Vermont	\$0	\$0	\$0	\$0
Virgin Islands (U.S.)	\$0	\$0	\$0	\$0
Virginia	\$0	\$500,000	\$0	\$500,000
Washington	\$0	\$0	\$0	\$0
West Virginia	\$0	\$0	\$0	\$0
Wisconsin	\$0	\$0	\$0	\$0
Wyoming	\$0	\$0	\$0	\$0
<b>Totals</b>	<b>\$13,176,246</b>	<b>\$5,563,807</b>	<b>\$15,360,740</b>	<b>\$34,100,793</b>
<b>Total # of ADAPs</b>	<b>9</b>	<b>10</b>	<b>4</b>	<b>18</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. A dash (--) indicates the ADAP did not report data. A zero (\$0) indicates the ADAP responded zero (\$0) to the question.



**Table 8: Total Clients Enrolled/Served and Program Expenditures, FY2011<sup>1</sup>**

State/Territory	FY2011 Clients Enrolled <sup>2</sup>	FY2011 New Clients Enrolled	FY2011 Clients Served <sup>2</sup>	Prescription Drugs	Prescription Dispensing Costs	Insurance Premiums	Insurance Co-payments and Deductibles	
Alabama	1,968	471	1,681	\$16,763,962	\$361,303	\$67,208	\$222,731	
Alaska	122	22	118	\$817,206	\$69,792	\$224,077	\$0	
American Samoa	--	--	--	--	--	--	--	
Arizona	1,025	167	1,008	\$10,568,011	\$256,127	\$1,364,223	\$3,553,380	
Arkansas	677	76	677	\$5,384,596	\$124,400	\$0	\$342,224	
California	44,390	4,858	40,416	\$460,793,227	\$2,944,515	\$3,290,095	\$33,715,944	
Colorado	--	--	--	\$13,746,838	\$397,597	\$1,618,792	\$1,294,201	
Connecticut	2,643	367	2,576	\$28,535,339	\$158,591	\$447,862	\$2,891,846	
Delaware	--	--	--	--	--	--	--	
District of Columbia	3,336	788	2,740	\$7,993,551	\$420,000	\$163,690	\$0	
Federated States of Micronesia	--	--	--	--	--	--	--	
Florida	15,722	3,453	13,144	\$82,630,341	\$0	\$10,000,226	\$591,500	
Georgia	4,980	548	4,197	\$37,947,356	\$0	\$0	\$0	
Guam	--	--	--	--	--	--	--	
Hawaii	454	113	420	\$3,519,943	\$83,532	\$265,537	\$206,387	
Idaho	230	54	210	\$3,509,433	\$0	\$0	\$0	
Illinois	7,129	1,512	6,072	\$43,360,586	\$1,495,572	\$0	\$3,618,676	
Indiana	2,313	646	2,313	\$825,000	\$4,409	\$4,158,239	\$5,377,268	
Iowa	763	161	722	\$3,035,650	\$91,745	\$274,768	\$237,453	
Kansas	1,541	235	1,264	\$12,395,579	\$56,434	\$292,049	\$3,179,588	
Kentucky	1,900	480	1,334	\$10,781,804	\$0	\$0	\$0	
Louisiana	3,428	685	3,428	\$14,616,455	\$355,797	\$0	\$1,624,295	
Maine	749	100	560	\$526,018	\$24,398	\$222,480	\$693,931	
Marshall Islands	--	--	--	--	--	--	--	
Maryland	7,441	1,020	6,629	\$27,212,104	\$437,735	\$25,072,334	\$6,389,510	
Massachusetts	7,104	546	6,745	\$4,625,133	\$5,313	\$11,366,104	\$3,585,452	
Michigan	4,448	958	3,924	\$28,800,197	\$151,895	\$1,445,716	\$5,014,233	
Minnesota	2,519	271	1,322	\$2,809,593	\$0	\$2,888,633	\$0	
Mississippi	1,599	404	1,592	\$5,841,101	\$0	\$0	\$0	
Missouri	3,741	501	3,597	\$22,279,544	\$77,786	\$1,601,916	\$2,483,983	
Montana	144	48	141	\$669,601	\$11,810	\$0	\$72,240	
Nebraska	542	75	356	\$2,852,723	\$0	\$27,480	\$0	
Nevada	1,313	320	972	\$6,958,270	\$288,264	\$243,565	\$916,542	
New Hampshire	547	65	428	\$2,563,836	\$7,971	\$274,718	\$398,769	
New Jersey	7,835	250	7,677	\$89,701,425	\$931,715	\$4,263,337	\$5,074,820	
New Mexico	938	341	938	\$181,701	\$0	\$1,485,261	\$166,464	
New York	24,533	3,113	22,323	\$267,450,331	\$1,969,849	\$35,464,799	\$0	
North Carolina	6,867	1,203	6,377	\$43,518,179	\$1,718,343	\$0	\$1,796,509	
North Dakota	140	25	140	\$862,850	\$0	\$0	\$0	
Northern Mariana Islands	--	--	--	--	--	--	--	
Ohio	5,023	716	4,053	\$0	\$463,858	\$1,848,222	\$2,726,322	
Oklahoma	1,656	216	1,551	\$5,676,803	\$203,562	\$761,084	\$1,243,417	
Oregon	3,120	490	3,118	\$14,201,569	\$1,269,880	\$8,069,353	\$1,475,610	
Pennsylvania	7,108	1,906	6,579	\$24,803,054	\$994,584	\$324,521	\$48,677,083	
Puerto Rico	6,820	925	6,820	\$23,880,389	\$45,706	\$0	\$0	
Republic of Palau	--	--	--	--	--	--	--	
Rhode Island	689	129	851	\$6,851,230	\$31,047	\$0	\$0	
South Carolina	4,298	729	3,915	\$16,956,240	\$805,097	\$698,541	\$2,008,164	
South Dakota	170	26	170	\$1,181,116	\$0	\$0	\$0	
Tennessee	6,124	954	5,276	\$20,798,989	\$855,302	\$4,491,352	\$2,636,593	
Texas	20,267	2,973	17,171	\$92,831,589	\$0	\$0	\$5,737,502	
Utah	647	77	592	\$3,709,296	\$93,694	\$526,728	\$436,755	
Vermont	374	64	267	\$451,146	\$21,475	\$86,668	\$0	
Virgin Islands (U.S.)	149	--	149	\$538,437	\$46,902	\$0	\$0	
Virginia	3,753	442	3,265	\$27,320,574	\$502,866	\$126,405	\$801,377	
Washington	4,767	714	4,270	\$1,262,924	\$455,025	\$19,448,933	\$6,726,987	
West Virginia	638	102	479	\$4,778,537	\$34,895	\$0	\$0	
Wisconsin	2,108	285	1,815	\$15,417,241	\$0	\$3,848,411	\$0	
Wyoming	140	12	79	\$932,686	\$10,690	\$0	\$0	
<b>Total</b>	<b>230,932</b>	<b>34,636</b>	<b>206,461</b>	<b>\$1,525,669,302</b>	<b>\$18,279,477</b>	<b>\$146,753,328</b>	<b>\$155,917,755</b>	

<sup>1</sup> This table represents ADAP program expenditures in FY2011 (April 1, 2011-March 31, 2012). Only expenditure categories requested in the National ADAP Monitoring Survey are represented in this table.

<sup>2</sup> For some states, enrolled clients reported may be a snapshot in time rather than a cumulative unduplicated client count. In this instance, some ADAPs may report a higher number of clients served throughout the fiscal year compared to the number of clients enrolled in the program at the end of the fiscal year.



FY2011 ADAP Expenditures							
	Client Outreach	Adherence and Monitoring	Quality Management	Program Administration	Client Enrollment Costs	Other <sup>3</sup>	Total Expenditures
	\$0	\$370,902	\$209,092	\$85,215	\$9,973	\$0	\$18,090,385
	\$0	\$0	\$0	\$123,286	\$52,811	\$0	\$1,287,172
	--	--	--	--	--	--	--
	\$0	\$0	\$49,940	\$504,175	\$0	\$0	\$16,295,856
	\$0	\$0	\$0	\$97,690	\$0	\$0	\$5,948,910
	\$0	\$0	\$0	\$1,955,777	\$1,004,908	\$5,432,862	\$509,137,328
	\$0	\$0	\$0	\$481,720	\$287,000	\$0	\$17,826,148
	\$0	\$547,654	\$399,428	\$557,816	\$0	\$0	\$33,538,536
	--	--	--	--	--	--	\$0
	\$255,930	\$952,706	\$0	\$1,100,109	\$0	\$0	\$10,885,986
	--	--	--	--	--	--	--
	\$0	\$0	\$60,102	\$4,806,586	\$0	\$0	\$98,088,755
	\$0	\$0	\$0	\$0	\$0	\$0	\$37,947,356
	--	--	--	--	--	--	--
	\$0	\$754	\$0	\$0	\$0	\$0	\$4,076,153
	\$0	\$27,326	\$22,837	\$116,046	\$0	\$0	\$3,675,642
	\$0	\$0	\$119,419	\$1,072,324	\$0	\$1,080,000	\$50,746,577
	\$0	\$0	\$263,430	\$1,183,572	\$0	\$0	\$11,811,918
	\$0	\$0	\$30,499	\$125,357	\$0	\$0	\$3,795,472
	\$0	\$135,534	\$130,900	\$363,971	\$0	\$0	\$16,554,055
	\$0	\$0	\$0	\$0	\$0	\$0	\$10,781,804
	\$0	\$0	\$0	\$0	\$0	\$0	\$16,596,547
	\$0	\$22,924	\$17,513	\$106,293	\$0	\$0	\$1,613,557
	--	--	--	--	--	--	--
	\$0	\$1,520,435	\$315,192	\$2,822,205	\$0	\$0	\$63,769,515
	\$0	\$593,852	\$0	\$1,180,707	\$0	\$0	\$21,356,562
	\$0	\$36,946	\$0	\$371,289	\$0	\$0	\$35,820,275
	\$0	\$28,350	\$51,636	\$108,902	\$0	\$0	\$5,887,114
	\$0	\$0	\$0	\$0	\$0	\$0	\$5,841,101
	\$0	\$0	\$39,832	\$115,317	\$0	\$0	\$26,598,378
	\$0	\$0	\$0	\$0	\$0	\$0	\$753,651
	\$0	\$0	\$0	\$163,488	\$0	\$0	\$3,043,691
	\$37,500	\$405,034	\$153,090	\$912,669	\$0	\$0	\$9,914,934
	\$0	\$0	\$44,677	\$159,801	\$0	\$0	\$3,449,772
	\$0	\$0	\$0	\$654,608	\$0	\$0	\$100,625,905
	\$0	\$0	\$147,315	\$318,570	\$0	\$0	\$2,299,311
	\$585,000	\$3,257,359	\$765,000	\$315,000	\$2,835,000	\$0	\$312,642,338
	\$0	\$0	\$0	\$150,000	\$0	\$0	\$47,183,031
	\$0	\$0	\$0	\$0	\$0	\$0	\$862,850
	--	--	--	--	--	--	--
	\$0	\$0	\$0	\$0	\$0	\$0	\$5,038,402
	\$0	\$86,493	\$334,073	\$767,440	\$143,560	\$198,629	\$9,415,061
	\$0	\$0	\$47,558	\$3,468,897	\$0	\$0	\$28,532,867
	\$0	\$343,744	\$0	\$653,240	\$390,691	\$0	\$76,186,917
	\$0	\$623,615	\$96,004	\$668,469	\$0	\$0	\$25,314,183
	--	--	--	--	--	--	--
	\$0	\$0	\$0	\$0	\$0	\$0	\$6,882,276
	\$0	\$0	\$0	\$1,711,567	\$0	\$0	\$22,179,610
	\$0	\$0	\$0	\$0	\$0	\$0	\$1,181,116
	\$0	\$0	\$0	\$0	\$0	\$0	\$28,782,236
	\$0	\$0	\$0	\$7,614,805	\$0	\$10,960,068	\$117,143,964
	\$0	\$0	\$33,536	\$170,814	\$0	\$0	\$4,970,823
	\$0	\$0	\$24,799	\$51,633	\$0	\$0	\$635,721
	\$0	\$27,674	\$26,696	\$53,998	\$14,721	\$2,752	\$711,180
	\$0	\$0	\$23,183	\$709,326	\$0	\$0	\$29,483,731
	\$0	\$0	\$206,107	\$1,962,072	\$0	\$0	\$30,062,048
	\$0	\$0	\$0	\$0	\$0	\$0	\$4,813,432
	\$0	\$0	\$0	\$161,747	\$0	\$0	\$19,427,399
	\$0	\$0	\$0	\$0	\$0	\$0	\$943,376
	<b>\$878,430</b>	<b>\$8,981,302</b>	<b>\$3,611,858</b>	<b>\$37,946,502</b>	<b>\$4,738,664</b>	<b>\$17,674,311</b>	<b>\$1,920,450,929</b>

<sup>3</sup>Other<sup>3</sup> includes, but is not limited to, contract services to dispense medications, determine eligibility, and manage enrollment; pharmacy charges, dispensing and shipping fees, central pharmacy fees; as well as medical, dental, lab, and nutritional services.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. A dash (--) indicates the ADAP did not report data.

**Table 9: Total Clients Enrolled and Served, June 2011 and June 2012**

State/Territory	June 2011 Clients Enrolled	June 2012 Clients Enrolled	% Change	June 2011 Clients Served	June 2012 Clients Served	% Change
Alabama	1,875	1,697	-9%	1,534	1,473	-4%
Alaska	90	91	1%	79	72	-9%
American Samoa	--	--	--	--	--	--
Arizona	1,122	1,025	-9%	1,114	1,008	-10%
Arkansas	407	710	74%	389	710	83%
California	36,738	37,113	1%	26,586	26,253	-1%
Colorado	3,067	3,625	18%	1,775	3,083	74%
Connecticut	2,053	2,136	4%	1,678	1,724	3%
Delaware	1,460	--	--	677	--	--
District of Columbia	1,458	1,404	-4%	861	785	-9%
Federated States of Micronesia	--	--	--	--	--	--
Florida	9,819	15,288	56%	8,396	12,005	43%
Georgia	4,004	5,590	40%	3,958	3,319	-16%
Guam	--	--	--	--	--	--
Hawaii	315	368	17%	266	329	24%
Idaho	146	145	-1%	123	143	16%
Illinois	5,604	6,112	9%	4,097	4,484	9%
Indiana	1,913	2,336	22%	1,885	2,336	24%
Iowa	617	682	11%	471	488	4%
Kansas	1,153	1,223	6%	778	680	-13%
Kentucky	1,745	2,127	22%	1,424	1,368	-4%
Louisiana	1,938	2,134	10%	1,938	2,134	10%
Maine	726	776	7%	285	299	5%
Marshall Islands	--	--	--	--	--	--
Maryland	5,672	6,217	10%	4,071	4,106	1%
Massachusetts	6,059	6,136	1%	4,285	4,121	-4%
Michigan	2,825	3,584	27%	2,205	2,779	26%
Minnesota	2,004	2,021	1%	653	667	2%
Mississippi	886	930	5%	886	888	0%
Missouri	2,519	2,596	3%	1,727	1,927	12%
Montana <sup>1</sup>	113	143	27%	92	116	26%
Nebraska	552	484	-12%	377	242	-36%
Nevada	1,113	1,304	17%	845	876	4%
New Hampshire	319	454	42%	177	268	51%
New Jersey	7,005	6,708	-4%	6,086	4,655	-24%
New Mexico	624	15	-98%	623	--	--
New York	19,462	20,320	4%	15,811	16,477	4%
North Carolina	5,463	5,707	4%	3,465	4,419	28%
North Dakota	67	119	78%	60	67	12%
Northern Mariana Islands	--	--	--	--	--	--
Ohio	3,415	4,244	24%	1,786	2,369	33%
Oklahoma	1,275	1,281	0%	1,035	973	-6%
Oregon	2,903	2,776	-4%	2,831	2,713	-4%
Pennsylvania	5,550	5,539	-0%	4,299	4,249	-1%
Puerto Rico	5,489	5,372	-2%	4,617	4,535	-2%
Republic of Palau	--	--	--	--	--	--
Rhode Island	660	714	8%	524	526	0%
South Carolina	3,022	4,146	37%	2,455	3,258	33%
South Dakota	95	137	44%	95	137	44%
Tennessee	3,931	4,359	11%	2,886	3,092	7%
Texas	14,123	14,019	-1%	10,959	10,881	-1%
Utah	510	592	16%	405	422	4%
Vermont	312	309	-1%	106	135	27%
Virgin Islands (U.S.)	--	134	--	--	134	--
Virginia	2,824	3,044	8%	1,992	2,299	15%
Washington	3,393	3,795	12%	3,115	2,823	-9%
West Virginia	529	587	11%	318	387	22%
Wisconsin	1,761	1,861	6%	1,003	613	-39%
Wyoming	135	143	6%	70	79	13%
<b>Total</b>	<b>180,860</b>	<b>194,372</b>		<b>138,173</b>	<b>143,926</b>	
<b>Comparison Total<sup>1</sup></b>	<b>179,400</b>	<b>194,238</b>	<b>8%</b>	<b>137,496</b>	<b>143,792</b>	<b>5%</b>

<sup>1</sup>Comparison Totals are based on only those ADAPs that reported data in both time periods.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. A dash (--) indicates the ADAP did not report data.

**Table 10: ADAP Clients Served, by Race/Ethnicity, June 2012**

State/Territory	June 2012 Clients Served	Non-Hispanic Black/African American	Non-Hispanic White	Hispanic	Asian	Native Hawaiian/ Pacific Islander	American Indian/ Alaskan Native	Multi-Racial	Other	Unknown
Alabama	1,473	65%	31%	4%	0.2%	0%	0.1%	0%	0%	0%
Alaska	72	18%	51%	19%	7%	4%	0%	0%	0%	0%
American Samoa	--	--	--	--	--	--	--	--	--	--
Arizona	1,008	10%	35%	49%	1%	1%	3%	1%	0%	0%
Arkansas	710	40%	50%	4%	0%	0.1%	0.4%	5%	0%	1%
California	26,253	12%	38%	42%	4%	0.3%	0.3%	3%	0%	1%
Colorado	--	--	--	--	--	--	--	--	--	--
Connecticut	1,724	36%	58%	5%	1%	0%	0.3%	0%	0%	0%
Delaware	--	--	--	--	--	--	--	--	--	--
District of Columbia	785	60%	16%	19%	1%	0%	0.1%	1%	0%	3%
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--
Florida	12,005	29%	31%	29%	0.5%	0.1%	0.1%	0.5%	9%	0.2%
Georgia	3,319	64%	22%	10%	1%	0.1%	0.2%	1%	1%	0.1%
Guam	--	--	--	--	--	--	--	--	--	--
Hawaii	329	5%	48%	11%	19%	8%	1%	8%	0.3%	0.3%
Idaho	143	4%	74%	17%	1%	0%	1%	3%	0%	0%
Illinois	4,484	39%	26%	25%	2%	0.1%	0.2%	1%	1%	6%
Indiana	2,336	29%	61%	6%	1%	0%	0.1%	1%	2%	0%
Iowa	488	19%	63%	12%	3%	0%	1%	2%	0%	0%
Kansas	680	25%	54%	18%	1%	0.4%	1%	0%	0%	0%
Kentucky	1,368	0%	0%	0%	0%	0%	0%	0%	0%	100%
Louisiana	2,134	60%	33%	5%	0.5%	0.1%	0.2%	0.5%	0.1%	1%
Maine	299	16%	77%	0%	1%	2%	0%	3%	1%	0%
Marshall Islands	--	--	--	--	--	--	--	--	--	--
Maryland	4,106	69%	18%	6%	1%	0.02%	0.2%	0.1%	5%	0.4%
Massachusetts	4,121	27%	43%	25%	2%	0.02%	0.1%	1%	1%	0.4%
Michigan	2,779	47%	44%	3%	1%	0.1%	1%	0%	0.4%	4%
Minnesota	667	27%	51%	1%	1%	1%	0.4%	0.4%	0.1%	19%
Mississippi	888	75%	21%	3%	0.2%	0%	0%	0%	0%	0%
Missouri	1,927	47%	49%	2%	1%	0.2%	0.3%	0.4%	0%	1%
Montana	116	3%	88%	2%	0%	1%	6%	0%	0%	0%
Nebraska	242	24%	52%	18%	3%	1%	1%	0%	0.4%	0%
Nevada	876	17%	42%	34%	3%	2%	0.3%	0%	0%	2%
New Hampshire	268	14%	65%	11%	1%	0%	0.4%	5%	1%	2%
New Jersey	4,655	48%	20%	29%	1%	1%	0%	2%	0%	0%
New Mexico	--	--	--	--	--	--	--	--	--	--
New York	16,477	34%	27%	31%	2%	0.3%	0.3%	0%	0%	5%
North Carolina	4,419	60%	29%	8%	0.5%	0.2%	1%	1%	0%	0%
North Dakota	67	0%	0%	0%	0%	0%	0%	0%	0%	100%
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--
Ohio	2,369	36%	54%	6%	1%	0.3%	0.4%	0.4%	2%	0%
Oklahoma	973	20%	61%	9%	1%	0%	8%	0%	0.4%	0%
Oregon	2,713	7%	67%	15%	1%	1%	2%	5%	3%	0%
Pennsylvania	4,249	46%	40%	8%	1%	0%	0.2%	0%	2%	3%
Puerto Rico	4,535	0%	0%	0%	0%	0%	0%	100%	0%	0%
Republic of Palau	--	--	--	--	--	--	--	--	--	--
Rhode Island	526	23%	48%	25%	2%	1%	1%	1%	0.2%	0%
South Carolina	3,258	68%	25%	5%	0.3%	0.03%	0.1%	1%	0%	0.2%
South Dakota	137	26%	60%	1%	1%	0%	12%	0%	0%	0%
Tennessee	3,092	47%	45%	2%	1%	0%	0%	0%	5%	0.0%
Texas	10,881	30%	28%	39%	1%	0%	0.3%	0%	1%	1%
Utah	422	8%	64%	26%	1%	1%	1%	0.2%	0.2%	0%
Vermont	135	14%	75%	5%	0%	0%	2%	1%	0%	3%
Virgin Islands (U.S.)	134	0%	7%	0%	0%	0%	0%	93%	0%	0%
Virginia	2,299	50%	33%	13%	1%	0.04%	0.2%	0%	0.1%	2%
Washington	2,823	12%	55%	18%	2%	1%	1%	10%	1%	0.4%
West Virginia	387	13%	82%	2%	1%	0%	0.3%	1%	0%	0%
Wisconsin	613	36%	42%	13%	2%	0.5%	1%	0%	0%	5%
Wyoming	79	3%	80%	10%	1%	0%	6%	0%	0%	0%
<b>Total</b>	<b>140,843</b>	<b>32%</b>	<b>34%</b>	<b>23%</b>	<b>2%</b>	<b>0.2%</b>	<b>0.4%</b>	<b>5%</b>	<b>1%</b>	<b>2%</b>

Note: 51 ADAPs reported data. American Samoa, Colorado, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Kentucky and North Dakota collect demographic information for clients served, but were unable to report data in this format. A dash (--) indicates the ADAP did not report data. A zero (0%) indicates the ADAP responded zero (0%) to the question.

**Table 11: ADAP Clients Served, by Gender, June 2012**

State/Territory	June 2012 Clients Served	Male	Female	Transgender	Unknown
Alabama	1,473	70%	30%	0%	0%
Alaska	72	79%	21%	0%	0%
American Samoa	--	--	--	--	--
Arizona	1,008	81%	18%	2%	0%
Arkansas	710	78%	22%	0%	0%
California	26,253	91%	9%	1%	0%
Colorado	3,083	84%	15%	1%	0%
Connecticut	1,724	72%	28%	0%	0%
Delaware	--	--	--	--	--
District of Columbia	785	75%	24%	0.4%	1%
Federated States of Micronesia	--	--	--	--	--
Florida	12,005	75%	25%	0.3%	0%
Georgia	3,319	76%	24%	0.1%	0.4%
Guam	--	--	--	--	--
Hawaii	329	91%	8%	1%	0%
Idaho	143	83%	17%	0%	0%
Illinois	4,484	78%	15%	1%	6%
Indiana	2,336	83%	17%	0%	0%
Iowa	488	78%	22%	0.4%	0%
Kansas	680	78%	21%	1%	0%
Kentucky	1,368	0%	0%	0%	100%
Louisiana	2,134	72%	27%	1%	0%
Maine	299	81%	19%	0%	0.3%
Marshall Islands	--	--	--	--	--
Maryland	4,106	66%	34%	0.1%	0%
Massachusetts	4,121	69%	31%	0.3%	0%
Michigan	2,779	0%	0%	0%	100%
Minnesota	667	75%	25%	0%	0%
Mississippi	888	74%	26%	0.3%	0%
Missouri	1,927	81%	18%	1%	0%
Montana	116	84%	16%	0%	0%
Nebraska	242	82%	17%	0.4%	0%
Nevada	876	81%	19%	1%	0%
New Hampshire	268	76%	24%	0%	0%
New Jersey	4,655	67%	33%	0%	0%
New Mexico	--	--	--	--	--
New York	16,477	77%	23%	0.2%	0%
North Carolina	4,419	29%	71%	0.3%	0%
North Dakota	67	0%	0%	0%	100%
Northern Mariana Islands	--	--	--	--	--
Ohio	2,369	84%	16%	0.3%	0%
Oklahoma	973	83%	17%	0%	0%
Oregon	2,713	87%	12%	1%	0%
Pennsylvania	4,249	77%	23%	0.1%	0%
Puerto Rico	4,535	63%	37%	0%	0%
Republic of Palau	--	--	--	--	--
Rhode Island	526	77%	22%	1%	0%
South Carolina	3,258	71%	29%	0.3%	0%
South Dakota	137	77%	23%	0%	0%
Tennessee	3,092	78%	22%	0.3%	0%
Texas	10,881	79%	21%	0.4%	0%
Utah	422	86%	14%	0%	0%
Vermont	135	81%	19%	0%	0%
Virgin Islands (U.S.)	134	52%	48%	0%	0%
Virginia	2,299	70%	28%	0.2%	2%
Washington	2,823	86%	12%	1%	0.3%
West Virginia	387	84%	16%	0%	0%
Wisconsin	613	84%	15%	1%	0%
Wyoming	79	81%	19%	0%	0%
<b>Total</b>	<b>143,926</b>	<b>75%</b>	<b>21%</b>	<b>0.3%</b>	<b>3%</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Kentucky and North Dakota collect demographic information for clients served, but were unable to report data in this format. A dash (--) indicates the ADAP did not report data. A zero (0%) indicates the ADAP responded zero (0%) to the question.

**Table 12: ADAP Clients Served, by Age, June 2012**

State/Territory	June 2012 Clients Served	≤12 Years	13-24 Years	25-44 Years	45-64 Years	>64 Years	Unknown
Alabama	1,473	0%	11%	55%	34%	0.3%	0%
Alaska	72	0%	3%	42%	53%	3%	0%
American Samoa	--	--	--	--	--	--	--
Arizona	1,008	0%	3%	55%	40%	2%	0%
Arkansas	710	0.1%	7%	51%	40%	1%	0%
California	26,253	0%	2%	42%	51%	5%	0%
Colorado	3,083	0.4%	2%	43%	51%	4%	0%
Connecticut	1,724	0.1%	2%	34%	58%	5%	0%
Delaware	--	--	--	--	--	--	--
District of Columbia	785	0.1%	2%	44%	50%	4%	0%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	12,005	0.1%	3%	37%	57%	3%	0%
Georgia	3,319	0.03%	4%	46%	48%	2%	0%
Guam	--	--	--	--	--	--	--
Hawaii	329	0%	1%	26%	62%	11%	0%
Idaho	143	0%	3%	54%	42%	1%	0%
Illinois	4,484	0.04%	6%	46%	42%	1%	6%
Indiana	2,336	0.04%	6%	48%	45%	1%	0%
Iowa	488	0%	5%	48%	45%	2%	0%
Kansas	680	1%	4%	45%	49%	3%	0%
Kentucky	1,368	0%	0%	0%	0%	0%	100%
Louisiana	2,134	0%	4%	47%	47%	3%	0%
Maine	299	0%	1%	34%	61%	4%	0%
Marshall Islands	--	--	--	--	--	--	--
Maryland	4,106	0.1%	2%	38%	54%	5%	0%
Massachusetts	4,121	0.02%	1%	29%	65%	5%	0%
Michigan	2,779	0.2%	6%	42%	49%	3%	0%
Minnesota	667	1%	6%	48%	42%	3%	0%
Mississippi	888	0%	9%	55%	35%	1%	0%
Missouri	1,927	0.1%	7%	52%	40%	0.8%	0%
Montana	116	0%	3%	49%	48%	0%	0%
Nebraska	242	1%	4%	43%	50%	2%	0%
Nevada	876	0.3%	3%	45%	47%	4%	0%
New Hampshire	268	1%	2%	30%	65%	2%	0.4%
New Jersey	4,655	0.1%	4%	39%	54%	2%	0%
New Mexico	--	--	--	--	--	--	--
New York	16,477	0.04%	2%	38%	54%	5%	0%
North Carolina	4,419	0.02%	5%	45%	48%	2%	0%
North Dakota	67	0%	0%	0%	0%	0%	100%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	2,369	0.04%	4%	40%	52%	3%	0%
Oklahoma	973	0%	5%	44%	49%	2%	0%
Oregon	2,713	0%	2%	39%	56%	3%	0%
Pennsylvania	4,249	0.05%	4%	36%	55%	5%	0%
Puerto Rico	4,535	0.3%	3%	33%	60%	3%	0%
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	526	0.4%	2%	37%	56%	4%	0%
South Carolina	3,258	0.1%	5%	42%	50%	2%	0.4%
South Dakota	137	1%	1%	41%	55%	1%	0%
Tennessee	3,092	0.1%	16%	59%	25%	0.4%	0%
Texas	10,881	0.1%	4%	48%	46%	3%	0%
Utah	422	0%	2%	54%	44%	1%	0%
Vermont	135	0%	1%	30%	64%	4%	0%
Virgin Islands (U.S.)	134	0%	0%	58%	40%	1%	0%
Virginia	2,299	0%	3%	37%	56%	5%	0.04%
Washington	2,823	0%	2%	43%	52%	3%	0%
West Virginia	387	0%	3%	40%	54%	3%	0%
Wisconsin	613	0.8%	7%	47%	43%	3%	0%
Wyoming	79	0%	3%	33%	63%	1%	0%
<b>Total</b>	<b>143,926</b>	<b>0.1%</b>	<b>3%</b>	<b>41%</b>	<b>50%</b>	<b>4%</b>	<b>1%</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Kentucky and North Dakota collect demographic information for clients served, but were unable to report data in this format. A dash (--) indicates the ADAP did not report data. A zero (0%) indicates the ADAP responded zero (0%) to the question.

**Table 13: ADAP Clients Served, by Income Level, June 2012**

State/Territory	June 2012 Clients Served	≤100% FPL	101-138% <sup>1</sup> FPL	139-200% FPL	201-300% FPL	301-400% FPL	>400% FPL	Unknown
Alabama	1,473	26%	37%	30%	7%	0%	0%	0%
Alaska	72	40%	19%	19%	21%	0%	0%	0%
American Samoa	--	--	--	--	--	--	--	--
Arizona	1,008	50%	17%	18%	14%	0.2%	0%	0%
Arkansas	710	45%	18%	37%	0%	0%	0%	0%
California	26,253	41%	11%	19%	18%	9%	2%	0%
Colorado	3,083	46%	16%	20%	16%	3%	0%	0%
Connecticut	1,724	30%	19%	26%	18%	6%	0%	0%
Delaware	--	--	--	--	--	--	--	--
District of Columbia	785	43%	8%	18%	17%	11%	3%	1%
Federated States of Micronesia	--	--	--	--	--	--	--	--
Florida	12,005	48%	17%	18%	13%	4%	0%	0%
Georgia	3,319	48%	40%	0%	12%	0.1%	0%	0.1%
Guam	--	--	--	--	--	--	--	--
Hawaii	329	33%	20%	27%	17%	4%	0%	0%
Idaho	143	66%	17%	17%	0%	0%	0%	0%
Illinois	4,484	51%	11%	16%	12%	3%	1%	6%
Indiana	2,336	49%	14%	22%	15%	0.3%	0.1%	0%
Iowa	488	44%	18%	24%	14%	1%	0%	0%
Kansas	680	51%	12%	19%	17%	1%	1%	0%
Kentucky	1,368	0%	100%	0%	0%	0%	0%	0%
Louisiana	2,134	51%	0%	37%	12%	0%	0%	0%
Maine	299	49%	16%	13%	16%	4%	2%	0%
Marshall Islands	--	--	--	--	--	--	--	--
Maryland	4,106	23%	13%	23%	21%	13%	7%	0%
Massachusetts	4,121	46%	9%	12%	15%	11%	7%	0%
Michigan	2,779	36%	16%	20%	15%	8%	4%	2%
Minnesota	667	23%	6%	27%	36%	6%	3%	0%
Mississippi	888	77%	0%	13%	6%	4%	0%	0%
Missouri	1,927	48%	18%	15%	18%	0%	0%	0%
Montana	116	39%	20%	18%	16%	3%	0%	4%
Nebraska	242	45%	0%	55%	0%	0%	0%	0%
Nevada	876	42%	16%	22%	14%	6%	0%	0%
New Hampshire	268	37%	15%	23%	25%	1%	0%	0%
New Jersey	4,655	35%	11%	10%	17%	17%	10%	0%
New Mexico	--	--	--	--	--	--	--	--
New York	16,477	33%	11%	24%	19%	11%	2%	0%
North Carolina	4,419	60%	20%	16%	4%	0%	0%	0%
North Dakota	67	0%	0%	0%	0%	0%	0%	100%
Northern Mariana Islands	--	--	--	--	--	--	--	--
Ohio	2,369	45%	13%	23%	19%	0%	0%	0.2%
Oklahoma	973	42%	0%	45%	13%	0%	0%	0%
Oregon	2,713	50%	18%	18%	12%	2%	0%	0%
Pennsylvania	4,249	26%	12%	19%	25%	13%	6%	0%
Puerto Rico	4,535	98%	2%	1%	0%	0%	0%	0%
Republic of Palau	--	--	--	--	--	--	--	--
Rhode Island	526	53%	22%	13%	10%	2%	0%	0%
South Carolina	3,258	46%	10%	19%	16%	6%	3%	0%
South Dakota	137	45%	15%	23%	18%	0%	0%	0%
Tennessee	3,092	70%	8%	13%	7%	1%	1%	0%
Texas	10,881	52%	13%	23%	12%	0.5%	0%	0%
Utah	422	52%	15%	21%	12%	0%	0%	0%
Vermont	135	35%	20%	36%	6%	2%	1%	0%
Virgin Islands (U.S.)	134	0%	0%	14%	86%	0%	0%	0%
Virginia	2,299	57%	14%	16%	9%	2%	0.1%	2%
Washington	2,823	36%	14%	25%	23%	2%	0%	0%
West Virginia	387	46%	30%	12%	7%	4%	0%	0%
Wisconsin	613	49%	0%	29%	22%	0%	0%	0.2%
Wyoming	79	47%	15%	9%	19%	10%	0%	0%
<b>Total</b>	<b>143,926</b>	<b>45%</b>	<b>14%</b>	<b>19%</b>	<b>15%</b>	<b>6%</b>	<b>2%</b>	<b>0.4%</b>

<sup>1</sup> In 2014, the ACA expands Medicaid eligibility to most people with income up to 133% of the federal poverty level (FPL). However, in addition to new income counting rules for most Medicaid populations (called "Modified Adjusted Gross Income"), there is an additional 5% disregard of income, effectively bumping the Medicaid income eligibility threshold to 138% FPL.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. Kentucky and North Dakota collect demographic information for clients served, but were unable to report data in this format. A dash (--) indicates the ADAP did not report data. A zero (0%) indicates the ADAP responded zero (0%) to the question. The 2012 Federal Poverty Level (FPL) was \$11,170 (slightly higher in Alaska and Hawaii) for a household of one.

**Table 14: ADAP Clients Served, by HIV/AIDS Status, June 2012**

State/Territory	June 2012 Clients Served	HIV positive, not AIDS	HIV positive, AIDS status unknown	CDC-defined AIDS	Unknown
Alabama	1,473	0%	0%	0%	100%
Alaska	72	0%	0%	0%	100%
American Samoa	--	--	--	--	--
Arizona	1,008	40%	0.1%	60%	0%
Arkansas	710	69%	3%	28%	0.4%
California	26,253	64%	0%	34%	2%
Colorado	--	--	--	--	--
Connecticut	1,724	43%	15%	42%	0%
Delaware	--	--	--	--	--
District of Columbia	785	0%	100%	0%	0%
Federated States of Micronesia	--	--	--	--	--
Florida	12,005	79%	3%	17%	0%
Georgia	3,319	84%	4%	12%	0%
Guam	--	--	--	--	--
Hawaii	329	36%	22%	43%	0%
Idaho	143	0%	0%	0%	100%
Illinois	4,484	74%	0%	20%	6%
Indiana	2,336	40%	0%	60%	0%
Iowa	488	51%	1%	48%	0%
Kansas	680	41%	5%	51%	2%
Kentucky	1,368	0%	0%	0%	100%
Louisiana	2,134	47%	19%	34%	0%
Maine	299	62%	10%	25%	3%
Marshall Islands	--	--	--	--	--
Maryland	4,106	72%	3%	25%	0%
Massachusetts	4,121	40%	6%	54%	0%
Michigan	2,779	0%	0%	0%	100%
Minnesota	667	70%	0%	30%	0%
Mississippi	--	--	--	--	--
Missouri	1,927	0%	100%	0%	0%
Montana	116	50%	10%	40%	0%
Nebraska	242	58%	0%	42%	0%
Nevada	876	0%	0%	0.0%	100%
New Hampshire	268	52%	1%	47%	0%
New Jersey	4,655	59%	0%	41%	0%
New Mexico	--	--	--	--	--
New York	16,477	6%	91%	3%	0%
North Carolina	4,419	0%	0%	0%	100%
North Dakota	67	0%	0%	0%	100%
Northern Mariana Islands	--	--	--	--	--
Ohio	2,369	57%	1%	29%	12%
Oklahoma	973	56%	0%	44%	0%
Oregon	2,713	23%	31%	46%	0%
Pennsylvania	4,249	0%	100%	0%	0%
Puerto Rico	4,535	0%	100%	0%	0%
Republic of Palau	--	--	--	--	--
Rhode Island	526	0%	0%	0%	100%
South Carolina	3,258	47%	1%	39%	13%
South Dakota	137	79%	0%	21%	0%
Tennessee	3,092	58%	2%	40%	0%
Texas	10,881	0%	100%	0%	0%
Utah	422	68%	0.2%	32%	0%
Vermont	135	0%	0%	0%	100%
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	2,299	31%	15%	54%	0%
Washington	2,823	0%	100%	0%	0%
West Virginia	387	58%	0%	42%	0%
Wisconsin	613	0%	100%	0%	0%
Wyoming	79	32%	0%	68%	0%
<b>Total</b>	<b>139,824</b>	<b>38%</b>	<b>31%</b>	<b>21%</b>	<b>10%</b>

Note: 49 ADAPs reported data. American Samoa, Colorado, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Mississippi, Northern Mariana Islands, Republic of Palau, and Virgin Islands (U.S.) did not respond. Kentucky and North Dakota collect demographic information for clients served, but were unable to report data in this format. A dash (–) indicates the ADAP did not report data. A zero (0%) indicates the ADAP responded zero (0%) to the question.

**Table 15: ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2012**

State/Territory	Number of Clients <sup>1</sup>	CD4 <200	CD4 between 201-350	CD4 between 351-500	CD4 > 500
Alabama	--	--	--	--	--
Alaska	--	--	--	--	--
American Samoa	--	--	--	--	--
Arizona	1,000	23%	23%	21%	34%
Arkansas	48	26%	21%	0%	0%
California	3,556	23%	19%	22%	36%
Colorado	--	--	--	--	--
Connecticut	--	--	--	--	--
Delaware	--	--	--	--	--
District of Columbia	135	27%	15%	18%	40%
Federated States of Micronesia	--	--	--	--	--
Florida	15,722	12%	18%	22%	47%
Georgia	926	54%	43%	3%	0%
Guam	--	--	--	--	--
Hawaii	99	24%	22%	16%	37%
Idaho	143	0%	0%	0%	100%
Illinois	1,512	15%	23%	25%	37%
Indiana	2,313	25%	12%	16%	47%
Iowa	161	21%	24%	22%	32%
Kansas	--	--	--	--	--
Kentucky	--	--	--	--	--
Louisiana	--	--	--	--	--
Maine	749	30%	17%	15%	39%
Marshall Islands	--	--	--	--	--
Maryland	981	22%	22%	23%	33%
Massachusetts	546	29%	20%	18%	33%
Michigan	--	--	--	--	--
Minnesota	2,016	11%	17%	22%	50%
Mississippi	--	--	--	--	--
Missouri	--	--	--	--	--
Montana	--	--	--	--	--
Nebraska	--	--	--	--	--
Nevada	1,768	78%	18%	4%	0%
New Hampshire	65	15%	11%	20%	54%
New Jersey	769	21%	19%	19%	41%
New Mexico	--	--	--	--	--
New York	2,532	21%	19%	22%	38%
North Carolina	1,029	31%	21%	20%	28%
North Dakota	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--
Ohio	562	30%	20%	20%	30%
Oklahoma	893	12%	16%	17%	54%
Oregon	490	10%	26%	25%	39%
Pennsylvania	--	--	--	--	--
Puerto Rico	--	--	--	--	--
Republic of Palau	--	--	--	--	--
Rhode Island	--	--	--	--	--
South Carolina	729	36%	24%	21%	18%
South Dakota	--	--	--	--	--
Tennessee	954	21%	19%	23%	37%
Texas	2,973	30%	25%	22%	23%
Utah	77	27%	30%	27%	16%
Vermont	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	442	35%	17%	22%	26%
Washington	4,697	10%	17%	23%	50%
West Virginia	102	15%	39%	26%	20%
Wisconsin	--	--	--	--	--
Wyoming	--	--	--	--	--
<b>Total</b>	<b>47,989</b>	<b>21%</b>	<b>19%</b>	<b>21%</b>	<b>39%</b>

<sup>1</sup>This number reflects only the number of clients for which CD4 count was reported.

Note: 30 ADAPs reported data. Data reflect clients enrolled in ADAPs over the past 12 months or the most recent 12 months for which data are available. A dash (--) indicates the ADAP did not report data.



**Table 16: ADAP Drug Expenditures (Including Purchases and Co-payments), June 2012**

State/Territory	June 2012 Drug Purchases	Drug Purchases % of Total Expenditures	June 2012 Co-Payment Expenditures	Co-Payment % of Total Expenditures	June 2012 Total Drug Expenditures (Including Purchases and Co-payments)
Alabama	\$1,224,426	100%	\$0	0%	\$1,224,426
Alaska	\$84,158	100%	\$0	0%	\$84,158
American Samoa	--	--	--	--	--
Arizona	\$770,506	62%	\$467,728	38%	\$1,238,234
Arkansas	\$455,772	96%	\$16,860	4%	\$472,632
California	\$38,142,929	100%	\$0	0%	\$38,142,929
Colorado	\$1,061,356	93%	\$83,812	7%	\$1,145,168
Connecticut	\$2,026,818	91%	\$209,481	9%	\$2,236,300
Delaware	--	--	--	--	--
District of Columbia	\$5,088,427	98%	\$92,080	2%	\$5,180,507
Federated States of Micronesia	--	--	--	--	--
Florida	\$1,934,461	100%	\$8,642	0.4%	\$1,943,103
Georgia	\$3,115,710	100%	\$0	0%	\$3,115,710
Guam	--	--	--	--	--
Hawaii	\$215,463	89%	\$26,529	11%	\$241,992
Idaho	\$322,913	100%	\$0	0%	\$322,913
Illinois	\$3,919,140	93%	\$305,508	7%	\$4,224,648
Indiana	\$76,564	25%	\$232,433	75%	\$308,998
Iowa	\$242,268	89%	\$29,902	11%	\$272,171
Kansas	\$656,094	70%	\$284,553	30%	\$940,646
Kentucky	\$930,341	100%	\$0	0%	\$930,341
Louisiana	\$1,102,870	83%	\$227,608	17%	\$1,330,478
Maine	\$106,288	75%	\$36,267	25%	\$142,555
Marshall Islands	--	--	--	--	--
Maryland	\$2,154,459	84%	\$408,631	16%	\$2,563,090
Massachusetts	\$304,839	57%	\$230,175	43%	\$535,014
Michigan	\$2,765,463	76%	\$871,532	24%	\$3,636,995
Minnesota	\$443,828	100%	\$0	0%	\$443,828
Mississippi	--	--	--	--	--
Missouri	\$1,866,346	100%	\$238,312	11%	\$2,104,658
Montana	\$165,103	94%	\$10,534	6%	\$175,637
Nebraska	--	--	--	--	--
Nevada	\$646,998	91%	\$61,574	9%	\$708,572
New Hampshire	\$215,012	87%	\$31,324	13%	\$246,336
New Jersey	\$7,634,344	100%	\$0	0%	\$7,634,344
New Mexico	\$18,295	100%	\$0	0%	\$18,295
New York	\$22,363,929	100%	\$0	0%	\$22,363,929
North Carolina	\$3,274,317	97%	\$112,284	3%	\$3,386,601
North Dakota	\$71,771	100%	\$0	0%	\$71,771
Northern Mariana Islands	--	--	--	--	--
Ohio	\$1,302,394	92%	\$107,205	8%	\$1,409,599
Oklahoma	\$380,896	82%	\$82,349	18%	\$463,245
Oregon	\$2,000,855	99%	\$27,347	1%	\$2,028,202
Pennsylvania	\$5,946,712	94%	\$383,023	6%	\$6,329,735
Puerto Rico	\$4,268,509	100%	\$0	0%	\$4,268,509
Republic of Palau	--	--	--	--	--
Rhode Island	\$622,349	100%	\$0	0%	\$622,349
South Carolina	\$1,761,825	88%	\$231,956	12%	\$1,993,782
South Dakota	\$129,085	100%	\$0	0%	\$129,085
Tennessee	\$1,896,208	100%	\$0	0%	\$1,896,208
Texas	\$7,520,739	96%	\$280,862	4%	\$7,801,601
Utah	\$378,367	93%	\$27,736	7%	\$406,103
Vermont	\$39,530	100%	\$0	0%	\$39,530
Virgin Islands (U.S.)	\$396,789	100%	\$0	0%	\$396,789
Virginia	\$1,734,056	97%	\$58,472	3%	\$1,792,528
Washington	\$80,761	31%	\$181,512	69%	\$262,273
West Virginia	\$437,813	100%	\$0	0%	\$437,813
Wisconsin	\$1,017,668	100%	\$0	0%	\$1,017,668
Wyoming	\$71,410	100%	\$0	0%	\$71,410
<b>Total</b>	<b>\$133,387,176</b>	<b>96%</b>	<b>\$5,366,231</b>	<b>4%</b>	<b>\$138,753,407</b>

Note: 50 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Mississippi, Nebraska, Northern Mariana Islands, and Republic of Palau did not respond. A dash (--) indicates the ADAP did not report data. A zero (\$0) indicates the ADAP responded zero (\$0) to the question.

**Table 17: ADAP Drug Expenditures (Including Purchases and Co-payments), by Drug Category, June 2012**

State/Territory	June 2012 Total Expenditures	June 2012 ARV Total Expenditures <sup>1</sup>	ARV % of Total Expenditures <sup>1</sup>	June 2012 "A1" OI Total Expenditures <sup>2</sup>	"A1" OI % of Total Expenditures <sup>2</sup>	June 2012 All Other Total Expenditures	All Other % of Total Expenditures
Alabama	\$1,224,426	\$1,204,897	98%	\$16,647	1%	\$2,882	0.2%
Alaska	\$84,158	\$82,073	99%	\$321	0.4%	\$1,764	1%
American Samoa	--	--	--	--	--	--	--
Arizona	\$1,238,234	\$1,123,367	91%	\$22,970	2%	\$91,897	7%
Arkansas	\$472,632	\$472,632	--	\$0	--	\$0	--
California	\$38,142,929	\$35,962,849	94%	\$477,267	1%	\$1,702,812	4%
Colorado	\$1,145,168	\$1,102,572	96%	\$15,839	1%	\$26,757	2%
Connecticut	\$2,236,300	\$1,947,974	87%	\$32,985	1%	\$255,341	11%
Delaware	--	--	--	--	--	--	--
District of Columbia	\$5,180,507	\$5,085,855	--	\$88,427	--	\$6,225	--
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	\$1,943,103	\$1,912,058	98%	\$31,045	2%	\$0	0%
Georgia	\$3,115,710	\$3,072,346	99%	\$42,617	1%	\$747	0.02%
Guam	--	--	--	--	--	--	--
Hawaii	\$241,992	\$226,712	94%	\$1,686	1%	\$13,594	6%
Idaho	\$322,913	\$319,147	99%	\$3,766	1%	\$0	0%
Illinois	\$4,224,648	\$4,097,216	97%	\$29,146	1%	\$98,287	2%
Indiana	\$308,998	\$131,722	43%	\$5,198	2%	\$172,078	56%
Iowa	\$272,171	\$261,594	96%	\$4,436	2%	\$6,141	2%
Kansas	\$940,646	\$872,314	93%	\$21,643	2%	\$46,688	5%
Kentucky	\$930,341	\$930,341	100%	\$0	0%	\$0	0%
Louisiana	\$1,330,478	\$1,277,596	96%	\$11,406	1%	\$41,476	3%
Maine	\$142,555	\$124,561	87%	\$1,898	1%	\$16,097	11%
Marshall Islands	--	--	--	--	--	--	--
Maryland	\$2,563,090	\$2,444,432	95%	\$47,694	2%	\$70,964	3%
Massachusetts	\$535,014	\$438,851	82%	\$2,780	1%	\$93,383	17%
Michigan	\$3,636,995	\$3,084,908	85%	\$27,711	1%	\$524,376	14%
Minnesota	\$443,828	\$427,915	96%	\$4,764	1%	\$11,149	3%
Mississippi	--	--	--	--	--	--	--
Missouri	\$2,104,658	\$1,969,325	94%	\$44,323	2%	\$91,010	4%
Montana	\$175,637	\$166,969	95%	\$7,962	5%	\$706	0.4%
Nebraska	--	--	--	--	--	--	--
Nevada3	\$708,572	\$693,845	98%	\$14,727	2%	\$0	0%
New Hampshire	\$246,336	\$221,490	90%	\$1,067	0.4%	\$23,779	10%
New Jersey	\$7,634,344	\$5,647,877	74%	\$18,544	0.2%	\$1,967,923	26%
New Mexico	\$18,295	\$9,102	50%	\$44	0.2%	\$9,149	50%
New York	\$22,363,929	\$20,187,067	90%	\$658,031	3%	\$1,518,831	7%
North Carolina	\$3,386,601	\$3,308,008	98%	\$47,156	1%	\$31,437	1%
North Dakota	\$71,771	\$71,771	100%	\$0	0%	\$0	0%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	\$1,409,599	\$1,359,001	96%	\$8,528	1%	\$42,071	3%
Oklahoma	\$463,245	\$437,557	94%	\$5,717	1%	\$19,971	4%
Oregon	\$2,028,202	\$1,838,296	91%	\$17,441	1%	\$172,465	9%
Pennsylvania	\$6,329,735	\$5,690,358	90%	\$74,585	1%	\$564,792	9%
Puerto Rico	\$4,268,509	\$4,266,499	100%	\$2,010	0.05%	\$0	0%
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	\$622,349	\$610,816	98%	\$7,807	1%	\$3,726	1%
South Carolina	\$1,993,782	\$1,968,116	99%	\$8,002	0.4%	\$17,664	1%
South Dakota	\$129,085	\$124,460	96%	\$4,518	4%	\$107	0.1%
Tennessee	\$1,896,208	\$1,848,823	98%	\$44,697	2%	\$2,689	0.1%
Texas	\$7,801,601	\$7,657,396	98%	\$63,087	1%	\$81,118	1%
Utah	\$406,103	\$394,542	97%	\$6,750	2%	\$4,811	1%
Vermont	\$39,530	\$36,438	92%	\$3,092	8%	\$0	0%
Virgin Islands (U.S.)	\$396,789	\$396,789	100%	\$0	0%	\$0	0%
Virginia	\$1,792,528	\$1,748,195	98%	\$42,563	2%	\$1,770	0.1%
Washington	\$262,273	\$235,386	90%	\$6,718	3%	\$20,169	8%
West Virginia	\$437,813	\$411,544	94%	\$8,757	2%	\$17,512	4%
Wisconsin	\$1,017,668	\$989,529	97%	\$20,409	2%	\$7,730	1%
Wyoming	\$71,410	\$69,590	97%	\$591	1%	\$1,230	2%
<b>Total</b>	<b>\$138,753,407</b>	<b>\$128,962,719</b>	<b>93%</b>	<b>\$2,007,372</b>	<b>1%</b>	<b>\$7,783,317</b>	<b>6%</b>

<sup>1</sup> ARV=Antiretrovirals.

<sup>2</sup> "A1" OI=Drugs recommended ("A1" for the prevention and treatment of opportunistic infections (OIs).

Note: 50 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Mississippi, Nebraska, Northern Mariana Islands, and Republic of Palau did not respond. A dash (--) indicates the ADAP did not report data. A zero (\$0) indicates the ADAP responded zero (\$0) to the question.

**Table 18: ADAP Prescriptions Filled (Including Purchases and Co-payments), June 2012**

State/Territory	June 2012 Drug Purchases Rx¹	Drug Purchases Rx % of Total Rx	June 2012 Co-Payment Rx	Co-Payment Rx % of Total Rx	June 2012 Total Rx
Alabama	4,079	100%	11	0%	4,090
Alaska	165	100%	0	0%	165
American Samoa	--	--	--	--	--
Arizona	4,883	49%	5,047	51%	9,930
Arkansas	362	50%	362	50%	724
California	94,267	100%	0	0%	94,267
Colorado	3,552	56%	2,837	44%	6,389
Connecticut	3,411	65%	1,834	35%	5,245
Delaware	--	--	--	--	--
District of Columbia	1,557	68%	741	32%	2,298
Federated States of Micronesia	--	--	--	--	--
Florida	21,031	99%	236	1%	21,267
Georgia	9,520	100%	0	0%	9,520
Guam	--	--	--	--	--
Hawaii	674	66%	346	34%	1,020
Idaho	322	100%	0	0%	322
Illinois	9,595	86%	1,612	14%	11,207
Indiana	208	2%	11,220	98%	11,428
Iowa	722	57%	550	43%	1,272
Kansas	945	45%	1,158	55%	2,103
Kentucky	--	--	--	--	--
Louisiana	3,154	44%	4,039	56%	7,193
Maine	179	15%	1,028	85%	1,207
Marshall Islands	--	--	--	--	--
Maryland	4,365	39%	6,826	61%	11,191
Massachusetts	1,004	6%	15,760	94%	16,764
Michigan	4,905	48%	5,346	52%	10,251
Minnesota	1,932	100%	0	0%	1,932
Mississippi	--	--	--	--	--
Missouri	3,243	100%	2,287	0%	5,530
Montana	453	87%	68	13%	521
Nebraska	286	46%	334	54%	620
Nevada	1,755	66%	909	34%	2,664
New Hampshire	371	32%	775	68%	1,146
New Jersey	21,030	100%	0	0%	21,030
New Mexico	32	100%	0	0%	32
New York	65,605	100%	0	0%	65,605
North Carolina	9,834	87%	1,422	13%	11,256
North Dakota	144	100%	0	0%	144
Northern Mariana Islands	--	--	--	--	--
Ohio	3,546	63%	2,064	37%	5,610
Oklahoma	1,752	53%	1,549	47%	3,301
Oregon	12,519	99%	140	1%	12,659
Pennsylvania	11,420	60%	7,667	40%	19,087
Puerto Rico	10,679	100%	0	0%	10,679
Republic of Palau	--	--	--	--	--
Rhode Island	1,193	100%	0	0%	1,193
South Carolina	6,024	69%	2,764	31%	8,788
South Dakota	256	100%	0	0%	256
Tennessee	3,950	100%	0	0%	3,950
Texas	21,416	71%	8,822	29%	30,238
Utah	997	84%	184	16%	1,181
Vermont	395	100%	0	0%	395
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	4,970	78%	1,366	22%	6,336
Washington	250	6%	4,263	94%	4,513
West Virginia	824	100%	0	0%	824
Wisconsin	1,646	100%	0	0%	1,646
Wyoming	165	100%	0	0%	165
<b>Total</b>	<b>355,587</b>	<b>79%</b>	<b>93,567</b>	<b>21%</b>	<b>449,154</b>

¹Rx=Prescription

Note: 49 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Kentucky, Marshall Islands, Mississippi, Northern Mariana Islands, Republic of Palau, and Virgin Islands (U.S.) did not respond. A dash (--) indicates the ADAP did not report data. A zero (0) indicates the ADAP responded zero (0) to the question.

**Table 19: ADAP Prescriptions Filled (Including Purchases and Co-payments), by Drug Category, June 2012**

State/Territory	June 2012 Total Rx <sup>1</sup>	June 2012 ARV Total Rx <sup>2</sup>	ARV % of Total Rx <sup>2</sup>	June 2012 "A1" OI Total Rx <sup>3</sup>	"A1" OI % of Total Rx <sup>3</sup>	June 2012 All Other Total Rx	All Other Rx % of Total Rx
Alabama	4,090	2,943	72%	1,095	27%	52	1%
Alaska	165	118	72%	10	6%	37	22%
American Samoa	--	--	--	--	--	--	--
Arizona	9,930	3,491	35%	741	7%	5,698	57%
Arkansas	724	724	100%	0	0%	0	0%
California	94,267	56,271	60%	7,749	8%	30,247	32%
Colorado	6,389	4,054	63%	512	8%	1,823	29%
Connecticut	5,245	2,547	49%	333	6%	2,365	45%
Delaware	--	--	--	--	--	--	--
District of Columbia	2,298	1,803	78%	116	5%	379	16%
Federated States of Micronesia	--	0	--	0	--	0	--
Florida	21,267	19,662	92%	1,605	8%	0	0%
Georgia	9,520	8,266	87%	1,254	13%	0	0%
Guam	--	--	--	--	--	--	--
Hawaii	1,020	733	72%	81	8%	206	20%
Idaho	322	302	94%	20	6%	0	0%
Illinois	11,207	9,686	86%	546	5%	975	9%
Indiana	11,428	2,215	19%	347	3%	8,866	78%
Iowa	1,272	1,013	80%	116	9%	143	11%
Kansas	2,103	1,550	74%	155	7%	398	19%
Kentucky	--	--	--	--	--	--	--
Louisiana	7,193	4,239	59%	450	6%	2,504	35%
Maine	1,207	552	46%	56	5%	599	50%
Marshall Islands	--	--	--	--	--	--	--
Maryland	11,191	7,075	63%	490	4%	3,626	32%
Massachusetts	16,764	5,665	34%	96	1%	11,003	66%
Michigan	10,251	5,638	55%	638	6%	3,975	39%
Minnesota	1,932	1,321	68%	83	4%	528	27%
Mississippi	--	--	--	--	--	--	--
Missouri	5,530	3,241	59%	394	7%	1,895	34%
Montana	521	494	95%	17	3%	10	2%
Nebraska	620	477	77%	27	4%	116	19%
Nevada <sup>4</sup>	2,664	2,026	76%	638	24%	0	0%
New Hampshire	1,146	470	41%	21	2%	655	57%
New Jersey	21,030	9,507	45%	471	2%	11,052	53%
New Mexico	32	25	78%	3	9%	4	13%
New York	65,605	30,650	47%	4,548	7%	30,407	46%
North Carolina	11,256	9,005	80%	1,688	15%	563	5%
North Dakota	144	144	100%	0	0%	0	0%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	5,610	4,679	83%	280	5%	651	12%
Oklahoma	3,301	1,711	52%	223	7%	1,367	41%
Oregon	12,659	5,905	47%	462	4%	6,292	50%
Pennsylvania	19,087	7,863	41%	961	5%	10,263	54%
Puerto Rico	10,679	10,606	99%	73	1%	0	0%
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	1,193	903	76%	92	8%	198	17%
South Carolina	8,788	7,029	80%	643	7%	1,116	13%
South Dakota	256	230	90%	17	7%	9	4%
Tennessee	3,950	3,242	82%	480	12%	228	6%
Texas	30,238	23,616	78%	1,127	4%	5,495	18%
Utah	1,181	989	84%	144	12%	48	4%
Vermont	395	274	69%	121	31%	0	0%
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	6,336	5,449	86%	855	13%	32	1%
Washington	4,513	2,420	54%	231	5%	1,862	41%
West Virginia	824	626	76%	90	11%	108	13%
Wisconsin	1,646	1,314	80%	197	12%	135	8%
Wyoming	165	96	58%	11	7%	58	35%
<b>Total</b>	<b>449,154</b>	<b>272,859</b>	<b>61%</b>	<b>30,307</b>	<b>7%</b>	<b>145,988</b>	<b>33%</b>

<sup>1</sup>Rx=Prescription.

<sup>2</sup>ARV=Antiretrovirals.

<sup>3</sup>"A1" OI=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs).

Note: 49 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Kentucky, Marshall Islands, Mississippi, Northern Mariana Islands, Republic of Palau, and Virgin Islands (U.S.) did not respond. A dash (--) indicates the ADAP did not report data. A zero (0) indicates the ADAP responded zero (0) to the question.

**Table 20: ADAP Drug Purchasing, June 2012**

State/Territory	Purchasing Mechanism	Participates in 340B Drug Discount Program	Participates in HRSA Prime Vendor Program
Alabama	Direct Purchase	Yes	Yes
Alaska	Direct Purchase	Yes	Yes
American Samoa	--	--	--
Arizona	Dual	Yes	Yes
Arkansas	Dual	Yes	Yes
California	Rebate	Yes	--
Colorado	Dual	Yes	Yes
Connecticut	Rebate	Yes	--
Delaware	--	--	--
District of Columbia	Direct Purchase	Yes	Yes
Federated States of Micronesia	--	--	--
Florida	Dual	Yes	Yes
Georgia	Dual	Yes	Yes
Guam	--	--	--
Hawaii	Dual	Yes	Yes
Idaho	Rebate	Yes	--
Illinois	Dual	Yes	Yes
Indiana	Rebate	Yes	--
Iowa	Dual	Yes	Yes
Kansas	Rebate	Yes	--
Kentucky	Dual	Yes	Yes
Louisiana	Dual	Yes	Yes
Maine	Rebate	Yes	--
Marshall Islands	--	--	--
Maryland	Rebate	Yes	--
Massachusetts	Rebate	Yes	--
Michigan	Rebate	Yes	--
Minnesota	Rebate	Yes	--
Mississippi	Direct Purchase	Yes	Yes
Missouri	Rebate	Yes	--
Montana	Dual	Yes	Yes
Nebraska	Hybrid	Yes	--
Nevada	Hybrid	Yes	--
New Hampshire	Rebate	Yes	--
New Jersey	Rebate	Yes	--
New Mexico	Direct Purchase	Yes	Yes
New York	Rebate	Yes	--
North Carolina	Dual	Yes	Yes
North Dakota	Rebate	Yes	--
Northern Mariana Islands	--	--	--
Ohio	Dual	Yes	Yes
Oklahoma	Dual	Yes	Yes
Oregon	Dual	Yes	Yes
Pennsylvania	Rebate	Yes	--
Puerto Rico	Dual	Yes	Yes
Republic of Palau	--	--	--
Rhode Island	Rebate	Yes	--
South Carolina	Dual	Yes	Yes
South Dakota	Rebate	Yes	--
Tennessee	Dual	Yes	Yes
Texas	Dual	Yes	Yes
Utah	Hybrid	Yes	--
Vermont	Rebate	Yes	--
Virgin Islands (U.S.)	Direct Purchase	Yes	No
Virginia	Dual	Yes	Yes
Washington	Rebate	Yes	--
West Virginia	Rebate	Yes	--
Wisconsin	Rebate	Yes	--
Wyoming	Rebate	Yes	--
<b>Total</b>		<b>52</b>	<b>25</b>

Direct Purchase states – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider.

Pharmacy Network (Rebate) states – These are ADAPs who pay retail pharmacies a pre-determined amount at the point of sale for drugs dispensed to ADAP clients. ADAP then bills drug manufacturers for the 340B Unit Rebate amount for the number of units dispensed.

Hybrid states – A direct purchase state that utilizes an existing entity (e.g., University Hospital) to purchase and distribute ADAP drugs. The entity maintains a single drug inventory purchased at 340B prices. To secure the additional supplemental discounts negotiated by the ADAP Crisis Task Force, these ADAPs must submit rebate claims for any supplemental discount amounts.

Dual Purchaser – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider and bill drug manufacturers for the 340B Unit Rebate amount for the number of units dispensed for clients accessing an insurance plan (public or private).

340B Drug Pricing Program – requires drug manufacturers to provide outpatient drugs to eligible health care organizations for eligible patients at significantly reduced prices. The 340B program is designed to provide a pricing benefit to safety-net providers. The 340B program is administered by the Office of Pharmacy Affairs.

HRSA Prime Vendor Program – Participants in the 340B Program may also participate in the 340B Prime Vendor Program. A “prime vendor” is an entity that negotiates with manufacturers on behalf of a group of drug purchasers, in order to obtain reduced drug prices. HRSA has chosen a prime vendor to negotiate additional discounts (i.e., lower than the 340B ceiling price or sub-340B ceiling price) for participants, including ADAPs.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. A dash (–) indicates the ADAP did not report data.

**Table 21: Federal ADAP Funds Used and Clients Served Through Insurance Purchasing and Continuation, 2012**

State/Territory	FY2012 Estimated Expenditures	June 2012 Expenditures	June 2012 Clients Served Through Insurance Purchasing or Continuation <sup>1</sup>
Alabama	\$289,939	\$5,472	85
Alaska	\$168,683	\$25,570	44
American Samoa	--	--	--
Arizona	\$0	\$0	0
Arkansas	\$500,000	\$16,860	100
California	\$14,016,333	\$1,168,028	9,122
Colorado	\$6,647,077	\$427,763	1,171
Connecticut	\$3,400,000	\$271,721	900
Delaware	--	--	--
District of Columbia	--	\$20,698	250
Federated States of Micronesia	--	--	--
Florida	\$21,960,731	\$892,233	2,377
Georgia	\$0	\$0	0
Guam	--	--	--
Hawaii	\$600,000	\$48,641	120
Idaho	\$0	\$0	0
Illinois	\$2,080,000	\$305,508	512
Indiana	\$7,772,804	\$5,364,842	2,270
Iowa	\$1,097,785	\$69,544	199
Kansas	\$300,000	\$260,664	358
Kentucky	\$0	\$0	0
Louisiana	\$7,000,000	\$250,000	734
Maine	\$150,000	\$53,063	288
Marshall Islands	--	--	--
Maryland	\$15,279,391	\$1,713,089	2,379
Massachusetts	\$12,000,000	\$1,001,748	3,447
Michigan	\$5,200,000	\$642,902	1,393
Minnesota	\$1,237,216	\$0	187
Mississippi	\$0	\$0	0
Missouri	\$4,200,000	\$98,135	886
Montana	\$186,000	\$10,534	27
Nebraska	\$77,000	\$5,937	112
Nevada	\$658,808	\$16,042	252
New Hampshire	\$583,000	\$53,882	172
New Jersey	\$5,000,000	\$355,000	90
New Mexico	\$1,933,186	\$2,010	775
New York	\$42,054,101	\$3,414,548	4,057
North Carolina	\$2,179,613	\$112,285	538
North Dakota	\$0	\$0	0
Northern Mariana Islands	--	--	--
Ohio	\$2,000,000	\$304,580	919
Oklahoma	\$2,075,200	\$168,847	485
Oregon	\$10,330,568	\$879,703	2,653
Pennsylvania	\$324,521	\$18,589	1,956
Puerto Rico	\$0	\$0	0
Republic of Palau	--	--	--
Rhode Island	\$0	\$0	0
South Carolina	\$4,000,000	\$347,972	1,016
South Dakota	\$0	\$0	0
Tennessee	\$8,000,000	\$563,901	1,539
Texas	\$6,000,000	\$280,862	1,449
Utah	\$525,000	\$53,526	135
Vermont	\$775,000	\$0	124
Virgin Islands (U.S.)	\$0	\$0	0
Virginia	\$9,517,110	\$71,068	330
Washington	\$24,406,735	\$283,725	2,706
West Virginia	\$0	\$0	0
Wisconsin	\$2,107,975	\$672,452	496
Wyoming	\$0	\$0	0
<b>Total</b>	<b>\$226,633,776</b>	<b>\$20,251,942</b>	<b>46,653</b>

<sup>1</sup>This number reflects only the number of clients for which an insurance payment has been made on their behalf.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. A dash (--) indicates the ADAP did not report data.

**Table 22: ADAP Client Financial Eligibility Requirements, as of June 30, 2012**

State/Territory	Financial Eligibility <sup>1</sup>	Gross or Net Income	Calculation Basis	Recognition of Domestic Partnerships
Alabama	250%	Gross	Family income	No
Alaska	300%	Gross	Family income	Yes
American Samoa	--	--	--	--
Arizona	300%	Gross	Household income	No
Arkansas	200%	Gross	Individual income	No
California	447%	Gross	Individual income	No
Colorado	400%	Gross	Household income	No
Connecticut	400%	Net	Household income	Yes
Delaware	--	--	--	--
District of Columbia	500%	Gross	Individual income	No
Federated States of Micronesia	--	--	--	--
Florida	400%	Gross	Household income	Yes
Georgia	300%	Gross	Household income	No
Guam	--	--	--	--
Hawaii	400%	Gross	Individual income	No
Idaho	200%	Gross	Family income	No
Illinois	300%	Gross	Household income	No
Indiana	300%	Gross	Household income	Yes
Iowa	200%	Gross	Household income	No
Kansas	300%	Gross	Household income	Yes
Kentucky	300%	Gross	Family income	No
Louisiana	300%	Gross	Household income	No
Maine	500%	Gross	Household income	No
Marshall Islands	--	--	--	--
Maryland	500%	Gross	Household income	No
Massachusetts	500%	Gross	Individual income	No
Michigan	450%	Gross	Individual income	No
Minnesota	300%	Gross	Household income	No
Mississippi	400%	Gross	Individual income	No
Missouri	300%	Gross	Family income	No
Montana	330%	Gross	Household income	No
Nebraska	200%	Gross	Individual income	No
Nevada	400%	Gross	Family income	Yes
New Hampshire	300%	Gross	Household income	Yes
New Jersey	500%	Gross	Household income	Yes
New Mexico	400%	Gross	Household income	No
New York	435%	Gross	Household income	Yes
North Carolina	300%	Gross	Family income	No
North Dakota	300%	Gross	Individual income	No
Northern Mariana Islands	--	--	--	--
Ohio	300%	Gross	Family income	No
Oklahoma	200%	Gross	Family income	No
Oregon	300%	Gross	Family income	No
Pennsylvania	337%	Gross	Family income	No
Puerto Rico	200%	Net	Family income	Yes
Republic of Palau	--	--	--	--
Rhode Island	400%	Gross	Household income	Yes
South Carolina	300%	Gross	Household income	No
South Dakota	300%	Gross	Family income	No
Tennessee	300%	Gross	Household income	No
Texas	200%	Gross	Family income	No
Utah	250%	Gross	Household income	No
Vermont	200%	Net	Household income	Yes
Virgin Islands (U.S.)	300%	Net	Individual income	No
Virginia	400%	Gross	Family income	Yes
Washington	300%	Gross	Family income	No
West Virginia	325%	Gross	Family income	No
Wisconsin	300%	Gross	Family income	Yes
Wyoming	332%	Gross	Individual income	No

<sup>1</sup>The 2012 Federal Poverty Level (FPL) was \$11,170 (slightly higher in Alaska and Hawaii) for a household of one.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. A dash (--) indicates the ADAP did not report data.

**Table 23: ADAP Client Eligibility Requirements, as of June 30, 2012**

State/Territory	Medical Eligibility <sup>1</sup>	Asset Limits	State Residency Requirement	Case Management Requirement
Alabama	--	--	Proof of state residency required	--
Alaska	--	--	Must be a resident for at least 30 days with the intent to stay	Yes
American Samoa	--	--	--	--
Arizona	--	--	Proof of state residency required	--
Arkansas	--	--	Proof of state residency required	Yes
California	--	--	Proof of state residency required	--
Colorado	--	--	Proof of state residency required	--
Connecticut	--	--	Yes	--
Delaware	--	--	--	--
District of Columbia	--	\$25,000	Proof of state residency required	--
Federated States of Micronesia	--	--	--	--
Florida	--	--	Proof of state residency required	--
Georgia	--	\$10,000	Proof of state residency required	--
Guam	--	--	--	--
Hawaii	--	--	Proof of state residency required	Yes
Idaho	--	--	Yes	Yes
Illinois	--	--	Proof of state residency required	--
Indiana	--	--	Proof of state residency required	Yes
Iowa	--	\$10,000 excluding house, vehicle, and household furnishings	Proof of state residency required	Yes
Kansas	--	--	Proof of state residency required	Yes
Kentucky	--	--	Proof of state residency required	Yes
Louisiana	--	\$4,000 excluding one house and one vehicle.	Proof of state residency required	--
Maine	--	--	Yes	--
Marshall Islands	--	--	--	--
Maryland	--	--	Must be a resident for at least six months plus one day of the year	--
Massachusetts	--	--	Proof of state residency required	--
Michigan	--	--	Yes	--
Minnesota	--	\$25,000	Yes	--
Mississippi	CD4<500	--	Proof of state residency required	--
Missouri	--	--	Proof of state residency required	Yes
Montana	--	--	Proof of state residency required	Yes
Nebraska	--	--	Yes	Yes
Nevada	--	\$10,000 excluding one house and one vehicle	Proof of state residency required	--
New Hampshire	Currently taking ART, CD4<500, symptomatic, or having documented risk behavior	--	Yes	--
New Jersey	--	--	Must be a resident for at least 30 days	--
New Mexico	--	\$9,900	Proof of state residency required	Yes
New York	--	\$25,000 excluding federally recognized retirement accounts.	Proof of state residency required	--
North Carolina	--	--	Proof of state residency required	--
North Dakota	--	--	Proof of state residency required	Yes
Northern Mariana Islands	--	--	--	--
Ohio	--	--	Proof of state residency required	--
Oklahoma	--	--	Proof of state residency required	--
Oregon	--	\$10,000 excluding one house, one vehicle, and federal recognized retirement accounts	Proof of state residency required	--
Pennsylvania	--	--	Proof of state residency required	--
Puerto Rico	--	--	Must be a resident for at least 60 days	Yes
Republic of Palau	--	--	--	--
Rhode Island	--	--	Proof of state residency required	--
South Carolina	--	--	Yes	--
South Dakota	--	--	Proof of state residency required	Yes
Tennessee	--	\$8,000	Proof of state residency required	--
Texas	--	--	Proof of state residency required	--
Utah	--	\$5,000 excluding one house and one vehicle	Yes	--
Vermont	--	--	Proof of state residency required	--
Virgin Islands (U.S.)	--	\$8,000	Proof of state residency required	--
Virginia	CD4<500	--	Proof of state residency required	--
Washington	--	\$10,000 for individual; \$15,000 for family	Proof of state residency required	--
West Virginia	--	--	Proof of state residency required	Yes
Wisconsin	--	--	Proof of state residency required	--
Wyoming	--	--	Proof of state residency required	Yes
<b>Total</b>	<b>3</b>	<b>13</b>	<b>52</b>	<b>17</b>

<sup>1</sup> CD4=CD4 cell count; VL = Viral load.

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.



**Table 24: ADAP Client Enrollment Processes, as of June 30, 2012**

State/Territory	Intake at Local ASOs, CBOs, and Local Health Department¹	Intake at ADAP Office	Intake at Private Clinical Settings	Online Application	Application Over the Phone	Mailed Application	Faxed Application	Other Enrollment Processes
Alabama	--	--	Yes	--	--	Yes	Yes	Yes
Alaska	--	Yes	--	--	Yes	Yes	Yes	--
American Samoa	--	--	--	--	--	--	--	--
Arizona	Yes	Yes	Yes	--	--	--	Yes	--
Arkansas	Yes	--	--	--	--	--	--	--
California	--	--	--	--	--	--	--	--
Colorado	Yes	Yes	Yes	--	--	Yes	Yes	--
Connecticut	--	Yes	--	--	--	Yes	Yes	--
Delaware	--	--	--	--	--	--	--	--
District of Columbia	--	Yes	Yes	--	--	Yes	Yes	--
Federated States of Micronesia	--	--	--	--	--	--	--	--
Florida	Yes	Yes	--	--	--	--	--	--
Georgia	Yes	--	--	--	--	--	--	--
Guam	--	--	--	--	--	--	--	--
Hawaii	Yes	--	--	--	--	--	--	--
Idaho	Yes	--	Yes	--	--	--	--	--
Illinois	Yes	Yes	Yes	Yes	--	Yes	Yes	--
Indiana	Yes	--	--	--	--	--	--	--
Iowa	Yes	--	--	--	--	--	--	--
Kansas	Yes	--	--	--	--	--	--	--
Kentucky	Yes	--	Yes	--	--	--	--	--
Louisiana	Yes	Yes	Yes	--	--	Yes	Yes	--
Maine	Yes	Yes	Yes	--	--	Yes	Yes	--
Marshall Islands	--	--	--	--	--	--	--	--
Maryland	Yes	Yes	Yes	--	--	Yes	Yes	--
Massachusetts	Yes	Yes	Yes	--	Yes	Yes	Yes	--
Michigan	Yes	Yes	Yes	--	--	Yes	Yes	--
Minnesota	--	Yes	--	--	--	Yes	Yes	--
Mississippi	--	--	Yes	--	--	Yes	--	--
Missouri	Yes	--	--	--	--	--	--	--
Montana	Yes	--	--	--	--	Yes	Yes	--
Nebraska	Yes	Yes	Yes	--	--	Yes	Yes	--
Nevada	Yes	--	--	--	--	--	--	--
New Hampshire	Yes	--	Yes	--	Yes	Yes	Yes	--
New Jersey	Yes	Yes	Yes	--	--	Yes	--	--
New Mexico	Yes	--	--	--	--	--	--	--
New York	--	--	--	--	--	Yes	Yes	--
North Carolina	Yes	--	Yes	--	--	Yes	--	--
North Dakota	--	--	--	--	--	--	--	Yes
Northern Mariana Islands	--	--	--	--	--	--	--	--
Ohio	--	Yes	--	--	--	--	--	--
Oklahoma	--	--	--	Yes	--	--	--	Yes
Oregon	--	Yes	--	--	--	Yes	Yes	--
Pennsylvania	--	--	--	--	--	Yes	Yes	--
Puerto Rico	Yes	--	--	--	--	--	Yes	--
Republic of Palau	--	--	--	--	--	--	--	--
Rhode Island	Yes	Yes	Yes	--	--	Yes	Yes	--
South Carolina	Yes	--	Yes	--	--	--	--	--
South Dakota	Yes	Yes	Yes	--	--	Yes	--	Yes
Tennessee	Yes	--	--	--	--	--	--	--
Texas	--	Yes	--	--	--	Yes	Yes	--
Utah	--	--	Yes	--	--	Yes	Yes	--
Vermont	Yes	Yes	Yes	--	--	Yes	Yes	--
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--
Virginia	Yes	--	--	--	Yes	Yes	Yes	Yes
Washington	--	Yes	--	--	--	Yes	Yes	--
West Virginia	Yes	Yes	Yes	--	Yes	Yes	--	Yes
Wisconsin	Yes	Yes	--	--	--	Yes	Yes	--
Wyoming	Yes	--	--	--	--	--	--	--
<b>Total</b>	<b>35</b>	<b>24</b>	<b>23</b>	<b>2</b>	<b>5</b>	<b>30</b>	<b>27</b>	<b>6</b>

¹ ASOs=AIDS Service Organizations; CBOs=Community-Based Organizations.

Note: 51 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Republic of Palau, and Virgin Islands (U.S.) did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 25: ADAP Management Policies in Place, as of June 30, 2012**

State/Territory	Client Cost-Sharing	Overall Program Enrollment Cap	Drug Specific Enrollment Cap	Maximum Cost Per Client	Maximum Number of Prescriptions Per Client Per Month	
Alabama	--	1,700	--	--	--	
Alaska	--	--	--	--	--	
American Samoa	--	--	--	--	--	
Arizona	--	--	--	--	--	
Arkansas	--	--	--	--	--	
California	Yes	--	--	--	--	
Colorado	--	--	--	--	--	
Connecticut	--	--	--	--	--	
Delaware	--	--	--	--	--	
District of Columbia	--	--	--	--	--	
Federated States of Micronesia	--	--	--	--	--	
Florida	--	--	--	--	--	
Georgia	--	--	Fuzeon (45 clients)	--	4 ARVs; no restrictions on the number of OIs	
Guam	--	--	--	--	--	
Hawaii	--	--	--	--	--	
Idaho	--	161	--	--	--	
Illinois	--	--	--	\$2,000 monthly	5 ARVs	
Indiana	--	2,250	--	--	--	
Iowa	--	--	--	--	--	
Kansas	--	--	--	--	--	
Kentucky	--	--	--	--	--	
Louisiana	--	--	--	--	--	
Maine	--	--	--	--	--	
Marshall Islands	--	--	--	--	--	
Maryland	--	--	--	--	--	
Massachusetts	--	--	--	--	--	
Michigan	--	--	--	--	--	
Minnesota	--	--	--	--	--	
Mississippi	--	--	--	--	--	
Missouri	--	--	--	--	--	
Montana	--	--	Fuzeon (1 client)	--	--	
Nebraska	--	--	--	--	--	
Nevada	--	--	--	--	--	
New Hampshire	--	--	--	--	--	
New Jersey	--	--	--	--	--	
New Mexico	--	--	--	\$600 monthly	--	
New York	--	--	--	--	--	
North Carolina	--	--	--	--	--	
North Dakota	--	--	--	--	--	
Northern Mariana Islands	--	--	--	--	--	
Ohio	--	--	--	--	--	
Oklahoma	--	--	--	--	--	
Oregon	Yes	--	--	--	--	
Pennsylvania	--	--	--	--	--	
Puerto Rico	--	--	--	--	--	
Republic of Palau	--	--	--	--	--	
Rhode Island	--	--	--	--	--	
South Carolina	--	--	--	--	--	
South Dakota	--	--	--	\$10,500 annually	--	
Tennessee	--	--	--	--	--	
Texas	--	--	--	--	4 ARVs	
Utah	--	--	--	--	--	
Vermont	--	--	--	--	--	
Virgin Islands (U.S.)	--	--	--	--	--	
Virginia	--	--	--	--	--	
Washington	Yes	--	--	--	--	
West Virginia	--	--	--	--	--	
Wisconsin	--	--	--	--	--	
Wyoming	--	135	--	--	--	
<b>Total</b>	<b>3</b>	<b>4</b>	<b>2</b>	<b>3</b>	<b>3</b>	

Step therapy - The practice of beginning drug therapy for a medical condition with the most cost-effective and safest drug therapy and progressing to other more costly or risky therapy, only if necessary. The aims are to control costs and minimize risks. Also called step protocol. Step therapy does not apply to antiretrovirals.

Drug(s) with Prior Authorization	Drug(s) with Clinical Criteria	Drug(s) with Required Resistance Testing	Step Therapy
Fuzeon, Procrit, Selzentry	Fuzeon, Procrit, Selzentry	Fuzeon	--
--	--	--	--
--	--	--	--
Egrifta, Fuzeon, Pregabalin, Serostim, Valgaciclovir	--	--	--
Crestor, Fuzeon, Imitrex, Loperamide, Nexium, Noxafil, Ondansetron, Prevacid, Promethazine, Selzentry, Tricor, Vfend, Zetia	--	--	--
Fuzeon, Methadone, Selzentry, Somatropin, Sporanox	Bupropion, Capreomycin, Caspofungin, Cycloserine, Dextroamphetamine, Ethionamide, Fentanyl patch, Imipenem/Cilastatin, Itraconazole, Lansoprazole, Linezolid, Methadone, Methylphenidate, Moxifloxacin, Nadralone, Omeprazole, Paclitaxel, Para-aminosalicylate, Selzentry, Somatropin, Testosterone, Valacyclovir, Valganciclovir, Voriconazole	--	Lansoprazole, Omeprazole
--	--	--	--
Serostim	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
Fuzeon, Selzentry	Selzentry	--	--
Fuzeon	--	Selzentry	--
--	--	--	--
Fuzeon	Baraclude	--	--
Fuzeon	--	--	--
Fuzeon, Mepron, Valcyte	--	--	--
--	--	--	--
Fuzeon	--	--	--
Fuzeon, Selzentry	--	Selzentry	--
Megastrol	--	--	--
--	--	--	--
Selzentry	--	Selzentry	--
--	--	--	--
--	--	--	--
--	--	--	--
Actos, Avandia, Duragesic, Epogen, Neupogen, Oxycontin, Procrit	Actos, Avandia, Duragesic, Epogen, Neupogen, Oxycontin, Procrit	Selzentry	Effexor, Famvir, Lexapro, Valtrex
--	--	--	--
--	--	--	--
--	--	--	--
Aptivus, Intelence, Selzentry	Selzentry	Aptivus	Intelence, Selzentry
Selzentry	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
Amikin, Cytovene, Diflucan, Epogen, Famvir, Fuzeon, G-CSF Neupogen, Megace, Mepron, Prenatal-S Multivitamin, Sporanox, Valcyte, Vfend	Epoetin Alfa, Filgrastim, Sargramostim, Immune globulin Rho, Neumega	--	--
Aptivus, Fuzeon, Mepron, Selzentry	--	--	--
Selzentry	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
Selzentry	--	--	--
--	--	--	--
--	--	--	--
Fuzeon, Peginterferon-alfa 2a, Peginterferon-alfa 2b, Ribavirin, Selzentry, Ziagen (or Ziagen containing medications)	--	--	--
--	--	--	--
Fuzeon, Selzentry	--	--	--
--	Opportunistic infection medications	--	--
--	--	--	--
Foscavir, Fuzeon, Neupogen, Selzentry, Valcyte, Vistide	--	Selzentry	--
--	--	--	--
Aptivus, Complera, Edurant, Fuzeon, Intelence, Prednisone, Selzentry, Voriconazole	Aptivus, Complera, Dapsone, Edurant, Fuzeon, Intelence, Prednisone, Selzentry, Voriconazole	--	--
--	--	--	--
Fuzeon, Foscarnet	--	Selzentry	--
--	--	--	--
--	--	--	--
26	9	8	3

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 26: ADAP Prescription Distribution, June 2012**

State/Territory	Mail order delivered to client's home	Mail order delivered to client's clinic	Central pharmacy pick-up	Central pharmacy distribution	Client choice of pharmacy or mail order	Designated ADAP pharmacy(ies) for pick-up	Other
Alabama	--	--	--	Yes	--	--	--
Alaska	Yes	Yes	Yes	Yes	Yes	Yes	Yes
American Samoa	--	--	--	--	--	--	--
Arizona	Yes	--	--	--	--	--	--
Arkansas	Yes	Yes	Yes	Yes	--	--	--
California	Yes	--	--	--	Yes	Yes	--
Colorado	Yes	Yes	Yes	Yes	Yes	Yes	--
Connecticut	--	--	--	--	Yes	--	--
Delaware	--	--	--	--	--	--	--
District of Columbia	--	--	--	--	--	Yes	--
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	Yes	Yes	--	Yes	Yes	Yes	Yes
Georgia	--	--	--	--	--	Yes	Yes
Guam	--	--	--	--	--	--	--
Hawaii	Yes	Yes	Yes	--	--	--	--
Idaho	--	--	--	--	--	--	Yes
Illinois	Yes	Yes	--	--	--	--	--
Indiana	--	--	--	--	Yes	--	--
Iowa	Yes	Yes	Yes	Yes	--	--	--
Kansas	--	--	--	--	--	--	Yes
Kentucky	Yes	Yes	Yes	Yes	Yes	--	--
Louisiana	--	--	--	--	--	Yes	--
Maine	--	--	--	--	Yes	--	--
Marshall Islands	--	--	--	--	--	--	--
Maryland	--	--	--	--	Yes	--	--
Massachusetts	--	--	--	--	Yes	--	--
Michigan	--	--	--	--	Yes	--	Yes
Minnesota	--	--	--	--	Yes	--	--
Mississippi	--	--	--	Yes	--	--	--
Missouri	--	--	--	--	Yes	--	--
Montana	Yes	Yes	--	--	--	Yes	--
Nebraska	Yes	Yes	Yes	Yes	--	Yes	--
Nevada	Yes	--	--	--	Yes	Yes	--
New Hampshire	--	--	--	--	Yes	--	--
New Jersey	--	--	--	--	Yes	--	Yes
New Mexico	Yes	Yes	Yes	Yes	--	Yes	--
New York	--	--	--	--	Yes	--	--
North Carolina	Yes	Yes	Yes	Yes	Yes	Yes	--
North Dakota	--	--	--	--	Yes	--	--
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	Yes	--	--	--	--	--	--
Oklahoma	Yes	Yes	--	--	--	Yes	--
Oregon	Yes	--	--	--	Yes	Yes	--
Pennsylvania	--	--	--	--	--	--	Yes
Puerto Rico	--	--	--	Yes	--	Yes	--
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	--	--	--	--	Yes	--	Yes
South Carolina	Yes	Yes	--	--	--	--	--
South Dakota	Yes	Yes	Yes	Yes	--	--	--
Tennessee	Yes	Yes	Yes	--	--	--	--
Texas	--	--	--	Yes	--	Yes	--
Utah	--	--	--	--	Yes	Yes	--
Vermont	--	--	--	--	Yes	--	--
Virgin Islands (U.S.)	--	--	--	--	--	Yes	--
Virginia	--	--	--	Yes	--	Yes	Yes
Washington	--	--	--	--	--	Yes	--
West Virginia	--	--	--	--	Yes	--	--
Wisconsin	--	--	--	--	Yes	--	--
Wyoming	--	--	--	--	Yes	--	--
<b>Total</b>	<b>21</b>	<b>16</b>	<b>11</b>	<b>15</b>	<b>26</b>	<b>20</b>	<b>10</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.



**Table 27: ADAP Coverage of HIV Antiretrovirals, as of June 30, 2012**

State/Territory	Multi-Class Combination Products			NRTIs												
	Atripla	Complera	Stribild <sup>1</sup>	Combivir	Emtriva	Epivir	Epzicom	Retrovir	Trizivir	Truvada	Videx	Viread	Zerit	Ziagen	Edurant	
Alabama	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Alaska	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Arizona	Yes	Yes	--	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Arkansas	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
California	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Colorado	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Connecticut	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Delaware	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
District of Columbia	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Florida	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Georgia	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Guam	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Hawaii	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Idaho	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Illinois	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Indiana	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Iowa	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Kansas	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Kentucky	Yes	Yes	--	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Louisiana	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Maine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Maryland	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Massachusetts	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Michigan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Minnesota	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Mississippi	Yes	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Missouri	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Montana 1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Nebraska	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Nevada	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
New Hampshire	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
New Jersey	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
New Mexico 2	Yes	Yes	--	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
New York	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
North Carolina	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
North Dakota	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Ohio	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Oklahoma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Oregon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Pennsylvania	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Puerto Rico	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Republic of Palau	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Rhode Island	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
South Carolina	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
South Dakota	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Tennessee	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Texas	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Utah	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Vermont	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Virgin Islands (U.S.)	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	
Virginia	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Washington	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
West Virginia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Wisconsin	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Wyoming	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
<b>Total</b>	<b>52</b>	<b>51</b>	<b>30</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>48</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>51</b>	

<sup>1</sup> Stribild was approved by the FDA in August 2012. ADAPs reported the inclusion on their formulary as of September 1, 2012.

NNRTIs					Protease Inhibitors										Fusion Inhibitor	Entry Inhibitor	Integrase Inhibitor	Total	
	Intelence	Rescriptor	Sustiva	Viramune	Agenerase	Aptivus	Crixivan	Invirase	Kaletra	Lexiva	Norvir	Prezista	Reyataz	Viracept	Fuzeon	Selzentry	ISENTRESS		
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	29
	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	30
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	30
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	30
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	30
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	30
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	29
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	32
	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	30
	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes															

**Table 28: ADAP Coverage of “A1” Opportunistic Infection Medications, as of June 30, 2012**

State/Territory	acyclovir (Zovirax)	amphotericin B (Fungizone)	azithromycin (Zithromax)	cidofovir (Vistide)	clarithromycin (Biaxin)	clindamycin (Cleocin)	ethambutol	famciclovir (Famvir)	fluconazole (Diflucan)	flucytosine (Ancobon)	foscarnet (Foscavir)	ganciclovir (Cytovene)	isoniazid, INH (Lanizid, Nydrazid)	itraconazole (Sporanox)	leucovorin calcium (Wellcovorin)	
Alabama	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Alaska	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Arizona	Yes	--	Yes	--	Yes	Yes	Yes	--	Yes	--	--	--	Yes	Yes	Yes	
Arkansas	Yes	--	--	--	--	--	Yes	--	--	--	--	--	--	--	--	
California	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Colorado	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Connecticut	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	--	Yes	Yes	
Delaware	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
District of Columbia	Yes	--	Yes	--	Yes	Yes	Yes	--	Yes	--	--	Yes	Yes	Yes	--	
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Florida	Yes	--	Yes	--	Yes	--	Yes	--	Yes	--	--	--	--	Yes	Yes	
Georgia	Yes	--	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	
Guam	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Hawaii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Idaho	Yes	--	Yes	--	Yes	--	--	Yes	Yes	--	--	--	--	--	--	
Illinois	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	Yes	Yes	Yes	
Indiana	Yes	--	Yes	--	Yes	--	Yes	--	Yes	Yes	--	--	Yes	Yes	Yes	
Iowa	Yes	--	Yes	Yes	--	--	--	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	
Kansas	Yes	--	Yes	--	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes	Yes	
Kentucky	Yes	--	Yes	--	Yes	--	Yes	--	Yes	--	--	--	Yes	--	Yes	
Louisiana	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Maine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Maryland	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Massachusetts	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Michigan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	--	Yes	Yes	
Minnesota	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Mississippi	Yes	--	Yes	--	Yes	Yes	Yes	--	Yes	--	--	Yes	Yes	Yes	Yes	
Missouri	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Montana 1	--	Yes	Yes	--	Yes	Yes	Yes	--	Yes	--	Yes	--	Yes	Yes	Yes	
Nebraska	Yes	--	Yes	--	Yes	Yes	Yes	Yes	Yes	--	--	--	Yes	Yes	--	
Nevada	Yes	--	Yes	--	Yes	Yes	Yes	--	Yes	--	--	--	--	Yes	Yes	
New Hampshire	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
New Jersey	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
New Mexico 2	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	--	Yes	Yes	
New York	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
North Carolina	Yes	--	Yes	--	Yes	Yes	Yes	Yes	Yes	--	--	Yes	Yes	Yes	Yes	
North Dakota	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Ohio	Yes	--	Yes	--	--	--	--	--	Yes	--	--	--	Yes	Yes	--	
Oklahoma	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	
Oregon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Pennsylvania	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Puerto Rico	--	--	Yes	--	--	Yes	--	--	Yes	--	--	--	--	Yes	Yes	
Republic of Palau	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Rhode Island	Yes	--	Yes	--	Yes	--	Yes	--	Yes	--	--	Yes	Yes	Yes	Yes	
South Carolina	Yes	--	Yes	--	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes	Yes	
South Dakota	Yes	--	Yes	--	Yes	--	Yes	Yes	Yes	--	--	--	--	Yes	--	
Tennessee	--	--	Yes	--	Yes	Yes	Yes	--	Yes	--	--	--	--	Yes	--	
Texas	Yes	--	Yes	--	Yes	--	Yes	--	Yes	--	--	--	--	Yes	--	
Utah	Yes	--	Yes	--	Yes	--	Yes	--	--	--	--	--	--	Yes	--	
Vermont	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	--	--	Yes	Yes	
Virgin Islands (U.S.)	Yes	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Virginia	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	
Washington	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	
West Virginia	Yes	--	Yes	--	Yes	Yes	Yes	--	Yes	--	Yes	Yes	--	Yes	Yes	
Wisconsin	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	--	Yes	--	
Wyoming	Yes	--	Yes	Yes	Yes	Yes	--	--	--	--	Yes	Yes	--	Yes	--	
<b>Total</b>	<b>49</b>	<b>23</b>	<b>50</b>	<b>27</b>	<b>47</b>	<b>40</b>	<b>46</b>	<b>33</b>	<b>48</b>	<b>20</b>	<b>30</b>	<b>30</b>	<b>33</b>	<b>48</b>	<b>40</b>	

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of “no” by the ADAP.



	liposomal amphotericin B	peginterferon alfa-2a (PEGASYS)	peginterferon alfa-2b (PEG- Intron)	pentamidine (NebuPent)	prednisone (Deltasone)	primaquine and clindamycin	probenecid	pyrazinamide, PZA	pyrimethamine (Daraprim, Fansidar)	ribavirin (Virazole, Rebetol, Copegus)	rifabutin (Mycobutin)	rifampin, RIF (Rifadin, Rimactane)	sulfadiazine (Microsulfon)	trimethoprim- sulfamethoxazole (Bactrim, Septra)	valacyclovir (Valtrex)	valganciclovir (Valcyte)	Total
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	--	--	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	21
	--	--	--	--	--	--	--	--	Yes	--	Yes	--	--	--	Yes	Yes	6
	--	Yes	--	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	28
	--	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	28
	--	Yes	Yes	Yes	Yes	Yes	--	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	25
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	--	Yes	Yes	Yes	--	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	22
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	--	--	--	--	--	--	--	--	Yes	--	Yes	--	Yes	Yes	Yes	Yes	13
	--	--	--	--	Yes	Yes	--	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	22
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	--	--	--	--	Yes	--	--	Yes	Yes	Yes	--	--	Yes	Yes	Yes	12
	--	--	--	Yes	--	Yes	--	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	22
	--	--	--	Yes	Yes	--	--	--	Yes	--	Yes	--	Yes	Yes	Yes	--	16
	--	Yes	Yes	Yes	--	--	--	--	--	Yes	Yes	--	Yes	Yes	Yes	Yes	19
	--	--	--	Yes	--	Yes	--	--	--	--	Yes	--	Yes	Yes	Yes	Yes	16
	--	--	--	--	--	Yes	--	--	Yes	--	Yes	Yes	Yes	Yes	--	Yes	14
	Yes	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	29
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	--	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	29
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	Yes	--	Yes	--	Yes	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	21
	--	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	27
	Yes	--	--	--	--	--	--	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	19
	--	--	--	Yes	--	--	--	Yes	--	--	Yes	Yes	--	Yes	Yes	Yes	16
	--	--	--	--	--	--	--	--	--	--	Yes	--	--	--	--	Yes	10
	Yes	--	--	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	28
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	--	--	Yes	--	Yes	--	--	Yes	--	Yes	--	Yes	Yes	Yes	Yes	20
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	30
	--	--	--	Yes	--	Yes	--	--	Yes	--	Yes	Yes	--	Yes	Yes	Yes	19
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	--	--	--	--	--	--	--	--	--	--	--	--	--	Yes	--	Yes	7
	--	--	--	Yes	--	--	--	Yes	Yes	--	Yes	--	Yes	Yes	--	Yes	20
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	31
	--	Yes	Yes	Yes	--	--	--	--	Yes	Yes	--	--	Yes	Yes	Yes	Yes	14
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
	--	Yes	Yes	Yes	--	--	--	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	19
	--	Yes	Yes	--	Yes	Yes	--	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	20
	--	Yes	Yes	Yes	--	--	--	--	Yes	Yes	Yes	--	--	Yes	Yes	Yes	16
	Yes	--	--	Yes	--	Yes	--	--	--	--	Yes	--	Yes	Yes	Yes	Yes	14
	--	--	--	Yes	--	--	--	--	--	--	Yes	--	--	Yes	Yes	Yes	11
	--	--	--	Yes	--	--	--	--	Yes	--	Yes	--	Yes	Yes	Yes	Yes	12
	Yes	--	--	Yes	--	Yes	--	--	Yes	--	Yes	--	Yes	Yes	Yes	Yes	21
	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	1
	--	--	--	--	Yes	Yes	--	Yes	Yes	--	Yes	Yes	Yes	Yes	--	Yes	22
	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	28
	--	--	--	Yes	Yes	--	--	--	--	--	--	--	--	Yes	--	--	13
	--	Yes	Yes	Yes	--	--	--	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes	22
	--	--	--	Yes	--	--	Yes	--	--	--	--	--	Yes	Yes	--	Yes	13
	17	25	24	41	26	33	17	26	42	29	47	27	42	49	43	49	

**Table 29: ADAP Coverage of HIV Diagnostics, as of June 30, 2012**

State/Territory	CD4 Count Testing	Viral Load Testing	Genotype Testing	Phenotype Testing	Virtual Phenotype Testing	Monogram Biosciences (LabCorp) Profile Test	Quest Diagnostics HIV-1 Coreceptor Tropism Test	Other Testing
Alabama	Yes	Yes	Yes	Yes	Yes	--	--	--
Alaska	--	--	--	--	--	Yes	Yes	Yes
American Samoa	--	--	--	--	--	--	--	--
Arizona	--	--	--	--	--	--	--	--
Arkansas	Yes	--	Yes	Yes	Yes	Yes	Yes	--
California	--	--	--	--	--	--	--	--
Colorado	--	--	--	--	--	--	--	--
Connecticut	--	--	--	--	--	--	--	--
Delaware	--	--	--	--	--	--	--	--
District of Columbia	--	--	--	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--	--	--	--
Florida	Yes	Yes	Yes	--	--	--	--	--
Georgia	--	--	--	--	--	--	--	--
Guam	--	--	--	--	--	--	--	--
Hawaii	Yes	Yes	Yes	--	--	--	--	Yes
Idaho	--	--	--	--	--	--	--	--
Illinois	--	--	--	--	--	--	--	--
Indiana	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--
Iowa	--	--	--	--	--	Yes	--	--
Kansas	Yes	Yes	Yes	Yes	Yes	Yes	--	--
Kentucky	Yes	Yes	--	--	--	--	--	--
Louisiana	--	--	--	--	--	--	--	--
Maine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--
Marshall Islands	--	--	--	--	--	--	--	--
Maryland	--	--	--	--	--	--	--	--
Massachusetts	--	--	Yes	--	Yes	Yes	--	--
Michigan	Yes	Yes	Yes	--	--	--	--	--
Minnesota	--	--	Yes	Yes	Yes	Yes	Yes	--
Mississippi	--	--	--	--	--	--	--	--
Missouri	--	--	--	--	--	--	--	--
Montana 1	--	--	--	--	--	--	--	--
Nebraska	--	--	--	--	--	--	--	--
Nevada	Yes	Yes	--	--	--	--	--	--
New Hampshire	Yes	Yes	Yes	Yes	Yes	--	--	--
New Jersey	--	--	--	--	--	--	--	--
New Mexico 2	--	--	--	--	--	--	--	--
New York	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
North Carolina	--	--	--	--	--	--	--	--
North Dakota	Yes	Yes	--	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--	--	--	--
Ohio	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Oklahoma	--	--	--	--	--	--	--	--
Oregon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--
Pennsylvania	Yes	Yes	Yes	Yes	Yes	--	--	Yes
Puerto Rico	--	--	--	--	--	Yes	--	Yes
Republic of Palau	--	--	--	--	--	--	--	--
Rhode Island	--	--	--	--	--	--	--	--
South Carolina	--	--	--	--	--	--	--	--
South Dakota	--	--	--	--	--	--	--	--
Tennessee	--	--	--	--	--	--	--	--
Texas	--	--	--	--	--	--	--	--
Utah	--	--	--	--	--	--	--	--
Vermont	--	--	--	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--
Virginia	--	--	--	--	--	--	--	--
Washington	Yes	Yes	Yes	--	Yes	--	--	Yes
West Virginia	--	--	--	--	--	--	--	--
Wisconsin	--	--	--	--	--	--	--	--
Wyoming	--	--	--	--	--	--	--	--
<b>Total</b>	<b>17</b>	<b>16</b>	<b>16</b>	<b>11</b>	<b>13</b>	<b>12</b>	<b>8</b>	<b>7</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 30: ADAP Coverage of Hepatitis B Treatment, as of June 30, 2012**

State/Territory	Adefovir Dipivoxil (Hepsera)	Entecavir (Baraclude)	Interferon Alfa-2b (Intron A)	Lamivudine (Epivir-HBV, Zeffix, Heptodin)	Peginterferon alfa-2a (Pegasys)	Telbivudine (Tyzeka, Sebivo)
Alabama	Yes	Yes	Yes	Yes	Yes	--
Alaska	Yes	Yes	Yes	Yes	Yes	--
American Samoa	--	--	--	--	--	--
Arizona	--	Yes	--	--	--	--
Arkansas	--	--	--	--	--	--
California	--	--	Yes	--	Yes	--
Colorado	--	--	--	--	--	--
Connecticut	--	Yes	--	Yes	Yes	--
Delaware	--	--	--	--	--	--
District of Columbia	Yes	Yes	--	--	Yes	--
Federated States of Micronesia	--	--	--	--	--	--
Florida	--	--	--	--	--	--
Georgia	--	--	--	--	--	--
Guam	--	--	--	--	--	--
Hawaii	--	Yes	--	--	Yes	--
Idaho	--	--	--	--	--	--
Illinois	--	Yes	--	Yes	--	--
Indiana	--	--	--	--	--	--
Iowa	--	--	--	--	Yes	--
Kansas	--	--	--	--	--	--
Kentucky	--	--	--	--	--	--
Louisiana	--	--	--	--	--	--
Maine	Yes	Yes	Yes	Yes	Yes	Yes
Marshall Islands	--	--	--	--	--	--
Maryland	Yes	Yes	Yes	Yes	Yes	Yes
Massachusetts	Yes	Yes	Yes	Yes	Yes	Yes
Michigan	--	Yes	Yes	--	Yes	--
Minnesota	--	Yes	--	Yes	Yes	--
Mississippi	--	--	--	--	--	--
Missouri	Yes	Yes	--	Yes	--	Yes
Montana	--	--	--	--	--	--
Nebraska	--	--	--	--	--	--
Nevada	--	--	--	--	--	--
New Hampshire	Yes	Yes	Yes	Yes	--	Yes
New Jersey	Yes	Yes	Yes	Yes	Yes	Yes
New Mexico	--	--	--	--	--	--
New York	Yes	Yes	--	Yes	--	--
North Carolina	--	--	--	Yes	--	--
North Dakota	Yes	--	Yes	Yes	Yes	--
Northern Mariana Islands	--	--	--	--	--	--
Ohio	--	--	--	--	--	--
Oklahoma	--	--	--	--	--	--
Oregon	Yes	Yes	Yes	Yes	Yes	Yes
Pennsylvania	Yes	Yes	Yes	Yes	Yes	Yes
Puerto Rico	--	--	--	--	Yes	--
Republic of Palau	--	--	--	--	--	--
Rhode Island	--	--	Yes	Yes	Yes	--
South Carolina	--	--	--	Yes	Yes	--
South Dakota	--	--	--	--	--	--
Tennessee	--	--	--	--	--	--
Texas	--	--	--	--	--	--
Utah	--	--	--	--	--	--
Vermont	--	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--
Virginia	--	--	--	Yes	--	--
Washington	Yes	Yes	Yes	Yes	Yes	--
West Virginia	--	--	--	Yes	--	--
Wisconsin	--	--	Yes	--	Yes	--
Wyoming	--	--	--	--	--	--
<b>Total</b>	<b>14</b>	<b>19</b>	<b>15</b>	<b>21</b>	<b>21</b>	<b>8</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 31: ADAP Utilization of Hepatitis B Treatment, June 2012 and FY2011**

State/Territory	June 2012 Prescriptions Filled	June 2012 Number of Clients	FY2011 Prescriptions Filled
Alabama	1	1	13
Alaska	--	--	--
American Samoa	--	--	--
Arizona	1	1	--
Arkansas	--	--	--
California	--	--	--
Colorado	--	--	--
Connecticut	36	34	714
Delaware	--	--	--
District of Columbia	4	3	--
Federated States of Micronesia	--	--	--
Florida	--	--	--
Georgia	--	--	--
Guam	--	--	--
Hawaii	--	--	--
Idaho	--	--	--
Illinois	10	10	--
Indiana	--	--	--
Iowa	--	--	--
Kansas	--	--	--
Kentucky	--	--	--
Louisiana	--	--	--
Maine	4	4	20
Marshall Islands	--	--	--
Maryland	10	10	171
Massachusetts	--	--	--
Michigan	11	11	69
Minnesota	3	2	33
Mississippi	--	--	--
Missouri	2	2	33
Montana	--	--	--
Nebraska	--	--	--
Nevada	--	--	--
New Hampshire	--	--	--
New Jersey	8	8	155
New Mexico	--	--	--
New York	45	44	497
North Carolina	4	4	29
North Dakota	--	--	--
Northern Mariana Islands	--	--	--
Ohio	--	--	--
Oklahoma	--	--	--
Oregon	60	59	--
Pennsylvania	114	111	1,624
Puerto Rico	--	--	--
Republic of Palau	--	--	--
Rhode Island	--	--	2
South Carolina	4	3	30
South Dakota	--	--	--
Tennessee	--	--	--
Texas	--	--	--
Utah	--	--	--
Vermont	--	--	--
Virgin Islands (U.S.)	--	--	--
Virginia	--	--	--
Washington	6	5	62
West Virginia	2	2	21
Wisconsin	--	--	--
Wyoming	--	--	--
<b>Total</b>	<b>325</b>	<b>314</b>	<b>3,473</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 32: ADAP Coverage of Hepatitis C Treatment, as of June 30, 2012**

State/Territory	Interferon Alfa-2b (Intron A)	Recombinant Interferon Alfa-2a (Roferon)	Consensus Interferon (Infergen)	Peginterferon Alfa-2a (Pegasys)	Peginterferon Alfa-2b (PEG-Intron)	Peginterferon alfa-2a (Pegasys) and Ribavirin (Copegus)	Peginterferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol)	Interferon alfa-2b (Intron A) and Ribavirin (Rebetol)	Recombinant Interferon Alfa-2a (Roferon) and Ribavirin	Incivek (telaprevir)	Victrelis (boceprevir)
Alabama	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--
Alaska	Yes	--	--	Yes	Yes	--	--	--	--	--	--
American Samoa	--	--	--	--	--	--	--	--	--	--	--
Arizona	--	--	--	--	Yes	--	Yes	--	--	--	--
Arkansas	--	--	--	--	--	--	--	--	--	--	--
California	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	--	--
Colorado	--	--	--	Yes	Yes	Yes	--	--	--	--	--
Connecticut	--	--	--	Yes	Yes	--	--	--	--	--	--
Delaware	--	--	--	--	--	--	--	--	--	--	--
District of Columbia	Yes	--	--	Yes	Yes	Yes	Yes	Yes	--	--	--
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--
Florida	--	--	--	--	--	--	--	--	--	--	--
Georgia	--	--	--	--	--	--	--	--	--	--	--
Guam	--	--	--	--	--	--	--	--	--	--	--
Hawaii	--	--	--	Yes	Yes	Yes	Yes	--	--	--	--
Idaho	--	--	--	--	--	--	--	--	--	--	--
Illinois	--	--	--	--	--	--	--	--	--	--	--
Indiana	--	--	--	--	--	--	--	--	--	--	--
Iowa	--	--	--	Yes	--	Yes	--	--	--	--	--
Kansas	--	--	--	--	--	--	--	--	--	--	--
Kentucky	--	--	--	--	--	--	--	--	--	--	--
Louisiana	--	--	--	--	--	--	--	--	--	--	--
Maine	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--
Maryland	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--
Massachusetts	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Michigan	Yes	--	--	Yes	Yes	Yes	Yes	Yes	--	--	--
Minnesota	--	--	--	Yes	Yes	--	--	--	--	Yes	Yes
Mississippi	--	--	--	Yes	--	Yes	--	--	--	--	--
Missouri	--	--	--	--	--	--	--	--	--	Yes	Yes
Montana	--	--	--	--	--	--	--	--	--	--	--
Nebraska	--	--	--	--	--	--	--	--	--	--	--
Nevada	--	--	--	--	--	--	--	--	--	--	--
New Hampshire	--	--	--	--	--	--	--	--	--	--	--
New Jersey	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
New Mexico	--	--	--	--	--	--	--	--	--	--	--
New York	Yes	Yes	--	Yes	Yes	--	--	--	--	--	--
North Carolina	--	--	--	--	--	--	--	--	--	--	--
North Dakota	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--
Ohio	--	--	--	--	--	--	--	--	--	--	--
Oklahoma	--	--	--	--	--	--	--	--	--	--	--
Oregon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Pennsylvania	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--	Yes
Puerto Rico	--	--	--	Yes	Yes	--	--	--	--	--	--
Republic of Palau	--	--	--	--	--	--	--	--	--	--	--
Rhode Island	Yes	--	--	Yes	Yes	Yes	Yes	Yes	--	--	--
South Carolina	--	--	--	Yes	Yes	Yes	Yes	--	--	--	--
South Dakota	Yes	--	--	Yes	Yes	Yes	Yes	Yes	--	--	--
Tennessee	--	--	--	--	--	--	--	--	--	--	--
Texas	--	--	--	--	--	--	--	--	--	--	--
Utah	--	--	--	--	--	--	--	--	--	--	--
Vermont	--	--	--	--	--	--	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--	--	--	--
Virginia	--	--	--	--	--	--	--	--	--	--	--
Washington	Yes	Yes	--	Yes	Yes	--	--	--	--	--	--
West Virginia	--	--	--	--	--	--	--	--	--	--	--
Wisconsin	Yes	--	--	Yes	Yes	--	--	--	--	Yes	--
Wyoming	--	--	--	--	--	--	--	--	--	--	--
<b>Total</b>	<b>17</b>	<b>9</b>	<b>7</b>	<b>25</b>	<b>24</b>	<b>18</b>	<b>15</b>	<b>13</b>	<b>7</b>	<b>7</b>	<b>7</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 33: ADAP Utilization of Hepatitis C Treatment, June 2012 and FY2011**

State/Territory	June 2012 Prescriptions Filled	June 2012 Number of Clients	FY2011 Prescriptions Filled
Alabama	--	--	--
Alaska	--	--	--
American Samoa	--	--	--
Arizona	1	1	5
Arkansas	--	--	--
California	210	151	1,830
Colorado	--	--	--
Connecticut	3	2	33
Delaware	--	--	--
District of Columbia	1	1	--
Federated States of Micronesia	--	--	--
Florida	--	--	--
Georgia	--	--	--
Guam	--	--	--
Hawaii	--	--	1
Idaho	--	--	--
Illinois	--	--	--
Indiana	--	--	--
Iowa	--	--	--
Kansas	--	--	--
Kentucky	--	--	--
Louisiana	--	--	--
Maine	6	3	9
Marshall Islands	--	--	--
Maryland	3	2	75
Massachusetts	2	1	55
Michigan	2	1	14
Minnesota	7	3	26
Mississippi	--	--	--
Missouri	--	--	--
Montana	--	--	--
Nebraska	--	--	--
Nevada	--	--	--
New Hampshire	--	--	--
New Jersey	1	1	70
New Mexico	--	--	--
New York	61	38	727
North Carolina	--	--	--
North Dakota	--	--	--
Northern Mariana Islands	--	--	--
Ohio	--	--	--
Oklahoma	--	--	--
Oregon	1	1	27
Pennsylvania	8	8	110
Puerto Rico	28	28	584
Republic of Palau	--	--	--
Rhode Island	--	--	2
South Carolina	--	--	7
South Dakota	--	--	--
Tennessee	--	--	--
Texas	--	--	--
Utah	--	--	--
Vermont	--	--	--
Virgin Islands (U.S.)	--	--	--
Virginia	--	--	--
Washington	--	--	--
West Virginia	--	--	--
Wisconsin	2	1	65
Wyoming	--	--	--
<b>Total</b>	<b>336</b>	<b>242</b>	<b>3,640</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 34: ADAP Coverage of Hepatitis C Diagnostics, June 2012**

State/Territory	HCV Screening	Qualitative HCV RNA	Quantitative Viral Load	HCV Genotype
Alabama	--	Yes	Yes	--
Alaska	Yes	Yes	Yes	Yes
American Samoa	--	--	--	--
Arizona	--	--	--	--
Arkansas	--	--	--	--
California	--	--	--	--
Colorado	--	--	--	--
Connecticut	--	--	--	--
Delaware	--	--	--	--
District of Columbia	--	--	--	--
Federated States of Micronesia	--	--	--	--
Florida	--	--	--	--
Georgia	--	--	--	--
Guam	--	--	--	--
Hawaii	Yes	Yes	Yes	--
Idaho	Yes	Yes	Yes	Yes
Illinois	--	--	--	--
Indiana	Yes	Yes	Yes	Yes
Iowa	--	--	--	--
Kansas	--	--	--	--
Kentucky	--	--	--	--
Louisiana	--	--	--	--
Maine	--	--	--	--
Marshall Islands	--	--	--	--
Maryland	--	--	--	--
Massachusetts	--	--	--	--
Michigan	--	--	--	--
Minnesota	--	--	--	--
Mississippi	--	--	--	--
Missouri	--	--	--	--
Montana	--	--	--	--
Nebraska	--	--	--	--
Nevada	--	--	--	--
New Hampshire	Yes	Yes	Yes	Yes
New Jersey	--	--	--	--
New Mexico	--	--	--	--
New York	Yes	Yes	Yes	Yes
North Carolina	--	--	--	--
North Dakota	--	--	--	--
Northern Mariana Islands	--	--	--	--
Ohio	--	--	--	--
Oklahoma	--	--	--	--
Oregon	Yes	Yes	Yes	Yes
Pennsylvania	Yes	--	Yes	--
Puerto Rico	--	--	--	--
Republic of Palau	--	--	--	--
Rhode Island	--	--	--	--
South Carolina	--	--	--	--
South Dakota	--	--	--	--
Tennessee	--	--	--	--
Texas	--	--	--	--
Utah	--	--	--	--
Vermont	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--
Virginia	--	--	--	--
Washington	Yes	Yes	Yes	Yes
West Virginia	--	--	--	--
Wisconsin	--	--	--	--
Wyoming	--	--	--	--
<b>Total</b>	<b>9</b>	<b>9</b>	<b>10</b>	<b>7</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.

**Table 35: ADAP Coverage of Hepatitis A and B Vaccines, as of June 30, 2012**

State/Territory	Hepatitis A and B Combination Vaccine	Hepatitis A Vaccine	Hepatitis B Vaccine
Alabama	Yes	Yes	Yes
Alaska	Yes	Yes	Yes
American Samoa	--	--	--
Arizona	Yes	Yes	Yes
Arkansas	--	--	--
California	Yes	Yes	Yes
Colorado	--	--	--
Connecticut	Yes	Yes	Yes
Delaware	--	--	--
District of Columbia	--	--	--
Federated States of Micronesia	--	--	--
Florida	--	--	--
Georgia	--	--	--
Guam	--	--	--
Hawaii	Yes	Yes	Yes
Idaho	--	--	--
Illinois	Yes	Yes	Yes
Indiana	--	--	--
Iowa	--	--	--
Kansas	--	--	--
Kentucky	Yes	Yes	Yes
Louisiana	--	--	--
Maine	Yes	Yes	Yes
Marshall Islands	--	--	--
Maryland	Yes	Yes	Yes
Massachusetts	Yes	Yes	Yes
Michigan	Yes	Yes	Yes
Minnesota	--	--	--
Mississippi	--	--	--
Missouri	Yes	Yes	Yes
Montana	--	--	--
Nebraska	--	--	--
Nevada	--	--	--
New Hampshire	--	--	--
New Jersey	--	--	--
New Mexico	Yes	Yes	Yes
New York	Yes	Yes	Yes
North Carolina	--	--	--
North Dakota	Yes	Yes	Yes
Northern Mariana Islands	--	--	--
Ohio	Yes	Yes	Yes
Oklahoma	Yes	Yes	Yes
Oregon	Yes	Yes	Yes
Pennsylvania	--	Yes	Yes
Puerto Rico	--	--	--
Republic of Palau	--	--	--
Rhode Island	--	--	--
South Carolina	--	--	--
South Dakota	Yes	--	--
Tennessee	--	--	--
Texas	--	--	--
Utah	--	--	--
Vermont	Yes	Yes	Yes
Virgin Islands (U.S.)	--	--	--
Virginia	Yes	Yes	Yes
Washington	Yes	Yes	Yes
West Virginia	Yes	Yes	Yes
Wisconsin	Yes	Yes	Yes
Wyoming	--	--	--
<b>Total</b>	<b>25</b>	<b>25</b>	<b>25</b>

Note: 52 ADAPs reported data. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond. For ADAPs that reported data, a dash (--) indicates a response of "no" by the ADAP.



**Table 36: HIV/AIDS Antiretroviral and Opportunistic Infection Medications**

FDA-Approved Antiretroviral Medications	
GENERIC NAME	BRAND NAME
<b>Multi-Class Combination Products</b>	
efavirenz, emtricitabine, and tenofovir disoproxil fumarate	Atripla
rilpivirine, emtricitabine, and tenofovir disoproxil fumarate	Complera
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate	Stribild
<b>NRTIs</b>	
abacavir sulfate, ABC	Ziagen
abacavir, zidovudine, and lamivudine	Trizivir
abacavir and lamivudine	Epzicom
didanosine, dideoxyinosine, ddI	Videx
emtricitabine, FTC	Emtriva
lamivudine and zidovudine	Combivir
lamivudine, 3TC	Epivir
stavudine, d4T	Zerit
tenofovir, disoproxil fumarate, TDF	Viread
tenofovir disoproxil fumarate and emtricitabine	Truvada
zidovudine, azidothymidine, AZT, ZDV	Retrovir
<b>NNRTIs</b>	
delavirdine, DLV	Rescriptor
efavirenz, EFV	Sustiva
etravirine	Intelligence
nevirapine, NVP	Viramune
rilpivirine	Edurant
<b>Protease Inhibitors</b>	
amprenavir, APV	Agenerase <sup>1</sup>
atazanavir sulfate, ATV	Reyataz
darunavir	Prezista
fosamprenavir calcium, FOS-APV	Lexiva
indinavir, IDV	Crixivan
lopinavir and ritonavir, LPV/RTV	Kaletra
nelfinavir mesylate, NFV	Viracept
ritonavir, RTV	Norvir
saquinavir mesylate, SQV	Invirase
tipranavir, TPV	Aptivus
<b>Fusion Inhibitors</b>	
enfuvirtide, T-20	Fuzeon
<b>Entry Inhibitors - CCR5 Co-Receptor Antagonist</b>	
maraviroc	Selzentry
<b>HIV Integrase Strand Transfer Inhibitors</b>	
raltegravir	Isentress
valganciclovir	Valcyte

<sup>1</sup> The manufacturer of Agenerase (amprenavir) discontinued the sale and distribution of the drug in capsule form, used for adult dosing, after 2004 and is instead manufacturing fosamprenavir (Lexiva), a “prodrug” of Agenerase (a prodrug is an inactive precursor of a drug, converted into its active form in the body). Agenerase is still available in pediatric dosing.

Source: FDA, “Drugs Used in the Treatment of HIV Infection”: <http://www.fda.gov/oashi/aids/virals.html>. Also see: DHHS, “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,” December 20, 2012: <http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1>.

“A1” Medications for the Prevention & Treatment of Opportunistic Infections (Highly Recommended) <sup>1</sup>	
GENERIC NAME	BRAND NAME
acyclovir	Zovirax
amphotericin B	Fungizone
azithromycin	Zithromax
cidofovir	Vistide
clarithromycin	Biaxin
clindamycin	Cleocin
ethambutol	--
famciclovir	Famvir
fluconazole	Diflucan
flucytosine	Ancobon
foscarnet	Foscavir
ganciclovir	Cytovene
isoniazid (INH)	Lanizid, Nydrazid
itraconazole	Sporonox
leucovorin calcium	Wellcovorin
liposomal amphotericin B	--
peg-interferon alfa-2a	PEG-Intron
peg-interferon alfa-2b	--
pentamidine	Nebupent
prednisone	Deltasone, Liquid Pred, Metocorten, Orasone, Panasol, Prednicen-M, Sterapred
probenecid	--
pyrazinamide (PZA)	--
pyrimethamine	Daraprim, Fansidar
ribavirin	Virazole, Rebetol, Copegus
rifabutin	Mycobutin
rifampin (RIF)	Rifadin, Rimactane
sulfadiazine (oral generic)	Microsulfon
trimethoprim- sulfamethoxazole (TMP/SMX)	Bactrim, Septra
valacyclovir	Valtrex

<sup>1</sup> “A” = “should always be offered”; “1” = “evidence from at least one properly randomized, controlled trial”

Sources: CDC, “Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus.” *MMWR*, 51 (No. RR08), 1-46; 2002; CDC, “Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents.” *MMWR*, 53 (No. RR15), 1-112; 2004. Also see: DHHS, “Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents,” December 20, 2012: <http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=211&ClassID=4>.

# Module Two

*April 2013*

*Prepared by*

National Alliance of State & Territorial AIDS Directors (NASTAD)

Amy Killelea

Britten Pund



## **Module Two: Detailed Findings**



## Highlights

Highlights from the data included in this *Report*:

- ADAP client enrollment and client utilization reached their highest levels during FY2012.
- The average annual cost per client served in a Pre-existing Condition Insurance Plan (PCIP) was \$6,188 in December 2012, approximately 49% of the annual average drug cost per client, based on estimated annual drug expenditures.

## Methodology

Since 1996, NASTAD's National ADAP Monitoring Project has surveyed all jurisdictions receiving federal ADAP earmark funding through the Ryan White Program. In FY2012, 59 jurisdictions received earmark funding and were surveyed; 52 responded. American Samoa, Delaware, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, and Republic of Palau did not respond; these jurisdictions represent less than one percent of estimated living HIV and AIDS cases. This 18<sup>th</sup> release of the *Annual Report* updates prior findings with data from ADAP's fiscal year 2012 as well as a detailed snapshot of data from the month of June 2012. This module of the *Annual Report* reflects the latest available data and discusses recent policy and programmatic changes affecting ADAPs.

The annual survey update requests data and other program information for a one-month period (December) and other periods as specified. After the survey is distributed, NASTAD conducts extensive follow-up to ensure completion by as many ADAPs as possible. Data used in this report are from December 2012, unless otherwise noted.

All data reflect the status of ADAPs as reported by survey respondents. It is important to note that some program information may have changed between data collection and this report's release. Due to differences in data collection and availability across ADAPs, some are not able to respond to all survey questions. Where trend data are presented, only states that provided data in relevant periods are included. In some cases, ADAPs have provided revised program data from prior years and these revised data are incorporated where possible. Therefore, data from prior year reports may not be comparable for assessing trends. It is also important to note that data from a one-month snapshot may be subject to one-time only events or changes that could in turn appear to impact trends; these are noted where information is available. Data exceptions specific to a particular jurisdiction are provided in the notes section on relevant charts and tables.

**A**IDS Drug Assistance Programs (ADAPs) provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS in all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, American Samoa, the Federated States of Micronesia, Guam, the Northern Mariana Islands, Republic of Palau and the Republic of the Marshall Islands. In addition, some ADAPs provide insurance continuation and Medicare Part D and Medicaid wrap-around services to eligible individuals. ADAPs are a component of the federal Ryan White Part B Program that provides necessary medical and support services to low income, uninsured and underinsured individuals living with HIV/AIDS in all states, territories and associated jurisdictions.

## **ADAP CLIENT ENROLLMENT AND UTILIZATION**

ADAP client enrollment and client utilization reached their highest levels during FY2012 (see Charts 1 and 2 and Table 1). ADAP enrollment reached 193,295 clients in December 2012. Client enrollment increased by two percent from June 2012 to December 2012 (based only on those ADAPs that reported data in both time periods). ADAPs provided medications to 138,569 clients across the country in December 2012. Client utilization remained relatively level between June 2012 and December 2012, decreasing by one percent (based only on those ADAPs that reported data in both time periods). Eighteen states experienced a decrease in client utilization over this time period; 27 states reported a stabilization or increase in client utilization. Client utilization reported for December 2012 could show a slight decrease as a result of holiday closings in state government.

## **ADAP COORDINATION WITH MEDICAID**

In June 2011, the Centers for Medicare and Medicaid Services (CMS) released an updated [guidance](#) on Section 1115 waivers for state Medicaid programs that allow states the option to cover eligible pre-disabled adults living with HIV. Without the waiver in place, eligible individuals must be disabled in order to qualify for Medicaid. States have significant flexibility in the design of the waivers under the guidance and application template issued by CMS in June 2011.

As of December 2012, 11 ADAPs indicated they have access to a CMS Section 1115 waiver in their state to enroll people living with HIV and six other states indicated they are currently applying for, or anticipate applying for, a CMS Section 1115 waiver.

As of December 2012, almost five percent of ADAP clients were enrolled in Medicaid. Of those clients, one-third were enrolled in Medicaid disability coverage, one-sixth were enrolled in Medicaid via a CMS 1115 Waiver, and almost half were reported to be Medicaid eligible and enrolled, but their specific coverage was unknown (see Table 2).

Thirty-four ADAPs reported signing a data sharing agreement with Medicaid in December 2012 in order to transmit data (see Chart 3).

## **ADAP COORDINATION WITH MEDICARE PART D**

In calendar year 2012, approximately 17% of ADAP clients were also Medicare-eligible (representing about 23,000 clients served). A subset of these clients was dually eligible for both Medicare and Medicaid (see Table 4).

The Affordable Care Act (ACA) included a provision that allows ADAP expenditures made on behalf of a Medicare Part D beneficiary to count towards the true out-of-pocket (TrOOP) calculation, which allows clients to move through the donut hole and into catastrophic coverage. This provision went into effect on January 1, 2011.

To meet the federal requirements and maintain appropriate medication coverage for their clients, 41 ADAPs have developed policies to coordinate with the Medicare Part D benefit (see Chart 4 and 5 and Table 3). As of December 31, 2012:

- 22 ADAPs pay Part D premiums for ADAP clients eligible for Part D.
- 31 ADAPs pay Part D deductibles for ADAP clients eligible for Part D.
- 39 ADAPs pay Part D co-payments for ADAP clients eligible for Part D.

In order for ADAP contributions to count toward clients TrOOP calculations, ADAPs must accurately transmit data to the Center's for Medicaid and



Medicare (CMS). Nineteen ADAPs reported signing a data sharing agreement with Medicare (including Medicare Part D) in December 2012 in order to transmit expenditures to Medicare Part D (see Chart 3).

### **ADAP COORDINATION WITH PRE-EXISTING CONDITION INSURANCE PLANS (PCIP)**

In an effort to help certain uninsured individuals obtain insurance coverage prior to 2014, ACA includes provisions that the Secretary of HHS establish state-specific Pre-existing Condition Insurance Plans (PCIP) by July 1, 2010. Individual states were given the option to establish a state administered PCIP or default to the option of having uninsured populations served under the federally administered PCIP.

Some ADAPs experienced barriers to coordinating with PCIPs, including the need to establish the infrastructure necessary to coordinate with the PCIP, that the PCIP in their state prohibits third-party payers (such as ADAP) and that the PCIP in their state utilizes a mail-order pharmacy that does not accept third-party payments for medications, and therefore were unable to coordinate with PCIP. PCIP ends on December 31, 2013. Effective February 16, 2013, enrollment in federally-run PCIPs was suspended and state-run PCIPs were instructed to suspend enrollment by March 1, 2013; however any individual already enrolled in PCIP (federally-run or state-run) would continue to receive coverage.

- As of December 2012, 23 ADAPs reported the ability to enroll clients in PCIPs and 4,693 clients have been enrolled (see Chart 6 and Table 5).
- The average annual cost per client served in a PCIP was \$6,188 in December 2012, approximately

49% of the annual average drug cost per client for all ADAP clients, based on estimated annual drug expenditures (\$12,648).

### **ADAP COORDINATION WITH STATE-RUN HIGH-RISK INSURANCE POOLS (NOT PCIP)**

State-run high-risk insurance pools (not PCIP) are special programs created by state legislatures to provide a safety net for the “medically uninsurable” population. These are people who have been denied health insurance coverage because of a pre-existing health condition, or who can only access private coverage that is restricted or has extremely high rates. Generally, the programs operate as a state-created nonprofit association overseen by a board of directors made up of industry, consumer, and state insurance department representatives. The board contracts with an established insurance company to collect premiums and pay claims and administer the program on a day-to-day basis. Insurance benefits vary, but risk pools typically offer benefits that are comparable to basic private market plans. State-run high-risk insurance pools have provided coverage for HIV-positive individuals long before the advent of PCIP, but will most likely also dissolve with the full implementation of health reform in 2014.


- As of December 2012, 17 ADAPs reported the ability to enroll clients in state-run high-risk insurance pools (not PCIP) and 7,024 clients have been enrolled (see Table 6).
- The average annual cost per client served in a state-run high-risk insurance pool was \$8,192 in December 2012, approximately 65% of the annual average cost per client, based on estimated annual drug expenditures (\$12,648).



## **Module Two: Charts**




**Chart 1: ADAP Clients Enrolled, June 2011-December 2012**




Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond.

**Chart 2: ADAP Clients Served, June 2011-December 2012**




Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond.

**Chart 3: ADAP Data Sharing Agreements, December 2012**




Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond.

**Chart 4: ADAP Policies Related to Medicare Part D, as of December 31, 2012**




Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond.

**Chart 5: ADAP Clients Enrolled in Medicare Part D, December 2012**



Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond.

**Chart 6: ADAP Coordination with Pre-existing Condition Insurance Plans (PCIPs), December 2012**



Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond. PCIPs are not administered in American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands.





## **Module Two: Tables**



**Table 1: Total Clients Enrolled and Served, June 2012 and December 2012**

State/Territory	Financial Eligibility <sup>1</sup>	Gross or Net Income	June 2012 Clients Enrolled	December 2012 Clients Enrolled	% Change	June 2012 Clients Served	December 2012 Clients Served	% Change
Alabama	250%	Gross	1,697	1,972	16%	1,473	1,689	15%
Alaska	300%	Gross	91	92	--	72	90	--
American Samoa	--	--	--	--	--	--	--	--
Arizona	300%	Gross	1,025	1,772	73%	1,008	1,736	72%
Arkansas	200%	Gross	710	797	12%	710	621	-13%
California	447%	Gross	37,113	34,435	-7%	26,253	23,545	-10%
Colorado	400%	Gross	3,625	3,275	-10%	3,083	2,296	-26%
Connecticut	400%	Net	2,136	2,114	-1%	1,724	1,566	-9%
Delaware	--	--	--	--	--	--	--	--
District of Columbia	500%	Gross	1,404	--	--	785	--	--
Federated States of Micronesia	--	--	--	--	--	--	--	--
Florida	400%	Gross	15,288	14,620	-4%	12,005	10,375	-14%
Georgia	300%	Gross	5,590	6,520	17%	3,319	4,956	49%
Guam	--	--	--	1	--	--	1	--
Hawaii	400%	Gross	368	367	-0%	329	289	-12%
Idaho	200%	Gross	145	192	32%	143	156	9%
Illinois	300%	Gross	6,112	7,788	27%	4,484	5,296	18%
Indiana	300%	Gross	2,336	2,256	-3%	2,336	2,206	-6%
Iowa	200%	Gross	682	657	-4%	488	494	1%
Kansas	300%	Gross	1,223	1,236	--	680	714	--
Kentucky	300%	Gross	2,127	20	-99%	1,368	1,342	-2%
Louisiana	300%	Gross	2,134	3,179	49%	2,134	2,359	11%
Maine	500%	Gross	776	787	1%	299	291	-3%
Marshall Islands	--	--	--	--	--	--	--	--
Maryland	500%	Gross	6,217	6,262	1%	4,106	3,433	-16%
Massachusetts	500%	Gross	6,136	5,700	-7%	4,121	3,236	-21%
Michigan	450%	Gross	3,584	4,176	17%	2,779	3,095	11%
Minnesota	300%	Gross	2,021	1,020	-50%	667	1,020	53%
Mississippi	400%	Gross	930	938	1%	888	928	5%
Missouri	300%	Gross	2,596	--	--	1,927	--	--
Montana	330%	Gross	143	187	31%	116	131	13%
Nebraska	200%	Gross	484	565	17%	242	364	50%
Nevada	400%	Gross	1,304	1,341	3%	876	861	-2%
New Hampshire	300%	Gross	454	484	7%	268	242	-10%
New Jersey	500%	Gross	6,708	6,618	-1%	4,655	3,984	-14%
New Mexico	400%	Gross	--	804	--	--	804	--
New York	435%	Gross	20,320	20,454	1%	16,477	16,703	1%
North Carolina	300%	Gross	5,707	6,253	10%	4,419	4,667	6%
North Dakota	300%	Gross	119	145	22%	67	119	78%
Northern Mariana Islands	--	--	--	--	--	--	--	--
Ohio	300%	Gross	4,244	4,500	6%	2,369	2,749	16%
Oklahoma	200%	Gross	1,281	1,326	4%	973	998	3%
Oregon	300%	Gross	2,776	2,822	2%	2,713	2,700	-0%
Pennsylvania	337%	Gross	5,539	5,506	-1%	4,249	5,230	23%
Puerto Rico	200%	Net	5,372	5,994	12%	4,535	4,564	1%
Republic of Palau	--	--	--	--	--	--	--	--
Rhode Island	400%	Gross	714	--	--	526	--	--
South Carolina	300%	Gross	4,146	4,518	9%	3,258	3,275	1%
South Dakota	300%	Gross	137	105	-23%	137	105	-23%
Tennessee	300%	Gross	4,359	4,763	9%	3,092	2,304	-25%
Texas	200%	Gross	14,019	15,904	13%	10,881	11,037	1%
Utah	250%	Gross	592	524	-11%	422	427	1%
Vermont	200%	Net	309	--	--	135	--	--
Virgin Islands (U.S.)	300%	Net	134	--	--	134	--	--
Virginia	400%	Gross	3,044	3,815	25%	2,299	2,765	20%
Washington	300%	Gross	3,795	3,779	-0%	2,823	2,330	-17%
West Virginia	325%	Gross	587	593	1%	387	417	8%
Wisconsin	300%	Gross	1,861	1,974	6%	613	--	--
Wyoming	332%	Gross	143	145	1%	79	59	-25%
<b>Total</b>			<b>194,357</b>	<b>193,295</b>		<b>143,926</b>	<b>138,569</b>	
<b>Comparison Total<sup>2</sup></b>			<b>189,200</b>	<b>192,490</b>	<b>2%</b>	<b>139,806</b>	<b>137,764</b>	<b>-1%</b>

<sup>1</sup> The 2012 Federal Poverty Level (FPL) was \$11,170 (slightly higher in Alaska and Hawaii) for a household of one.

<sup>2</sup> Comparison Totals are based on only those ADAPs that reported data in both time periods.

Note: 52 ADAPs reported data for June 2012 (American Samoa, Delaware, Federated States of Micronesia, Guam, New Mexico, Northern Mariana Islands, and Republic of Palau did not respond). 48 ADAPs reported data for December 2012 (American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond).

**Table 2: ADAP Clients Enrolled in Medicaid, December 2012**

State/Territory	Total Clients Enrolled in Medicaid	CMS 1115 Waiver	Disability	Affordable Care Act Expansion Option	Other Low Income Adult	Unknown
Alabama	100	100%	0%	0%	0%	0%
Alaska	0	--	--	--	--	--
American Samoa	--	--	--	--	--	--
Arizona	0	--	--	--	--	--
Arkansas	6	0%	50%	0%	50%	0%
California	1,696	0%	100%	0%	0%	0%
Colorado	4	0%	100%	0%	0%	0%
Connecticut	0	--	--	--	--	--
Delaware	--	--	--	--	--	--
District of Columbia	--	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--	--
Florida	76	0%	0%	0%	0%	100%
Georgia	0	--	--	--	--	--
Guam	14	--	--	--	--	--
Hawaii	0	--	--	--	--	--
Idaho	0	0%	0%	0%	0%	0%
Illinois	86	0%	7%	0%	93%	0%
Indiana	0	--	--	--	--	--
Iowa	200	75%	26%	0%	0%	0%
Kansas	164	--	--	--	--	--
Kentucky	1,342	0%	0%	0%	0%	100%
Louisiana	60	0%	0%	0%	0%	0%
Maine	198	0%	0%	0%	0%	100%
Marshall Islands	--	--	--	--	--	--
Maryland	0	--	--	--	--	--
Massachusetts	489	100%	0%	0%	0%	0%
Michigan	0	--	--	--	--	--
Minnesota	127	0%	0%	100%	0%	0%
Mississippi	0	--	--	--	--	--
Missouri	--	--	--	--	--	--
Montana	0	0%	0%	0%	0%	0%
Nebraska	0	0%	0%	0%	0%	0%
Nevada	--	--	--	--	--	--
New Hampshire	18	0%	0%	0%	0%	100%
New Jersey	93	0%	0%	0%	100%	0%
New Mexico	0	--	--	--	--	--
New York	385	100%	0%	0%	0%	0%
North Carolina	0	--	--	--	--	--
North Dakota	--	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--	--
Ohio	0	0%	0%	0%	0%	0%
Oklahoma	0	--	--	--	--	--
Oregon	439	0%	8%	0%	56%	36%
Pennsylvania	750	0%	0%	0%	0%	100%
Puerto Rico	0	0%	0%	0%	0%	0%
Republic of Palau	--	--	--	--	--	--
Rhode Island	--	--	--	--	--	--
South Carolina	0	--	--	--	--	--
South Dakota	26	0%	0%	0%	0%	100%
Tennessee	0	0%	0%	0%	0%	0%
Texas	362	0%	100%	0%	0%	0%
Utah	0	--	--	--	--	--
Vermont	--	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--
Virginia	2	0%	0%	0%	0%	100%
Washington	267	0%	0%	0%	0%	100%
West Virginia	13	0%	69%	0%	31%	0%
Wisconsin	276	0%	0%	0%	0%	100%
Wyoming	38	0%	0%	0%	0%	100%
<b>Total</b>	<b>7,376</b>	<b>15%</b>	<b>29%</b>	<b>2%</b>	<b>6%</b>	<b>48%</b>

Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond. A dash (--) indicates the ADAP did not report data or responded "no."

**Table 3: ADAP Policies Related to Medicare Part D, as of December 31, 2012**

State/Territory	ADAP Pays Premiums		ADAP Pays Deductibles		ADAP Pays Co-payments				Eligible for ADAP				Provide Medications During the Donut Hole
	Partial Subsidy Clients	Standard Clients	Partial Subsidy Clients	Standard Clients	Dually Eligible Clients	Full Subsidy Clients	Partial Subsidy Clients	Standard Clients	Dually Eligible Clients	Full Subsidy Clients	Partial Subsidy Clients	Standard Clients	
Alabama	--	Yes	--	--	--	--	--	Yes	--	--	--	Yes	Yes
Alaska	--	--	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--	--
Arizona	--	--	--	--	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
Arkansas	--	--	Yes	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes
California	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Colorado	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Connecticut	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
Delaware	--	--	--	--	--	--	--	--	--	--	--	--	--
District of Columbia	--	--	--	--	--	--	--	--	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--	--
Florida	--	--	Yes	Yes	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Georgia	--	--	--	--	--	--	--	--	--	--	Yes	Yes	--
Guam	--	--	--	--	--	--	--	--	--	--	--	--	--
Hawaii	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Idaho	--	--	--	Yes	--	--	--	Yes	--	--	--	--	Yes
Illinois	--	--	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	--
Indiana	--	--	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
Iowa	--	--	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kansas	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kentucky	--	--	--	--	--	--	--	--	--	Yes	--	--	--
Louisiana	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Maine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--	--
Maryland	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	--	--	--	Yes	Yes
Massachusetts	Yes	Yes	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Michigan	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
Minnesota	--	Yes	--	--	--	--	Yes	Yes	--	--	Yes	Yes	--
Mississippi	--	--	--	--	--	--	--	--	--	--	--	Yes	Yes
Missouri	--	--	--	--	--	--	--	--	--	--	--	--	--
Montana	--	--	Yes	Yes	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Nebraska	--	--	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
Nevada	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	--	--	--	--	Yes
New Hampshire	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
New Jersey	Yes	Yes	Yes	Yes	--	--	Yes	Yes	--	Yes	Yes	Yes	Yes
New Mexico	--	--	--	--	--	--	--	--	--	--	--	--	--
New York	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
North Carolina	--	--	--	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
North Dakota	--	--	--	--	--	--	--	--	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--	--
Ohio	Yes	Yes	--	--	Yes	Yes	Yes	Yes	--	--	--	Yes	--
Oklahoma	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Oregon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Pennsylvania	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Puerto Rico	--	--	--	--	--	--	--	--	--	--	--	--	--
Republic of Palau	--	--	--	--	--	--	--	--	--	--	--	--	--
Rhode Island	--	--	--	--	--	--	--	--	--	--	--	--	--
South Carolina	--	--	Yes	Yes	--	--	Yes	Yes	--	--	Yes	Yes	--
South Dakota	--	--	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Tennessee	--	--	--	--	--	--	--	--	--	--	--	--	--
Texas	--	--	Yes	Yes	--	--	Yes	Yes	--	--	Yes	Yes	Yes
Utah	Yes	Yes	Yes	Yes	--	Yes	Yes	Yes	--	Yes	Yes	Yes	Yes
Vermont	--	--	--	--	--	--	--	--	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--	--	--	--	--	--
Virginia	--	--	--	--	--	--	--	--	--	--	Yes	Yes	--
Washington	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
West Virginia	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wisconsin	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wyoming	Yes	Yes	Yes	Yes	--	--	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Total</b>	<b>19</b>	<b>22</b>	<b>30</b>	<b>31</b>	<b>20</b>	<b>30</b>	<b>37</b>	<b>39</b>	<b>21</b>	<b>30</b>	<b>35</b>	<b>39</b>	<b>36</b>

Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond. A dash (--) indicates the ADAP did not report data or responded "no."

**Table 4: ADAP Clients Enrolled in Medicare Part D, December 2012**

State/Territory	Total Clients Enrolled in Medicare Part D	Dual Eligible <sup>1</sup>	Full Subsidy <sup>2</sup>	Partial Subsidy <sup>3</sup>	Standard Benefit <sup>4</sup>	Unknown	Data Source(s) for Benefit Level			
							Medicaid Match	ADAP data	Client self-reporting	Other
Alabama	85	0%	0%	0%	100%	0%	Yes	Yes	Yes	Yes
Alaska	8	--	--	--	--	--	Yes	Yes	Yes	Yes
American Samoa	--	--	--	--	--	--	--	--	--	--
Arizona	547	0%	24%	10%	55%	11%	--	Yes	--	--
Arkansas	110	3%	0%	93%	5%	0%	Yes	Yes	Yes	--
California	3,794	38%	13%	4%	45%	0%	--	Yes	--	Yes
Colorado	416	1%	21%	26%	50%	3%	--	Yes	Yes	--
Connecticut	516	0%	0%	0%	0%	100%	--	Yes	--	--
Delaware	--	--	--	--	--	--	--	--	--	--
District of Columbia	--	--	--	--	--	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--
Florida	657	3%	0%	4%	93%	0%	Yes	Yes	Yes	Yes
Georgia	588	0%	30%	16%	54%	0%	Yes	Yes	--	Yes
Guam	0	--	--	--	--	--	Yes	Yes	Yes	--
Hawaii	32	0%	0%	9%	91%	0%	--	Yes	Yes	Yes
Idaho	33	0%	0%	0%	0%	0%	--	--	Yes	--
Illinois	607	7%	17%	13%	63%	0%	--	Yes	--	--
Indiana	50	0%	38%	16%	46%	0%	--	Yes	--	--
Iowa	85	52%	6%	2%	40%	0%	--	Yes	--	Yes
Kansas	112	--	--	--	--	--	--	Yes	Yes	--
Kentucky	1,342	0%	0%	0%	0%	100%	--	Yes	--	--
Louisiana	257	0%	0%	0%	0%	0%	--	--	Yes	--
Maine	22	0%	0%	0%	0%	100%	--	Yes	--	--
Marshall Islands	--	--	--	--	--	--	--	--	--	--
Maryland	1,569	0%	65%	5%	25%	4%	--	Yes	--	--
Massachusetts	642	76%	5%	1%	17%	0%	--	Yes	--	--
Michigan	581	0%	31%	14%	56%	0%	--	Yes	--	Yes
Minnesota	246	0%	0%	19%	81%	0%	--	Yes	--	--
Mississippi	27	0%	0%	0%	100%	0%	--	Yes	Yes	--
Missouri	--	--	--	--	--	--	--	--	--	--
Montana	16	0%	0%	0%	0%	0%	--	Yes	Yes	--
Nebraska	59	0%	0%	0%	0%	0%	--	Yes	--	--
Nevada	--	--	--	--	--	--	--	--	--	Yes
New Hampshire	78	18%	24%	8%	50%	0%	--	Yes	--	--
New Jersey	422	10%	5%	2%	82%	0%	Yes	--	--	--
New Mexico	3	0%	0%	0%	0%	100%	--	Yes	Yes	Yes
New York	3,150	0%	41%	10%	49%	0%	--	Yes	--	--
North Carolina	1,026	0%	48%	16%	36%	0%	--	Yes	Yes	--
North Dakota	--	--	--	--	--	--	--	Yes	Yes	--
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--
Ohio	0	0%	0%	0%	0%	0%	--	--	--	Yes
Oklahoma	310	19%	0%	0%	0%	81%	Yes	Yes	Yes	--
Oregon	868	12%	53%	9%	26%	0%	Yes	Yes	Yes	--
Pennsylvania	1,270	13%	1%	9%	76%	0%	--	--	Yes	--
Puerto Rico	0	0%	0%	0%	0%	0%	--	--	--	Yes
Republic of Palau	--	--	--	--	--	--	--	--	--	--
Rhode Island	--	--	--	--	--	--	--	--	--	--
South Carolina	162	0%	6%	15%	78%	0%	Yes	Yes	Yes	--
South Dakota	16	31%	0%	0%	0%	69%	--	--	Yes	--
Tennessee	0	0%	0%	0%	0%	0%	--	Yes	--	--
Texas	1,732	0%	0%	24%	76%	0%	Yes	Yes	Yes	Yes
Utah	1	0%	0%	0%	100%	0%	--	Yes	Yes	--
Vermont	--	--	--	--	--	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--	--	--
Virginia	343	0%	0%	62%	38%	0%	--	Yes	Yes	--
Washington	1,587	16%	47%	7%	29%	0%	Yes	Yes	--	Yes
West Virginia	127	21%	24%	15%	31%	8%	--	Yes	--	--
Wisconsin	276	96%	0%	0%	0%	4%	Yes	Yes	Yes	Yes
Wyoming	44	20%	48%	5%	27%	0%	--	Yes	--	--
<b>Total</b>	<b>23,816</b>	<b>13%</b>	<b>23%</b>	<b>10%</b>	<b>44%</b>	<b>11%</b>	<b>13</b>	<b>40</b>	<b>24</b>	<b>15</b>

<sup>1</sup> Dual eligible clients are individuals who are eligible for both Medicare and Medicaid.

<sup>2</sup> Full subsidy clients are those with an income less than 135% FPL and assets below \$7,790 for individuals and \$12,440 for couples.

<sup>3</sup> Partial subsidy clients are those with an income between 136% and 150% FPL and assets below \$11,990 for individuals and \$23,972 for couples.

<sup>4</sup> Standard benefit clients are those with an income greater than 150% FPL.

Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond. A dash (–) indicates the ADAP did not report data or responded “no.”

**Table 5: ADAP Coordination with Pre-existing Condition Insurance Plans (PCIP), December 2012**

State/Territory	Administration of PCIP <sup>1</sup>	ADAP Able to Enroll Clients in PCIP	Clients Enrolled in PCIP	Established Transition Plan from PCIP to Another Form of Insurance
Alabama	Federal	--	--	Unknown
Alaska	State	--	--	--
American Samoa	--	--	--	--
Arizona	Federal	Yes	625	Unknown
Arkansas	State	--	--	--
California	State	Yes	240	Unknown
Colorado	State	Yes	67	Yes
Connecticut	State	Yes	0	Unknown
Delaware	Federal	--	--	--
District of Columbia	Federal	--	--	--
Federated States of Micronesia	--	--	--	--
Florida	Federal	Yes	20	--
Georgia	Federal	Yes	300	Yes
Guam	--	--	--	Unknown
Hawaii	Federal	--	--	Yes
Idaho	Federal	--	--	--
Illinois	State	Yes	73	Yes
Indiana	Federal	--	--	--
Iowa	State	--	--	--
Kansas	State	Yes	4	--
Kentucky	Federal	Yes	0	Unknown
Louisiana	Federal	Yes	705	--
Maine	State	--	--	--
Marshall Islands	--	--	--	--
Maryland	State	--	--	Unknown
Massachusetts	Federal	--	--	--
Michigan	State	Yes	419	Yes
Minnesota	Federal	--	--	--
Mississippi	Federal	--	--	Unknown
Missouri	State	--	--	--
Montana	State	--	--	--
Nebraska	Federal	Yes	3	Yes
Nevada	Federal	--	--	--
New Hampshire	State	Yes	22	Unknown
New Jersey	State	--	--	Unknown
New Mexico	State	--	--	Yes
New York	State	Yes	1,240	Unknown
North Carolina	State	Yes	0	--
North Dakota	Federal	Yes	1	--
Northern Mariana Islands	--	--	--	--
Ohio	State	Yes	50	Unknown
Oklahoma	State	--	--	--
Oregon	State	Yes	300	Yes
Pennsylvania	State	--	--	Unknown
Puerto Rico	--	--	--	Unknown
Republic of Palau	--	--	--	--
Rhode Island	State	--	--	--
South Carolina	Federal	Yes	82	--
South Dakota	State	--	--	--
Tennessee	Federal	Yes	76	Unknown
Texas	Federal	--	--	Unknown
Utah	State	Yes	2	--
Vermont	Federal	--	--	--
Virgin Islands (U.S.)	--	--	--	--
Virginia	Federal	--	--	--
Washington	State	Yes	424	Yes
West Virginia	Federal	--	--	Yes
Wisconsin	State	Yes	40	--
Wyoming	Federal	--	--	--
<b>Total</b>		<b>23</b>	<b>4,693</b>	

<sup>1</sup> PCIPs are not administered in American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands.

Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond. A dash (--) indicates the ADAP did not report data.

**Table 6: ADAP Coordination with State-run High-risk Insurance Pools (not PCIP), December 2012**

State/Territory	ADAP Able to Enroll Clients in State-run High-risk Insurance Pool (not PCIP)	Clients Enrolled in State-run High-risk Insurance Pool (not PCIP)	Plan to Continue State-run High-risk Insurance Pool post 2014	Established Transition Plan from State-run High-risk Insurance Pool to Another Form of Insurance
Alabama	--	--	Unknown	Unknown
Alaska	Yes	22	Unknown	Unknown
American Samoa	--	--	--	--
Arizona	--	--	No	--
Arkansas	--	--	Unknown	Unknown
California	--	--	Unknown	Unknown
Colorado	--	--	Unknown	Yes
Connecticut	--	--	Unknown	Unknown
Delaware	--	--	--	--
District of Columbia	--	--	--	--
Federated States of Micronesia	--	--	--	--
Florida	--	--	Unknown	Unknown
Georgia	--	--	Unknown	Unknown
Guam	--	--	Unknown	Unknown
Hawaii	--	--	--	--
Idaho	--	--	Unknown	Unknown
Illinois	Yes	26	Unknown	Unknown
Indiana	Yes	2,115	No	--
Iowa	--	--	Unknown	--
Kansas	Yes	7	Unknown	--
Kentucky	--	--	Unknown	Unknown
Louisiana	Yes	47	Unknown	--
Maine	Yes	35	No	--
Marshall Islands	--	--	--	--
Maryland	Yes	1,361	Unknown	--
Massachusetts	--	--	No	--
Michigan	--	--	Unknown	--
Minnesota	Yes	657	Unknown	Yes
Mississippi	--	--	Unknown	Unknown
Missouri	--	--	--	--
Montana	--	--	No	--
Nebraska	Yes	2	Unknown	Yes
Nevada	--	--	No	--
New Hampshire	--	--	Unknown	Unknown
New Jersey	--	--	Unknown	Unknown
New Mexico	Yes	538	Yes	Yes
New York	--	--	Unknown	Unknown
North Carolina	--	--	Unknown	--
North Dakota	Yes	0	Unknown	Unknown
Northern Mariana Islands	--	--	--	--
Ohio	--	--	Unknown	Unknown
Oklahoma	Yes	65	No	Unknown
Oregon	Yes	766	No	Yes
Pennsylvania	--	--	Unknown	Unknown
Puerto Rico	--	--	Unknown	Unknown
Republic of Palau	--	--	--	--
Rhode Island	--	--	--	--
South Carolina	--	--	No	--
South Dakota	Yes	4	Unknown	Unknown
Tennessee	--	--	Unknown	Unknown
Texas	--	--	Unknown	Unknown
Utah	Yes	39	Unknown	Unknown
Vermont	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--
Virginia	--	--	No	--
Washington	Yes	1,183	Unknown	--
West Virginia	--	--	No	--
Wisconsin	Yes	157	Unknown	--
Wyoming	--	--	Unknown	Unknown
<b>Total</b>	<b>17</b>	<b>7,024</b>		

<sup>1</sup> PCIPs are not administered in American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands.

Note: 48 ADAPs reported data. American Samoa, Delaware, District of Columbia, Federated States of Micronesia, Marshall Islands, Missouri, Northern Mariana Islands, Republic of Palau, Rhode Island, Vermont, and the U.S. Virgin Islands did not respond. A dash (--) indicates the ADAP did not report data or responded "no."



## Glossary



**340B Drug Discount Program** – The federal 340B Drug Discount Program, authorized under the Veterans Health Care Act of 1992, enables ADAPs to purchase drugs at or below the statutorily defined 340B ceiling price.

**AIDS Drug Assistance Program (ADAP)** - A state administered program authorized under Part B (formerly Title II) of the Title XXVI of the Public Health Service Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2009 (Ryan White Program) that provides Food and Drug Administration (FDA) approved medications to low-income individuals with HIV disease who have limited or no coverage from private insurance or Medicaid. ADAPs may also purchase insurance and provide adherence monitoring and outreach under the flexibility policy.

**ADAP Crisis Task Force** – A group of state ADAP and AIDS directors, convened by NASTAD, that negotiates with the manufacturers of HIV antiretrovirals and other high-cost medications to secure supplemental discounts/rebates benefitting all ADAPs.

**ADAP Earmark** - The amount of federal Ryan White Program, Part B dollars specifically designated by Congress through the annual appropriations process to ADAP for the federal fiscal year.

**ADAP Supplemental Drug Treatment Grant** – ADAP Supplemental grants are used for the purchase of medications by states and territories with demonstrated severe need to increase access to HIV/AIDS related medications. These grants must be used to expand ADAP formularies, target resources to reflect the changes in the epidemic, and enhance the ADAP's ability to remove eligibility restrictions. States must meet HRSA eligibility criteria in order to apply for ADAP Supplemental funds. The overall supplemental amount is mandated by law to be five percent of the congressionally appropriated ADAP earmark.

**Back-billing** – In some instances, ADAP covers an individual's prescription costs but later determines there is another payer source, for example, state Medicaid. Once it is certain that another payer should have covered a client's previous claims, the ADAP can request reimbursement for expenditures previously incurred or "back bill." Another scenario for back billing is when individuals apply and are eligible for Medicaid. Their eligibility coverage dates back three months PRIOR to the application date. ADAP covers the individual while they wait for their Medicaid eligibility determination and then "back-bills" Medicaid for any drugs or services they paid for during the interim wait time (see also pay and chase).

**Co-payment** - Some ADAPs pay the co-payments for ADAP formulary drugs, which can be a cost-effective way to help clients access medications through existing insurance coverage. In those states where ADAPs largely use their funding to purchase or maintain health insurance coverage, co-payments accounted for a much greater share of expenditures. Co-payments are a set amount an individual must pay upon receiving medical services or prescriptions. For example, there may be a \$10 co-payment required each time a prescription is purchased at a retail pharmacy.

**Cost-recovery** - Reimbursement from third party entities such as private insurers and Medicaid.

**Cost-sharing** – The payment of a premium or fee by an enrolled ADAP client to the ADAP as a portion of the cost for medications and/or services received.

**Deductible** - The amount a health insurance beneficiary must pay before a third party payer begins to provide coverage for health services. Amounts can change from year to year. Some ADAPs pay this cost for eligible clients.

**Direct Purchase States** – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider.

**Dual Eligible** – Individuals who are eligible for both Medicare and Medicaid.

**Dual Purchaser** – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider and also bill drug manufacturers for the 340B Unit Rebate Amount for the number of units dispensed for clients accessing an insurance plan (public or private).

**Formulary** - ADAP drug list that establishes the number of drugs available within a therapeutic class for purposes of drug purchasing, dispensing and/or reimbursement. Effective July 1, 2007, all ADAPs were required to include at least one drug from each antiretroviral drug class. The minimum formulary requirement does not apply to multi-class combination products (not considered a unique class of drugs), drugs for preventing and treating opportunistic infections (OIs), hepatitis C treatments, or drugs for other HIV-related conditions (e.g., depression, hypertension, and diabetes).

- **Closed/restricted formulary** – allows only those drug products listed to be dispensed or reimbursed.
- **Open formulary** – covers all FDA-approved drugs prescribed by a physician with no restrictions or with restrictions such as higher patient cost-sharing requirements for certain drugs.
- **Tiered formulary** – also referred to as “step therapy” and is a cost containment measure that categorizes medications for a particular condition based upon their cost. For example, a tier one medication would be one that is lowest cost and recommended to be used first, unless there are medical restrictions for doing so. Tier two would be a different medication that is prescribed for the same condition as the tier one drug but is more expensive. Step therapy or tiered formularies are most commonly used by ADAPs with medications prescribed for depression, respiratory problems and opportunistic infections.

**Hybrid states** – A direct purchase state that utilizes an existing entity (e.g., University Hospital) to purchase and distribute ADAP drugs. The entity maintains a single drug inventory purchased at 340B prices. To secure the additional supplemental discounts negotiated by the ADAP Crisis Task Force, these ADAPs must submit rebate claims for any supplemental discount amounts.

**Insurance Continuation** - The payment of all or some combination of insurance premiums, co-pays, or deductibles for clients who have existing insurance policies through their current employment, Consolidated Omnibus Budget Reconciliation Act (COBRA) or other supplemental programs. HRSA allows ADAP funds to be used for insurance continuation with certain restrictions.

**Insurance Purchasing** - The purchase of new insurance policies through the insurance industry market, state high risk insurance pools or Pre-existing Condition Insurance Plans (PCIPs).

**Part A funding** - Provided to metropolitan jurisdictions, some of whom make local decisions to allocate funds to ADAPs.

**Part B “base”** - Formula-based funding to states (other than that earmarked for ADAP); some states choose to allocate some of this funding to ADAPs, but are not required to do so.

**Part B supplemental funding** – Funding to states with “unmet need;” some states choose to allocate some of this funding to ADAPs, but are not required to do so.

**Patient Assistance Programs (PAPs)** - Programs through which many pharmaceutical manufacturers provide free or greatly subsidized medications to indigent patients. To see information on pharmaceutical company co-payment assistance and patient assistance programs, please visit the Positively Aware [website](#) or the Fair Pricing Coalition’s [website](#).

**Rebate states** – ADAPs who pay retail pharmacies a pre-determined amount at the point of sale for drugs dispensed to ADAP clients. ADAP then bills drug manufacturers for the 340B Unit Rebate Amount for the number of units dispensed.

**The Ryan White HIV/AIDS Treatment Modernization Act of 2009** - The Ryan White CARE Act, “Title XXVI of the PHS Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2009”, or “Ryan White Program” is the single largest federal program designed specifically for people with HIV/AIDS. First enacted in 1990, it provides care and treatment to individuals and families affected by HIV/AIDS. The Ryan White Program has five parts - **Part A** (formerly Title I) funds eligible metropolitan areas and transitional grant areas, 75% of grant funds must be spent for core services; **Part B** (formerly Title II) funds States/Territories, 75% must be spent for core services; **Part C** (formerly Title III) funds early intervention services, 75% must be spent for core services; **Part D** (formerly Title IV) grants support services for women, infants, children and youth and **Part F** comprises Special Projects of National Significance, AIDS Education & Training Centers (AETCs), Dental Programs and the Minority AIDS Initiative.

**State funding** - General revenue support from state budgets. States are not required to provide funding to their ADAPs (except in limited cases of matching requirements), although many have historically done so either over a sustained period of time or at critical junctures to address gaps in funding. Such funding is, for the most part, dependent on individual state decisions and budgets; even where states are required to provide a match of federal Part B Ryan White funds, they are not required to put this funding toward ADAP. The only exception to this is the ADAP supplemental, where states must provide a 1:4 match (or seek a waiver of the requirement, if eligible to do so).

**True Out of Pocket Expenditures (TrOOP) –**

This is the amount of money that a Medicare Part D enrolled client will have to pay from their own money to reach the “catastrophic limit” making Part D the primary payer for medications. Payments for drugs, co-payments, and coinsurance made by the beneficiary, friends, family members, State Pharmacy Assistance Programs, charities and the Medicare low-income subsidy (LIS) count towards TrOOP costs. Payments for premiums, drugs not on plan formularies, costs incurred by the ADAP and payments by other types of insurance are not counted as TrOOP costs.

